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The Role Of Antibody Subclass In The Pathogenesis Of Pemphigus Vulgaris 
Abstract 
A marvel of evolution, the adaptive immune system has the capacity to respond to almost any foreign 
antigen in a highly specific manner. Antibodies, Y-shaped glycoproteins containing both diverse variable 
regions responsible for antigen binding and constant regions responsible for effector function, are a key 
part of this capacity. However, this vast diversity comes with several drawbacks, one of which is the fact 
that the immune system can deleteriously respond to self-antigens. The focus of this thesis is to 
characterize the role of class-switching (the changing of antibody constant regions) in the pathogenesis 
of autoimmune disease, and in particular to trace the lineage of antigen-specific autoreactive B cells by 
analyzing clonal relationships between antibodies of different constant regions. Analyzing such lineages 
has the potential to shed light on mechanisms of autoantibody-mediated disease pathogenesis, leading 
to better understanding of autoimmunity and better therapeutics. 
The work presented in this thesis focuses on pemphigus vulgaris, or PV, a model antibody-mediated 
autoimmune disease characterized by a response to the cell adhesion protein desmoglein (Dsg) 3, which 
holds keratinocytes together in the epidermis. An enigmatic feature of this disease is the predominance 
of antibodies from the IgG4 subclass during active disease, which ordinarily appears to have few effector 
functions and may serve as a “brake” on the immune system in the setting of continuous stimulation by 
antigen. PV patients also display autoantibodies of the IgG1 subclass during disease and remission, but 
the relationship between IgG1 and IgG4 in the disease in unclear. Because the majority of cases of PV 
also harbor anti-Dsg antibodies of the IgA1 and IgA2 subclasses, we sought to determine the 
relationships between autoantibodies belonging to each of these subclasses. First, we address whether 
the same anti-Dsg variable region, grafted onto either IgG1 or IgG4 constant regions, can show differing 
affinity or pathogenicity, in order to determine whether antibody subclass is directly modulating 
pathogenic effect (chapter 2). Finding that the subclass has very little effect on antibody affinity, 
pathogenicity, or epitope preference, we then sought to determine whether B cells expressing 
autoantibodies of different subclasses share lineages, indicating common pathways of development 
(chapter 3). Using a combination of antigen-specific antibody cloning through phage display, and next-
generation sequencing of subclass specific repertoires in a panel of PV patients, we managed to trace 80 
lineages of anti-Dsg B cells across all four subclasses tested. In particular, we found that anti-Dsg IgG4 B 
cells, which are believed to be central to disease pathogenesis, tended to not share lineages with other 
subclasses, and in in general do not appear to share a precursor-product relationship with anti-Dsg IgG1 B 
cells. We have also found that anti-Dsg IgA1 and IgA2 were tightly related and often arose directly from 
IgG precursors. These findings are key to understanding the role of class-switching in the pathogenesis of 
PV, and may shed light on the class-switch mechanisms driving other autoimmune diseases and states of 
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A marvel of evolution, the adaptive immune system has the capacity to respond 
to almost any foreign antigen in a highly specific manner. Antibodies, Y-shaped 
glycoproteins containing both diverse variable regions responsible for antigen binding 
and constant regions responsible for effector function, are a key part of this capacity. 
However, this vast diversity comes with several drawbacks, one of which is the fact that 
the immune system can deleteriously respond to self-antigens. The focus of this thesis is 
to characterize the role of class-switching (the changing of antibody constant regions) in 
the pathogenesis of autoimmune disease, and in particular to trace the lineage of 
antigen-specific autoreactive B cells by analyzing clonal relationships between 
antibodies of different constant regions. Analyzing such lineages has the potential to 
shed light on mechanisms of autoantibody-mediated disease pathogenesis, leading to 
better understanding of autoimmunity and better therapeutics. 
The work presented in this thesis focuses on pemphigus vulgaris, or PV, a model 
antibody-mediated autoimmune disease characterized by a response to the cell 
adhesion protein desmoglein (Dsg) 3, which holds keratinocytes together in the 
epidermis. An enigmatic feature of this disease is the predominance of antibodies from 
the IgG4 subclass during active disease, which ordinarily appears to have few effector 
functions and may serve as a “brake” on the immune system in the setting of 
continuous stimulation by antigen. PV patients also display autoantibodies of the IgG1 
subclass during disease and remission, but the relationship between IgG1 and IgG4 in 
the disease in unclear. Because the majority of cases of PV also harbor anti-Dsg 
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antibodies of the IgA1 and IgA2 subclasses, we sought to determine the relationships 
between autoantibodies belonging to each of these subclasses. First, we address 
whether the same anti-Dsg variable region, grafted onto either IgG1 or IgG4 constant 
regions, can show differing affinity or pathogenicity, in order to determine whether 
antibody subclass is directly modulating pathogenic effect (chapter 2). Finding that the 
subclass has very little effect on antibody affinity, pathogenicity, or epitope preference, 
we then sought to determine whether B cells expressing autoantibodies of different 
subclasses share lineages, indicating common pathways of development (chapter 3). 
Using a combination of antigen-specific antibody cloning through phage display, and 
next-generation sequencing of subclass specific repertoires in a panel of PV patients, we 
managed to trace 80 lineages of anti-Dsg B cells across all four subclasses tested.  In 
particular, we found that anti-Dsg IgG4 B cells, which are believed to be central to 
disease pathogenesis, tended to not share lineages with other subclasses, and in in 
general do not appear to share a precursor-product relationship with anti-Dsg IgG1 B 
cells. We have also found that anti-Dsg IgA1 and IgA2 were tightly related and often 
arose directly from IgG precursors. These findings are key to understanding the role of 
class-switching in the pathogenesis of PV, and may shed light on the class-switch 
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Adaptive immunity in higher vertebrates, like humans, relies on generating 
highly diverse antibody molecules capable of responding to almost any target. While 
conferring protection against a variety of antigens, the adaptive immune system also 
has the power to respond to self-antigens, causing autoimmunity. As a geneticist, I view 
the adaptive immune system as a Darwinian mechanism, searching through a 
staggeringly diverse space of biological sequences. This can be analogized as a group of 
evolving and mutating B cells walking through an antibody-encoding Library of Babel*, 
finding useful, protective antibody sequences amongst a vast background of irrelevant 
and potentially dangerous ones. The focus of my thesis work has been understanding 
the development, lineage, and sequence properties of autoreactive B cells in the model 
antibody-mediated autoimmune disease pemphigus vulgaris, to better understand the 
pathogenesis of autoimmunity. Separating the features of autoreactive cells from the 
larger repertoire will not only shed light on the pathogenesis of autoimmune disease, it 
may also help design better treatment strategies for the ever-increasing population of 
autoimmune disease sufferers worldwide (5). 
 
 
                                                          
*The Library of Babel is a short story by the Argentinian author Jorge Luis Borges(1). It considers a fictional 
universe containing all possible 410-page books housed in an “indefinite, perhaps infinite” number of 
linked hexagonal rooms. A similar analogy has been used to describe the total space of DNA or protein 
sequences by the philosopher Daniel Dennett (calling it the “Library of Mendel”)(2) and others (3)(4). 
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1.1  Antibody Development 
1.1.1  Introduction 
 Antibodies, or immunoglobulins (Ig), are highly diverse glycoproteins generated 
as a key component of the adaptive immune system in higher vertebrates (6).  The 
antibody macromolecule consists of four polypeptide chains, with two heavy and two 
light chains linked together by disulfide bonds forming a Y shape. The variable region of 
each monomer is contributed to by both the heavy and light chain, and serves to 
recognize and bind to antigen. The constant region, by contrast, determines the isotype 
and effector function of each antibody. The genesis, development and genetic basis of 
antibody constant and variable region diversity will be described in this section. 
 
1.1.2 Antibody Genesis 
 In humans, the peptides that comprise a mature antibody are encoded by 
separate Ig loci located on chromosome 14 (heavy chain, IgH), chromosome 2 (kappa 
light chain, IgK), and chromosome 22 (lambda light chain, IgL)(7)(8)(9). During 
development, each B-cell precursor rearranges these loci in a stepwise process called 
V(D)J recombination, so named because each Ig heavy chain locus contains several 
variable (V), diversity (D), and joining (J) segments that will be joined together to 
generate a contiguous immunoglobulin-coding DNA segment (10)(11).  The light chain 
loci have a similar architecture and are rearranged in a similar fashion, though without 
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the D genes; therefore, the final heavy chain of an antibody is coded by three apposed 
gene segments, while the light chain is coded by two. 
Hematopoietic stem cells in the bone marrow differentiate into multipotent 
progenitors, then common lymphoid progenitors (CLP), then pro-B cells, which are 
committed to the B cell lineage via the expression of the transcription factor Pax5 (12). 
At the pro-B cell stage, the Ig loci have not yet been made productive. At this point, 
transcription factors including BCL11A/B, FOG1, and FOG2 induce expression of the 
heterodimeric RAG1/2 recombinase, which initiates the process of VDJ recombination at 
the heavy chain locus (13)(14)(15)(16). First, a D gene and J gene are randomly selected, 
and RAG1/2 creates a double-strand break in the recombination signal sequences (RSS) 
adjacent to the selected D and J exons; the intervening segment is ligated to form a 
circular intermediate called the signal end complex, and the sequence adjacent to the D 
and J genes self-anneal to form hairpin structures (17)(18)(19). At this stage, the Artemis 
nuclease nicks and opens each hairpin, which generates a linear stretch of DNA 
containing palindromic (P) nucleotides (so-called since hairpins necessarily have 
palindromic sequences to self-anneal). This stretch of P nucleotides can subsequently be 
chewed back by variety of exonucleases to chew back the DNA, and/or extended by 
terminal deoxynucleotidyl transferase (TdT), which adds non-template (N) nucleotides 
adjacent to the original P nucleotides to generate additional diversity 
(20)(21)(22)(23)(24)(25). Subsequently, these two D and J genes are recombined 
together in an error-prone process of non-homologous end-joining (NHEJ)(26)(27). The 
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same process then occurs between a selected V gene and the DJ segment, creating one 
continuous VDJ region encoding the heavy chain variable region (Figure 1-1) (28). 
At this stage, the mature heavy chain with an IgM constant region, paired with a 
surrogate light chain, is expressed on the surface of the developing B cell as part of the 
pre-B cell receptor (pre-BCR), along with invariant Ig-alpha and Ig-beta signaling 
molecules (29). Signaling through this receptor, which is only possible when the product 
of the heavy chain locus can successfully pair with the surrogate light chain, ends VDJ 
recombination at the IgH locus by down-regulating RAG1/2 (30)(31)(32) . Furthermore, 
signaling at this step ensures that only one antibody heavy chain is expressed per B cell, 
in a process called allelic exclusion (33)(34)(35). This signaling allows the pro-B cell to 
transition to a pre-B cell, which subsequently divides repeatedly and rearranges its light 
chain locus in a similar fashion (Figure 1-2). In this stage, the pre-B cell does not yet 
express mature IgM on its surface, but does show cytoplasmic IgM heavy chains, which 
are rapidly degraded as they cannot yet pair with a mature light chain (36). After the 
light chain rearranges and pairs properly with the already-rearranged heavy chain, the 
pre-B cell becomes an immature B-cell and expresses a mature BCR complex on its 
surface (37). After crossing a few critical checkpoints detailed in section 1.1.5, immature 
B-cells move to the periphery, where they can divide and diversify to give rise to clonal 
lineages originating from a single VDJ recombination event. These later steps of 
antibody maturation and diversification in the periphery are discussed in later sections 
of this chapter. 
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Note that at the point of the B cell exiting the bone marrow, there are three key 
sources of sequence diversity in the variable heavy chain. First, the combinatorial 
diversity generated by selecting different V, D and J genes is substantial. According to 
the IMGT database, in the human IgH locus, there are 38-46* functional V genes, 23 
functional D genes, and 6 J genes, generating 4002-5244 different joins (39)(40)(41). 
Human light chains are encoded by 29-33 V and 4-5 J chains in the lambda locus or 31-
35 V and 5 J chains at the kappa locus, for a total of 271-340 different joins 
(41)(42)(43)(44). Random pairing of heavy and light chains generates a final 
combinatorial diversity of between 1.08 x 106 and 1.78 x 106. This is further increased by 
the imprecise nature of each V-D and D-J join in the heavy chain and V-J joins in the light 
chain, resulting in a final naïve B-cell repertoire diversity of approximately 1011 in a 
single individual and theoretically greater than 1014 across the entire space of variable 
region sequences (45)(46)(47).  
However, this diversity comes at a significant cost. The NHEJ mechanism doesn’t 
take reading frame into account, meaning that approximately two-thirds of 
recombination events will not produce functional protein (48)(49). When these 
nonproductive rearrangements fail to signal through the pre-BCR complex, they can be 
rescued by subsequent rearrangements on the same chromosome (selecting V genes 
upstream or J genes downstream of the unproductive VDJ locus) or, if those options are 
                                                          
* IMGT reports a range, because there’s variability from person to person in the number of functional V, 
D, and J genes in each locus. The loci also contain non-functional ORFs (which have an open reading frame 
but lack other features needed for function) and pseudogenes (which contain stop codons or frameshifts). 
For more information on the variability in the germline VDJ complement, please see (38) 
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exhausted, by subsequent rearrangement on the other chromosome. A similar process 
occurs in the light chain locus at the pre-B cell stage, resulting in a productive V-J 
rearrangement from either the lambda or kappa locus and isotypic exclusion of the 
other (35)(50). In sum, this results in approximately half of all pro-B cells going on to 
produce functional antibody (41).  
The sequence structure of a mature antibody variable region gives some insight 
into its function (Figure 1-3). Each heavy and light chain can be divided into three loop-
shaped hypervariable complementarity-determining regions (CDRs) interspersed with 
relatively rigid  beta sheets called framework regions (FWRs) (51)(52). In general, CDRs 
are responsible for the antigen specificity of a given antibody, while the FWRs are 
responsible for stabilizing the antibody’s three-dimensional structure, though this 
distinction isn’t absolute (53)(54)(55)(56)(57)(58). CDR1 and CDR2 are entirely encoded 
by the V gene in both the heavy and light chain, and the CDR3 spans the V-J junction in 
the light chain and the V-D-J junction in the heavy chain. Because the CDR3 spans all 
segments and the junctional diversity therein, it is almost impossible for two 
independent pro-B cells to give rise to the same heavy chain CDR3 region after 
recombination, and therefore the CDR3 is commonly used as a marker of clonal 
relatedness between B cells (59).  
As the B cell circulates and migrates into secondary lymphoid organs, it 
undergoes further diversification through two processes, somatic hypermutation and 
class switching. These processes, and their effects on the repertoire, will be described in 
the following sections. 
7 
 
1.1.3  Variable Region Development 
 Immature B cells further differentiate into transitional B cells as they exit the 
bone marrow (60)(61). At this stage, the transitional B cell migrates to follicles in 
secondary lymphoid organs (lymph node, spleen, Peyer’s patches in the ileum, etc.). 
Either during or after its migration, the transitional B cell further differentiates into a 
mature naïve B cell, capable of responding to antigen and co-stimulatory signals 
(61)(62). At this stage, the B cell can enter a germinal center (GC) within a secondary 
lymphoid organ, which are sites of rapid B cell proliferation and differentiation (63). 
Before entering the GC, B cells can bind to and endocytose circulating antigen using its 
BCR, subsequently presenting linear peptides derived from said antigen on their surface 
using major histocompatibility complex (MHC) (64)(65).  At this point, the antigen-
experienced B cell can enter the GC, where it can form an immunological synapse with a 
helper T cell (TH cell) expressing a cognate T-cell receptor (TCR) for the same antigen** 
(67)(68). Through this MHC:TCR interaction, as well as co-stimulatory ligand-receptor 
interactions like CD40:CD40L, CD80:CD28, and CD86:CD28, the antigen-experienced B 
cell undergoes clonal expansion and further maturation, fine-tuning its affinity for its 
target antigen (69)(70)(71)(72). 
 The key molecule that catalyzes B cell affinity maturation is Activation-Induced 
Cytidine Deaminase (AID), a tightly-controlled enzyme which catalyzes C-to-U de-
amination in the IgH, IgL, and/or IgK variable regions in a transcription-dependent 
                                                          
** TCRs undergo a similar VDJ recombination process as antibodies, though their function is to respond to 
linear peptides displayed on MHC molecules by antigen-presenting cells. The theoretical maximum of TCR 
diversity approaches 1020, though humans only have ~1012 total T cells. For more information, see (66) 
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manner (73)(74)(75)(76). The subsequent G:U mismatch can be dealt with after 
MSH2/MSH6 binding by the mismatch repair, or by uracil-DNA glycosylase creating an 
abasic site that is subsequently filled by base excision repair (77)(78)(79)(80). The 
former pathway can also induce mutations in nearby A/T residues on the same strand 
by recruiting the error-prone DNA polymerase eta (81)(82). This process, called somatic 
hypermutation (SHM), creates point mutations across the variable region, substantially 
increasing the total sequence space available to the immune system for antigen binding 
and antigen-driven selection. Mutations that increase the affinity of the BCR are 
subsequently selected and propagated by outcompeting lower-affinity sequences for 
limited T cell help, resulting in a clonally-related B cell pool with greatly increased 
affinity for the target antigen (83). These affinity-matured B cells can undergo further 
differentiation into plasma cells and memory cells (84). The former take up long-term 
residence in specified niches in the bone marrow, mucosa-associated lymphoid tissue 
(MALT), and spleen and secrete soluble antibody into the bloodstream and lymphatic 
system like so much biochemical artillery, while the latter express matured antibody in a 
transmembrane form, lying in wait to respond when re-challenged with the same 
antigen (85)(86)(87). 
 There also exists an alternative pathway for B cell maturation outside the GC, 
called the “extrafollicular pathway”, where B cells can mature without T cell help. This 
pathway is particularly important in first-line defenses requiring rapid production of 
antibody, and appears to function as part of the innate immune system. For example, in 
the marginal zone of the spleen, which samples antigens from circulation, simultaneous 
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engagement of toll-like receptors (TLRs) and BCR on the B cell surface can serve as a co-
stimulatory signal, allowing B cell activation and differentiation into antibody-secreting 
plasma cells in the absence of T cells (88)(89). Antigen-presenting dendritic cells, which 
reside in areas in contact with the environment, can also directly induce activation and 
class switching by engaging BCR and secreting the B cell activating factors BLyS and 
APRIL (90). Finally, intestinal epithelial cells can sense bacterial antigens in the gut 
through TLRs, secreting APRIL and activating dendritic cells to induce T-independent 
class switch to IgA (91). In general, these extrafollicular responses create low-affinity 
antibodies with fewer somatic mutations than in B cells that pass through the GC, 
making these two repertoires, in theory, distinguishable (92,93). 
 Mutations induced during SHM are not perfectly uniform across the variable 
region, for a variety of reasons. AID preferentially mutates cytosines belonging to the 
“hotspot” motifs WRCY/RGYW and avoids cytosines in the SYC/GRS “coldspot” motif 
(94)(95)(96)(97). A secondary SHM hotspot, WA/TW, is due to DNA polymerase eta 
activity (98)(99)(100). High-throughput sequencing work has largely corroborated this 
hotspot-coldspot model, with the additional complication that hotspots can show a 
wide range of “hotness”, i.e. mutability (101). It has also been shown that through 
evolutionary pressure, hotspot motifs, and in particular hotspot motifs in which the 
mutable cytosine is in a position likely to result in amino acid replacement upon 
mutation, have been preferentially clustered into the CDR regions, while coldspot motifs 
segregate to FWR regions (102)(103)(104)(105). In theory, this ensures that SHM 
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preferentially mutates sections of the variable region responsible for antigen-binding, 
and avoids regions required for structural integrity. 
 In addition to point mutations, SHM can also add insertions and deletions 
(indels) to the variable region (106). Up to 6.5% of circulating B-cells encode indel-
containing antibody variable regions; though rare, they add substantially to the overall 
diversity of the antibody repertoire (107). Indels tend to occur near AID hotspots, tend 
to localize to CDRs or CDR-adjacent residues, and rapidly decrease in frequency with 
length (108)(109).  While the exact mechanism of indel creation isn’t known, in vitro 
studies have shown that AID is necessary for this mechanism of diversification (107), 
and in vivo studies have shown that indels preferentially occur in repetitive or loop-
forming tracts of DNA near AID hotspots, suggesting a model in which a repair 
polymerase “slips” while correcting an AID-induced mutation, either creating a deletion 
or duplicating adjacent nucleotides to create an insertion (110). 
SHM-induced indels allow the adaptive immune system to sample relatively 
inaccessible regions of sequence space; those B cells fortunate enough to reach these 
obscure rooms in the library can produce antibodies with particularly interesting 
reactivity. For example, an antibody capable of neutralizing both the 1918 and 2009 
H1N1 influenza virus shows a 3-amino acid insertion in the heavy chain FR3 region; 
crystallization showed that this insertion pushed the CDR2 loop into a useful 
conformation for binding to hemagglutinin and was necessary for the antibody’s ability 
to neutralize both strains (111–113). In another study, around 40% of surveyed broadly-
neutralizing HIV antibodies (bnAbs) were found to have variable region indels, and in 
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several cases the indels are either required for high-affinity binding or required for 
subsequent affinity maturation of the bnAb lineage (114). In interesting recent work, 
two patients from a malaria-endemic region in Kenya were found to express unusual 
broadly-reactive antibodies against Plasmodium falciparum. Shockingly, these 
antibodies contained not mere SHM-derived indels, but a 100-amino-acid insertion 
between the V and D genes consisting of the entire collagen-binding domain of the 
collagen receptor LAIR1. The mechanism for this last example is remains unknown - 
authors found that the LAIR1 insert contained cryptic RSS site on either side, but both 
copies of LAIR1 were still extant in the genomic DNA, which is inconsistent with RAG1’s 
copy-paste mechanism (115). These results all suggest that indels are a particularly 
powerful way of diversifying the antibody repertoire, with the potential of creating 
reactivity to traditionally “difficult” antigens.  
The combination of a “seed” VDJ recombination in the bone marrow and the 
Darwinian pull of SHM in the periphery allows a single unique variable region in a pro-B 
cell to give rise to an entire lineage of B cells after affinity maturation. Conceptually, a 
particular B cell lineage can be discerned by its usage of shared V, D and J genes and 
CDR3 sequence (with some mutation within the CDR3), with the highly diverse CDR3 
sequence serving as a natural barcode propagated within said lineage. Therefore, the 
antibody repertoire can be viewed as a series of disjoint lineages, each originating from 
a single VDJ recombination event. This idea is reflected by high-throughput sequencing 
experiments. In these data sets, binning all sequences by their assigned V and J gene 
(which are presumed shared by any given lineage), then calculating the pairwise 
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nearest-neighbor distance between CDR3 sequences within a given bin, gives a bimodal 
distribution with a “near” peak corresponding to pairs of clonally-related sequences and 
a more pronounced “far” peak corresponding to unrelated CDR3 (Figure 1-4) (116). The 
task of sorting the repertoire into lineages, and the general difficulties of antibody 
repertoire sequencing, will be discussed in the final section of this introduction.  
 
1.1.4 Isotypes and Class-Switching  
The constant region of an antibody is encoded by the C-terminal portions of the 
heavy and light chain. The heavy chain constant region, in particular, is the sole 
determinant of the antibody isotype, which determines the antibody’s effector function 
(117). In humans, there are 5 antibody isotypes (IgM, IgD, IgG, IgA, and IgE), some of 
which can be further divided into subclasses (IgG1 through IgG4, and IgA1 through 
IgA2)(118). The 3’ end of the heavy chain locus contains exons corresponding to each of 
these isotypes and subclasses, with a small repetitive switch region (S-region) and 
intronic promoter (I-region) immediately 5’ of each exon (Figure 1-5) (119)(120). 
Late-stage transitional B cells display both membrane-bound IgD and membrane-
bound IgM through alternative splicing (121)(122)(123)(124)(125). Later, during affinity 
maturation in the GC, AID (in addition to catalyzing SHM) can also catalyze class-switch 
recombination (CSR) (126)(127)(128). In this process, the cytokine milieu generated by 
TH cells and other cells within the GC epigenetically triggers transcription from a donor 
and acceptor I-promoter in the IgH locus. The single-stranded DNA at the transcription 
bubbles serves as a substrate for AID, inducing double-strand breaks due to a very high 
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density of overlapping AID hotspot motifs. These lesions are subsequently repaired by 
NHEJ between corresponding donor and accept S-regions, “looping out” the DNA 
between them and forming a “switch circle” byproduct (129).   
CSR is therefore a one-directional process – a B cell can switch from a 5’ exon 
(like IgM) to a more 3’ one (like IgE), but the reverse is impossible. In particular, it is 
worth noting that class-switching is often sequential, rather than direct from IgM. For 
example, by cloning switch circles from ex vivo allergen-challenged human B cells, one 
group showed that B cells can switch directly from IgM to IgE, or switch sequentially 
from IgM to IgG4 to IgE (130). Similar results have been found in allergen-challenged 
mice, with one study noting that a sequential switch was necessary to develop high-
affinity IgE (131)(132). A high throughput sequencing study of IgE lineages from the 
peripheral blood of 33 human subjects showed, based on shared somatic mutations 
between sequences of different subclasses, that IgE-expressing B cells predominantly 
arose through sequential switch, primarily from somatically-mutated clones in IgG1 
(133). Another group proposed a model of sequential class-switching between IgG 
subclasses (IgG3 > IgG1 > IgG2 > IgG4) over the course of an immune response, which is 
supported by the presence of the requisite switch remnants in IgG1 and IgG2 B cells 
(134)(135)(136). In a more expansive study, Stephen Quake’s group has recently 
published a comprehensive landscape of human CSR by sequencing peripheral blood 
cells from 11 pairs of healthy human twins and lineage tracing every variable region 
sequence found. This work demonstrated that direct switching from IgM to downstream 
14 
 
subclasses like IgA2, IgG4, and IgE is rare, and the majority of switches to these 
subclasses pass through more upstream subclasses like IgG1 or IgA1 first (137). 
 Much as SHM diversifies the antigen-binding function of a given antibody, CSR 
diversifies the effector function of each antibody (though with ten orders of magnitude 
less diversity). A complete survey of each subclass and the signaling pathways leading to 
their synthesis is the subject of ongoing research and is beyond the scope of this thesis; 
however, those subclasses and cytokines most important for pemphigus pathogenesis 
will be reviewed in section 1.2. 
 
1.1.5 Autoreactivity and Tolerance 
 The vast capacity of the antibody repertoire to respond to nearly any antigen 
over the course of an organism’s lifetime has a serious drawback – it has the capacity to 
produce antibodies against self-antigens (138)(139). A seminal study showed that a 
staggering 50 to 75% of immature B cells in the bone marrow react to cytoplasmic 
and/or nuclear antigens in HEp-2 cell-line extracts (a standard assay for autoreactivity) 
(140). There are several checkpoints in place to prevent these autoreactive clones from 
propagating, both within the bone marrow (central tolerance) and in the periphery 
(peripheral tolerance). These mechanisms are demonstrably impaired in several 
autoimmune diseases, including multiple sclerosis (141), rheumatoid arthritis (142), 
myasthenia gravis (143), Sjogren’s syndrome (144), and systemic lupus erythematosus 
(SLE) (145), all of which demonstrate increased numbers of autoreactive B cell clones in 
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the peripheral blood. The mechanisms of these checkpoints will be elucidated in this 
section. 
 Upon expression of a pre-BCR at the pre-B cell stage, the nascent B cell is 
challenged by a panoply of self-antigens within the bone marrow, beginning the process 
of central tolerance (146). Subsequently, a high-affinity interaction between the pre-
BCR and a self-antigen at this stage can trigger a number of different central tolerance 
mechanisms, including receptor editing, anergy, and clonal deletion (147)(148)(149). In 
receptor editing, a self-reactive pre-B cell arrests development, reactivates RAG1 and 
RAG2, and attempts to abolish self-reactivity by re-rearranging the light chain locus 
(150). Typically, the kappa locus is rearranged first, then the lambda 
(151)(152)(153)(154). Subsequently, if the clone remains autoreactive, an analogous 
process can occur at the heavy chain variable region, replacing the current VH gene with 
a more upstream one (155)(156). This process can even occur serially, with multiple 
upstream VH genes tested for autoreactivity (157). However, the details remain 
controversial. Another study used a  knock-in mouse model to show that that VH 
replacement occurred before light-chain rearrangement, suggesting that VH 
replacement isn’t involved in editing autoreactive antibodies (158). Furthermore, while 
VH replacement typically results in lengthening of the CDR3 and leaves a “footprint” of 
the replaced VH gene that can theoretically be detected algorithmically in sequencing 
data (159)(160), other studies suggest many of these footprints may arise through other 
mechanisms, including sequencing error and chance (161). Therefore, while VH 
replacement is known to occur, both its overall frequency and its relevance to tolerance 
16 
 
remains controversial. Chapter 3 of this thesis includes analysis of cloned antibodies for 
autoreactivity, but for the above reasons it cannot reliably be determined which 
receptor editing processes these clones have undergone within the bone marrow before 
migration into the periphery. 
If the B cell remains autoreactive after receptor editing, its differentiation is 
arrested and it undergoes apoptosis after 2-3 days in a process called clonal deletion 
(162)(163)(164). Deletion is the last central tolerance mechanism for eliminating a high-
affinity autoreactive B cell before it enters the periphery; however, clones expressing 
BCRs with low affinity can still escape. At this stage, those low-affinity clones that react 
to abundant soluble antigen in the periphery can undergo tonic BCR stimulation in the 
absence of co-stimulatory signals; this causes them to down-regulate surface IgM, 
ignore mitogenic signals, and decreases their half-life, a state called anergy 
(165)(166)(167)(168)(169). Anergic mature naïve B cells are excluded from the GC and 
are unable to solicit T cell help; this prevents them from receiving critical survival signals 
from the follicular niche and results in their death (170)(171)(172). The importance of 
anergy in preventing autoimmunity can be seen in transgenic mice deficient for 
inhibitory components of the BCR, like SHP-1 and SHIP-1; both of these are required for 
anergy, and their knockout causes severe autoimmunity (173)(174)(175). 
In healthy individuals, these central tolerance mechanisms manage to eliminate 
most autoreactive B cells, but 5-20% of mature naïve B cells remain autoreactive (140). 
At the level of GC and post-GC B cell development, there are a few more tolerance 
mechanisms to consider. As previously stated, T cell help is required for the production 
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of high-affinity antibodies (176), and more importantly a lack of T cell help in the GC 
leads to B cell apoptosis (177)(178). T cells must cross their own tolerance checkpoints, 
both within the thymus and the periphery; this decreases the chances that an escaping 
autoreactive B cell and its cognate T cell both survive and meet in the GC (179)(180). 
Affinity maturation in the GC can create autoreactive clones, some even 
managing to differentiate into long-lived memory B cells (181)(182)(183)(184); however 
apoptosis usually prevents newly-autoreactive B cells from escaping the GC (185). These 
autoreactive B cells can undergo outright deletion in the periphery, as demonstrated in 
several double-transgenic mouse experiments in which an antigen and B cell expressing 
a cognate antigen-specific BCR are both expressed (186)(187). Subsequent experiments 
showed that in these systems, deletion occurs due to the absence of T cell help (188). 
Deletion isn’t the only fate for a new autoreactive clone, however. There’s some 
evidence that receptor editing acts on autoreactive clones in the periphery (189), 
though some mouse models suggest that heavy chain rearrangements in the periphery 
actually improve autoantigen binding, rather than abolishing it (190)(191). In other 
cases, further mutation and/or glycosylation of the variable region and further mutation 
“redeemed” autoreactive clones (192)(193).  
 A simple analogy can be drawn between autoimmunity and cancer. Just as 
cancer represents a failure of multiple checkpoints to prevent the unchecked cell 
division of initially rare aberrant cells, autoimmunity is the result of a (sometimes quite 
polyclonal) sub-population of autoreactive lymphocytes escaping multiple tolerance 
mechanisms. Just as understanding the mechanisms of tumorigenesis has ushered in 
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powerful targeted therapy for a variety of cancers, understanding the genesis of 
autoreactive B cells has the potential to herald a new era in targeted therapy for 
autoimmune disease. In chapter 3, we have combined antigen-specific screening and 
high-throughput sequencing to trace the lineage of autoreactive B cells across several 
subclasses, to better understand the origin and development of autoimmune disease. In 
particular, we’re interested in tracing the B cell lineages responsible for the organ-
specific autoimmune disease pemphigus vulgaris (PV), which we describe in the next 
section. 
 
1.2 Pemphigus as a Model 
1.2.1 Introduction  
Pemphigus is a group of rare autoimmune diseases of the skin and mucous 
membranes characterized by serum antibodies to cell adhesion proteins, causing 
intraepidermal blistering (194)(195). The various subtypes of pemphigus are categorized 
based on the adhesion proteins targeted by autoantibodies, and show different clinical 
and histological presentations (Table 1-1). PV is the most common disease in this group, 
occurring in 0.1-0.5 of every 100,000 people (196). In particular, the incidence of PV 
seems to increase in populations with Middle Eastern, Jewish, or Mediterranean 
ancestry. For example, in Hartford County, Connecticut, the incidence of PV in the 
Jewish population was 3.2 per 100,000 people, while the overall adult population had an 
incidence of 0.42 per 100,000. In Isfahan, central Iran, the incidence is even higher, at 5 
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per 100,000 (197), though in the more southwestern city of Shiraz the incidence 
dropped to 0.59 per 100,000 in another, suggesting some degree of geographic 
variation (198). Among European populations, the UK seems to have a slight increase 
over the continent, with a PV incidence of 0.7 per 100,000 (199), compared to 0.5-1.5 
per million in Switzerland (200), France (201), Finland (202), and Germany (203). 
Clinically, PV is characterized by suprabasal blistering of the oropharynx and a 
positive ELISA against the cell adhesion protein desmoglein (Dsg) 3. Suprabasal blistering 
of the skin can occur with the subsequent development of antibodies against a 
homologous cell adhesion protein, Dsg1 (204)(205). This is reminiscent of another 
disease in the group, pemphigus foliaceus, which is characterized by antibodies to Dsg1 
and superficial skin blistering. The serum autoantibody profile of PV is used to 
categorize it into its mucosal and mucocutaneous subtypes, the former expressing anti-
Dsg3 antibodies, the latter expressing both anti-Dsg3 and anti-Dsg1. The reasons for this 
tissue distribution will be made clear later in this section.  
Pemphigus is a model autoantibody-mediated disease for a few reasons. First, 
the autoantigens are well-characterized, with highly sensitive and specific ELISA assays 
available for both Dsg3 and Dsg1. Second, antibodies have been shown to be both 
necessary and sufficient for disease. For example, PV serum IgG causes blisters by 
passive transfer into neonatal mice, while IgG from the serum of healthy subjects and 
from PV serum with anti-Dsg3 antibodies removed by adsorption does not (206)(207). 
Furthermore, monoclonal anti-Dsg3 antibodies cloned from PV patients can cause 
blisters in neonatal mice and human skin (208)(209). These features make PV ideal for 
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studying an antigen-specific autoantibody response, and for understanding the 
evolution of an autoimmune repertoire. 
 
1.2.2 Pathogenesis 
The association between pemphigus vulgaris and autoantibodies was first 
demonstrated in the 1960s, by immunofluorescence showing that patient sera binds in a 
cell-surface pattern to human skin (210)(211). Almost three decades later, the 
autoantigen was described by John Stanley’s group as a novel epithelial cadherin, later 
cloned as Dsg3 (212)(213).  Dsg3 mediates cell-cell adhesion as part of the desmosome, 
which connects keratinocytes in stratified squamous epithelia. Within the desmosome, 
desmogleins can undergo both homophilic interactions (214) and heterophilic 
interactions (215)(216). Intracellularly, the C-terminal domain of desmogleins bind to a 
complex of proteins including plakoglobin, plakophilin, and desmoplakin, which mediate 
interactions with the keratin cytoskeleton (217). This allows the desmosome to resist 
mechanical stress, such as rubbing of the skin; it is thus apropos that one of the clinical 
signs of PV is “Nikolsky’s sign”, in which rubbing of normal skin forms a blister (218). 
The extracellular domain of Dsg3 consists four extracellular cadherin-like 
domains (EC1-EC4), which lie distal to a fifth extracellular domain dubbed EC5. The N-
terminal EC1 and EC2 domains, which are the most and second-most distal to the cell 
surface, respectively, have been shown to mediate cis (e.g. interactions between 
proteins on the same cell) and trans interactions (interactions between proteins on 
different cells) (219)(220). Because of this, binding of autoantibodies to these N-
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terminal domains can directly disrupt trans interactions by disrupting desmosomal 
assembly(221)(222) and/or causing internalization of Dsg3 into endosomes(223), 
leading to blistering.  
The N-terminal preference of PV autoantibodies is well-established, though 
reactivity is not exclusive to that domain (224)(225). A longitudinal study of pemphigus 
sera from 53 patients showed predominant reactivity with the EC1 domain at all stages 
of disease, with decreasing percentages of sera showing reactivity as one moves to EC2-
5 (226). A previous repertoire cloning experiment using phage display showed that 
antibodies capable of causing a blister in neonatal mice by injection (“pathogenic” 
antibodies) bound to the N-terminal 161 amino acids of Dsg3 (which covers EC1 and 
part of EC2), while non-pathogenic antibodies preferentially bound to more C-terminal 
domains (208). These studies all suggest that the autoantibodies most critical for PV 
pathogenesis bind to the N-terminal EC domains of Dsg3. However, the role of 
antibodies binding to C-terminal EC domains should not be overlooked. Injecting 
multiple non-pathogenic antibodies together can cause a blister, suggesting that so-
called non-pathogenic antibodies can work synergistically to have pathogenic activity 
(227). 
Dsg1 acts as a secondary target in PV, specifically appearing in its 
mucocutaneous variant (204,205). The anti-Dsg1 and anti-Dsg3 ELISA have been 
correlated to disease activity in skin and oral mucosa respectively (228), and anti-Dsg1 
ELISA titer can predict skin relapse (229). These studies suggest that anti-Dsg1 
antibodies are required for skin involvement in PV, and that anti-Dsg3 antibodies are 
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insufficient to cause cutaneous blistering. This feature has been explained by the fact 
that both Dsg3 and Dsg1 are expressed in the epidermis in an inverse fashion (Dsg3 
being basal and Dsg1 superficial) (230)(231)(232), while Dsg3 is expressed much more 
strongly than Dsg1 across all layers of the oral mucosa (233). These observations led to 
the development of the desmoglein compensation hypothesis to explain pathogenesis. 
The hypothesis states that in the skin, Dsg1 is capable of mediating adhesion when Dsg3 
function is abrogated because it is expressed throughout the epidermis (including the 
basal layer), while the expression of Dsg1 is both completely lacking in the basal layer 
and significantly less than that of Dsg3 throughout the mucosa, making it unable to 
maintain adhesion in the basal layer in the presence of anti-Dsg3 antibodies (234).  
Evidence for this theory mainly comes from experiments in transgenic mice. One 
experiment showed that antibodies to both Dsg1 and Dsg3 are required for blister 
formation in neonatal wild-type mice, while Dsg3-null neonatal mice only required 
antibodies to Dsg1 for blister formation (235). A transgenic mouse expressing Dsg3 
ectopically in superficial layers of the skin is resistant to blistering when injected with 
anti-Dsg1 serum (236). And finally, Dsg3(-/-) mice rescued with a Dsg1 transgene are 
resistant to blistering upon injection with the anti-Dsg3 antibody AK23 (237). 
From an antibody repertoire perspective, the fact that two homologous proteins 
are targeted by the same disease, in a successive fashion, is very interesting. It may be 
the case, for example that the anti-Dsg1 repertoire is entirely descended from anti-Dsg3 
clones over the course of the autoimmune response – this would be a parsimonious 
explanation to explain the transition from mucosal to mucocutaneous PV. Supporting 
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this idea is the fact that antibodies cross-reactive to Dsg3 and Dsg1 have been isolated 
from PV patients (208). Alternately, the Dsg1 repertoire may arise completely 
independently from the Dsg3 repertoire, despite the homology between the two. This is 
supported by a study which showed that affinity purified anti-Dsg3 serum from PV 
patients lacks reactivity to Dsg1 and vice versa (238), though it leaves open the 
possibility that anti-Dsg1 and anti-Dsg3 antibodies share a lineage and somatic 
mutations have modulated their reactivity. In chapter 3 of this thesis, we analyze both 
anti-Dsg1 and anti-Dsg3 antibodies from a panel of patients through phage display as 
part of a larger effort to define lineage relationships among autoreactive B cell clones in 
PV. 
 
1.2.3 The Features of Autoantibodies in Pemphigus Vulgaris 
 Like a handful of other autoimmune diseases, like anti-MuSK Myasthenia Gravis 
(239) (240), thrombotic thrombocytopenia purpura (241), and others (242), PV shows an 
IgG4 predominance during active disease. In particular, PV patients in active stages of 
the disease predominantly show anti-Dsg3 IgG4 and less often anti-Dsg3 IgG1 (243). 
Furthermore, autoantibodies show a 4-8 fold enrichment in IgG4 vs IgG1 sera by ELISA 
(244). Other studies have demonstrated that healthy relatives of PV patients (rarely), 
HLA-matched controls (rarely), and patients in remission can show anti-Dsg3 antibodies 
of the IgG1 subclass, while those with active disease show both IgG1 and IgG4 anti-Dsg3 
antibodies (245)(246). Another study suggested that during IVIG treatment, the levels of 
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anti-Dsg IgG4 correlated better with clinical disease activity than anti-Dsg IgG1, 
suggesting the IgG4 antibodies have a more critical role in mediating disease (247).  
Structurally and functionally, the IgG4 subclass is unusual for several reasons. 
IgG4 appears to arise in situations of chronic antigen stimulation, including in 
beekeepers (248), chronic helminth infection (249)(250), and patients undergoing 
allergen desensitization therapy (251). Because the constant region of IgG4 cannot fix 
complement, only weakly binds to Fc receptors, and cannot form immune complexes, 
IgG4 antibodies are believed to interfere with the binding of other antibody subclasses 
to prevent overreaction of the immune system to a particular antigen 
(252)(253)(254)(255). Also intriguing is the reciprocal relationship between IgG1 and 
IgG4 over the course of an immune response. In beekeepers, repeated stimulation by 
bee venom shifts the immune response to bee antigens from an IgG1 to an IgG4 
predominant state (256). In a form of pemphigus foliaceus endemic to Brazil (fogo 
selvagem), patients living in the endemic area in the preclinical stages have anti-Dsg1 
IgG1, while patients with active disease show an IgG4 predominance (257). Taken 
collectively, these observations suggest that anti-Dsg autoantibodies undergo a class-
switch from IgG1 to IgG4 during active disease, potentially acquiring mutations that 
cause epitope spreading or increase their affinity.  
 In addition to IgG1 and IgG4, the majority of PV patients have anti-Dsg IgA as 
well (243)(258)(259). Note that there exists a rare clinical entity called IgA pemphigus, 
which is characterized by a neutrophilic infiltrate and reactivity to desmocollins, but this 
is considered a separate disease (see Table 1-1) and is therefore not relevant to our 
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results. IgA is the subclass primary responsible for maintaining immunity on mucosal 
surfaces as a first line of defense and to maintain homeostasis with normal flora 
(260)(261). The mucosal immune system accomplishes this by using secretory IgA to 
continuously sample antigens from the surface of the mucosa and modifying its 
repertoire in response (262). There exist two IgA subclasses, IgA1 and IgA2; the former is 
more prominent in the serum, while the latter is more common in the GI and GU tracts 
(263)(264). Furthermore, because 25% of IgA secreting plasmablasts in the gut are 
polyreactive, the mucosal immune repertoire may be a harbor of autoreactivity (265). 
That fact, taken alongside the observation that PV often starts in the oral mucosa, led us 
to hypothesize that IgA (specifically, IgA1) may contain clones cross-reactive to Dsg3 
that eventually switch to IgG4 and cause disease.  
The coexistence of four different antibody subclasses, which normally have 
radically different functions in healthy subjects, all targeting 1-2 two autoantigens (Dsg1, 
Dsg3, or both) makes PV an ideal model disease for studying the role of class switching 
and antibody subclass in autoimmunity. An analysis of the lineage relationships between 
anti-Dsg IgG1, IgG4, IgA1, and IgA2 can be found in chapter 3 of this thesis. We now 
review a method of high-throughput B cell repertoire analysis using next-generation 






1.3 Methods and Challenges of Antibody Repertoire Sequencing 
1.3.1 Overview  
The advent of high-throughput DNA and RNA sequencing has drastically changed 
the way that genomes and transcriptomes are studied. By isolating all of the DNA or 
RNA from a tissue sample (or even a single cell), scientists can gain unprecedented 
insights into the genome or transcriptome at a much finer resolution than allowed by 
previous microarray-based or Sanger-sequencing based efforts. Further improvements 
to the technology, like ultra-deep sequencing and sequencing of targeted loci (266), has 
allowed for detecting rare resistant viral sub-populations in HIV patients (267), rare 
subclonal populations in cancer (268)(269), and previously unknown splice variants of 
well-characterized genes (270).  
High-throughput sequencing technology has also revolutionized the study of the 
B cell repertoire (46). For example, experiments sequencing bulk DNA or RNA from 
peripheral B cells have characterized the immune repertoire in healthy subjects 
(271)(272)(273), assayed changes in repertoire during aging (274), found convergent 
sequences across patients in infection (275), identified and lineage-traced broadly-
neutralizing antibodies to HIV (276)(277), and studied the vaccination response 
(278)(279)(280)(281)(282). Repertoire sequencing of autoimmune are not as common 
yet, but experiments have shown exchange of pathogenic B cells between the periphery 
and cerebrospinal fluid in multiple sclerosis (283)(284)(285), analyzed clonal expansions 
over time in Sjogren’s syndrome (286), and demonstrated polyclonal nature of lupus 
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flares (287). These studies have shed light on the fundamental mechanisms of 
autoimmunity and have the potential to guide the future development of therapy. 
The problems of sequencing the antibody repertoire are many-fold, and push the 
limits of high-throughput sequencing technology in many ways. The most trivial of these 
is the overall length of the VDJ locus; at ~450 bp, reliable sequencing of the entire 
variable region reaches the upper limit of current sequencing read lengths, and 
including an identifiable stub of the constant region (20-40 bp) and accessory barcode 
sequences pushes this limit even further. Full length VDJ sequencing with acceptable 
read numbers has been recently made possible in the last few years by Illumina’s MiSeq 
2x300 bp paired-end platform, which outputs up to 25 million reads (288). Previously, 
experiments have either sacrificed coverage using primers within the FWR2 (271) or 
FWR3 (289) region, or sacrificed depth by using 454 Life Science’s GS FLX Titanium 
platform, which touts read lengths up to 600-1000 bp but only obtains 106 reads per run 
(290)(291).  
Other issues in repertoire sequencing are largely due to the fact that repertoire 
sizes push the 1011 range. Each and every one of those 100 billion sequences may be 
important, in some broad sense, to any given antigen response. This has a few 
implications. First, detection and reliable annotation of rare sequences is vital, much like 
in ultra-deep sequencing; this is compounded by the fact that the B cell repertoire is 
spread amongst the entire blood, lymphatic system, and potentially other tissues, AND 
across several different B cell subtypes with differing functions. Furthermore, given the 
clonal evolution of the repertoire by SHM, the ability to distinguish closely-related 
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sequences from one another is critical to understanding the shape of a given antibody’s 
lineage; this is especially difficult because amplification and sequencing error can 
confound such efforts. Next, unlike the small handful of SNPs or mutations found in a 
typical human or viral genome (which allows relatively painless annotation of 
sequencing reads against a reference), the human VDJ locus contains a large number of 
closely-related V, D and J genes, with many allelic variants, which are then further 
mutated by SHM (sometimes on the order of 40 or greater mutations from germline 
(292)), making VDJ assignment much more difficult. This is particularly difficult for the D 
gene, which lies in the middle of the hypervariable CDR3 region. Next, assigning given 
antibody sequences to clonal lineages is confounded by the above problem of VDJ 
assignment, by sequencing and amplification error, and by the simple fact that 
sequencing only captures the current VDJ sequence of a given B cell, and will not be able 
interrogate its entire life story. Finally, the issue of assigning functional characteristics to 
a given antibody sequence is currently impossible computationally, requiring additional 
nontrivial experiments to be carried out alongside repertoire sequencing. Each of these 
challenges will be addressed in the subsequent sections. 
 
1.3.2  Sampling and Reproducibility 
 Humans have around 5 liters of blood, and a typical peripheral blood draw will 
capture only 0.1-1% of this. In addition, only 2% of the 1011 B cells in the average human 
are circulating at any given time, with the rest sequestered in bone marrow, spleen, 
lymph nodes, mucosal tissue, etc (46). Both of these facts make sampling the overall 
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repertoire challenging. Early experiments performed on Danio rerio managed to evade 
both of these constraints by simply snap-freezing, lysing, and extracting the RNA from 
entire fish, making all 3 x 105 B cells accessible to sequencing (293)(294).  Repertoire 
sequencing experiments on mice also manage to avoid these constraints, because in 
addition to having a thousand-fold smaller B cell repertoire than humans, the lymphoid 
tissue of mice is more easily obtained by surgery (295)(296).  
 Because of these technical, practical, and ethical constraints, repertoire analysis 
in humans will necessarily be limited by sample. These limits can be assessed using 
biological and technical replicates for estimating the overall depth of sampling (47,296). 
Data from biological replicates (e.g. multiple blood or tissue samples from the same 
subject) quantifies the amount of biological undersampling, while technical replicates 
(e.g. multiple PCR or sequencing experiments on the same biological sample) quantifies 
the sufficiency of sequencing depth. This kind of replicate data is particularly useful for 
capture-recapture analysis, in which the degree of overlap (either in terms of lineages or 
individual sequences) between two samples is used to estimate the amount of the total 
population captured; this is similar to the mark-and-recapture analysis used to estimate 
populations in ecology (291)(293)(297). A popular unbiased statistic used for this 
purpose is Chapman’s modification of the Lincoln-Petersen estimator, which uses the 
overlap between a pair of samples from a population to calculate the total population  
(297)(298).  
A key assumption of capture-recapture methods is that each individual member 
of the population is equally likely to be “caught” by sampling (299); this assumption is 
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usually untenable, since lineage sizes and sequence copy numbers within the repertoire 
are not uniform, at either the RNA or DNA level. In other words, a B cell clone with 
multiple copies is more likely to be “trap happy”, e.g. more likely to be sampled multiple 
times, artificially inflating the overlap between samples. Methods to decrease the 
effects of trap heterogeneity are the subject of ongoing research, though none have yet 
been applied to antibody repertoire sequencing (300)(301).  
Another ecology-inspired method, less subject to heterogeneity bias, is 
abundance-based rarefaction analysis, in which subsampling the reads from a given 
sample is used to create an accumulation curve (296)(302) . Some measure of diversity 
(e.g. number of unique sequences or lineages) in each subsample is plotted against the 
number of reads in the subsample, with the hope that the subsequent curve shows 
saturation as the number of subsampled reads approaches the actual number of reads. 
As the number of reads increases, the curves tend to quickly rise and plateau, as the 
common species (equivalent to large lineages) are quickly added to the curve, leaving 
only rare species (smaller lineages) to be found. 
Recently, this analysis has extended this kind of analysis to include extrapolation 
and nonparametric asymptotic estimation of diversity, allowing the construction of 
smooth rarefaction curves using both interpolation and extrapolation via the Chao 
method (303)(304). The nonparametric nature of this analysis means its results are not 
reliant on the distribution of species in the population, unlike the capture-recapture 
estimation outlined above. The mathematical details are outside the scope of this 
thesis, however a thought experiment is illustrative. Imagine a sample containing one 
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thousand different lineages, each of them with only one read (singletons). Compare that 
with a sample containing 25 different lineages, 20 of which have 100 or more reads and 
5 of which have a single read. It is easy to see why the second sample is closer to 
saturation than the first. If our sample predominantly consists of singletons, it suggests 
that collecting a larger sample will easily find new species. By contrast, if singletons are 
only a small proportion of the sample, further sampling will probably not find many new 
species. The Chao method takes the proportion of singletons, two-read species, etc up 
to 10-read species into account, using this to infer the number of unfound species for 
extrapolation. 
A drawback of the Chao method is that it is exquisitely sensitive to the presence 
of singleton lineages (i.e. lineages with only one sequencing read assigned to them); this 
is a particular concern because sequencing error often inflates the number of low-
frequency members in a sample (305)(306). Some non-statistical methods of removing 
erroneous sequences are discussed in the next section; however, for the purposes of 
diversity estimation, we can also statistically deflate the number of low-frequency 
counts according to some expected distribution. Sampling analysis in chapter 3 employs 
a method that uses Good-Turing frequency estimation (307)(308) to deflate the 
singleton count by generating an “expected” singleton count from the number of 
doubletons, tripletons, and quadrupletons (lineages containing 2, 3, and 4 reads, 
respectively), thus giving a more accurate estimation of diversity (309). However, it is 
worth noting that sequencing error inflates all low-frequency counts, including 
doubletons, tripletons, and quadrupletons, suggesting that even with statistical 
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correction we may be inflating our lineage counts slightly.  Future developments in the 
field, including better statistical methods and technical improvements in sequencing, 
will lead to more accurate estimation of diversity and coverage in high-throughput 
sequencing datasets. 
 The effects of tissue choice on sampling are less well-known, as studies of B cell 
repertoires from non-blood tissues in humans has just begun. One group has conducted 
a repertoire sequencing study using RNA samples from peripheral blood, bone marrow, 
small intestine, lung, stomach, lymph node, tonsil, spleen, and thymus, discovering that 
the mucosal repertoire was quite different than that of the peripheral blood and 
lymphoid tissues in terms of VDJ use, CDR3 length, and somatic mutation frequency 
(310). Another group has also conducted B cell repertoire sequencing from both blood 
and cerebrospinal fluid in patients with multiple sclerosis, showing extensive exchange 
of B cells between the two compartments (311).  
Because previous repertoire cloning studies in PV have used peripheral blood, 
managing to find several anti-Dsg clones (208), and because of the difficulty of sampling 
other compartments, the studies in chapter 3 are restricted to blood, and therefore may 
miss relevant B cell diversification events in the mucosa, spleen, or other 
compartments. It is entirely feasible, for example, that skin-draining lymph nodes in 
pemphigus contain distinct repertoire of anti-Dsg antibodies. Further studies comparing 





1.3.3 Error Correction 
 In any high-throughput sequencing experiment, there are two main sources of 
mutational error – from amplification, and from sequencing. The Illumina MiSeq 
platform used in this thesis is known to be prone to substitution error, especially in GC-
rich regions, on the order of 1-2 bases per 1000 nucleotides (312)(313). While this error 
rate may be sufficient for simple RNA-seq expression studies, it is unfortunately on the 
order of the mutation rate for SHM (which is approximately 1 in 1000 bp per cell 
division) (102). This is compounded by the fact that the mutation rate for the 
commonly-used Q5 Hi-Fidelity polymerase is around 1 in 10,000 bp (314).  
Computational and experimental methods of dealing with this error will be discussed in 
this section.  
A common method of eliminating PCR error in diverse sequence sets (e.g 
bacterial metagenomics studies) is full-length clustering using an algorithm like 
USEARCH, which sorts all sequences by their copy number, using the most abundant 
sequences as centroids to agglomerate less-abundant sequences within a certain 
number of mutations (315). USEARCH has been incorporated into the SONAR pipeline 
(316), and into our custom pipeline. A conceptually similar homology-based centroid 
clustering approach, called AbCorrect, has also been developed (317). More advanced 
clustering schemes incorporating multiple alignment to a VDJ reference and 
incorporating quality scores also exist (318)(319). 
Unfortunately, many clustering schemes cannot distinguish between a PCR-
induced error and a rare somatically mutated variant within the clustering radius. A 
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clever graph-theoretic approach developed as part of the IgRepertoireConstructor 
package attempts to address this problem (320). First, each unique sequence is assigned 
to a vertex, and all vertices within a certain mutational distance are connected by an 
edge. Putative “real” sequences correspond to well-connected components called 
corrupted cliques within the graph; unfortunately, finding corrupted cliques is a 
computationally difficult (NP-hard (321)) problem. Within each clique, edges connecting 
sequences that differ at an SHM hotspot are treated distinctly from other mutations, in 
order to separate out “real” antibodies within a larger cluster from PCR errors. This 
algorithm, while clever, is also rather slow, though improvements published in 2016 are 
touted to decrease runtime from days to minutes for a typical dataset (322). 
A widely-adopted experimental method to reduce error and the effects of 
amplification bias in transcriptomics is the incorporation of unique molecular identifiers 
(UMIs), short stretches of degenerate nucleotides, to cDNA during reverse transcription 
(323–325).  Because the UMI is incorporated before subsequent amplification, all 
mutated “descendants” of that molecule erroneously created by PCR and sequencing 
will inherit the same UMI. Thus, clustering all reads sharing a UMI can not only be used 
to eliminate mutations, it can also be used to smooth over PCR-induced amplification 
biases that prevent accurate quantitation. Several recently-developed experimental 
pipelines, including MAF (326) and MIGEC (327)(328), incorporate UMIs into antibody 




However, UMIs are not a panacea, and require appropriate experimental design 
for proper use. First, it is important to select a UMI scheme with sufficient diversity to 
uniquely tag every single mRNA molecule in a given sample (329)(330)(331). Insufficient 
UMI diversity will cluster together completely unrelated sequences, resulting in the 
elimination of the less-abundant one in the cluster. An easy method to increase UMI 
diversity is simply lengthening the UMI; however, this also makes the UMI more prone 
to mutations, which artificially increase the diversity of the sample (47)(332)(333). 
Methods of correcting mutations within the UMI include using histograms to find 
nearest neighbor distances between UMI variants and treating rarer variants as errors 
(334), and network-based methods (335). A final issue, which is especially noticeable 
when searching for rare variants, is the fact that the initial UMI tagging during reverse 
transcription may lack perfect efficiency; in some extreme cases, only 0.2% of the initial 
templates were successfully tagged (332)(333). No well-validated method for 
overcoming this bias has been implemented in antibody repertoire sequencing, though 
a recently-developed scheme in which single nucleic acid templates are encased in 
picoliter droplets and individually barcoded could theoretically eliminate competition 
between templates (336).  
 The use of UMIs has been widely adopted in repertoire sequencing, though 
some issues remain. Improved quantification and error correction comes at the 
potential of significantly decreased sequencing depth. Experiments in chapter 3 eschew 
the use of UMIs, partly because of our focus on deeply sampling the rare IgG4 subclass 
(necessitating high inputs of RNA), reliably separating the IgG4 subclass from the others 
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(necessitating an additional amplification step), and our desire to use phage display 
libraries for antigen-specific selection. For fine lineage analysis, we instead used 
USEARCH and a minimum read cutoff to filter out likely erroneous sequences, using a 
monoclonal amplicon subject to the same amplification steps to validate our method. 
 
1.3.4 VDJ Assignment and Lineage Analysis 
 Because the IgH variable locus is highly polymorphic and contains several similar 
families of sequences, the assignment of germline VDJ genes to a transcript is not trivial, 
even before taking SHM and the existence of N and P nucleotides into account. The 
original zebrafish repertoire sequencing experiment had a 99.6% V-gene assignment 
rate (293); with a more complex, mutated repertoire, this is bound to be worse. This is 
made even more difficult because several V gene alleles remain undiscovered (337). The 
simplest VDJ assignment algorithms are the alignment-based IgBlast (338) and IMGT-
HighVquest (339), which are well-established tools with high throughput and simple 
web interfaces. Some alignment algorithms are particularly focused on the CDR3 region 
and purport to improve D gene assignment; examples include Ab-origin (340), which has 
a tweaked scoring scheme, and Joinsolver (341,342), which used Monte Carlo 
simulations to do the same. More advanced algorithms based on Hidden Markov 
Models (HMMs) include the SODA2 (343) and iHMMuneAlign (344), both of which use a 
negative binomial distribution for transition states, and the more complex multi-HMM 




 VDJ assignment is particularly important for analyzing lineages of related 
antibodies arising from a single naïve B cell clone (sometimes called a “clonotype”). 
Many pipelines (e.g. Change-O (116) and ClonalRelate (346)) assign sequences to 
lineages by first partitioning by assigned V gene, J gene, and CDR3 length, then 
separating out related sequences using a CDR3 distance cutoff between members of the 
lineage based on statistics. Alternately, a shared somatic mutation cutoff along the 
entire variable region can be used instead of CDR3 distance after partitioning, for 
example only allowing variable regions that share five mutations from their calculated 
germline sequence to share a lineage (296)(347) . Either approach would naturally 
separate related sequences mis-assigned to different V or J genes; this is of particular 
concern in sets of highly mutated sequences, like HIV bnAbs. One method to overcome 
this is to use phylogenetics on a database of V and J genes to improve the initial 
assignment, such as in IgSCUEAL (348). An alternative method is to assign sequences to 
lineages without first assigning V and J genes. This can be done, for example, by directly 
calculating a pairwise distance matrix between sequences (349), though this can 
become computationally intensive for large number of sequences. 
 In chapter 3, novel approaches are employed to deal with both VDJ assignment 
errors and clonal assignment. After performing germline and CDR3 assignments using 
IMGT-HighVquest, all sequences in the dataset are binned by V gene, J gene, and CDR3 
length. However, in order to assign reads to lineages with more confidence, we chose to 
calculate the nearest-neighbor CDR3 nucleotide identity between different patients, 
rather than within the same patient, to set a per-patient cutoff. Because sequences 
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between patients should not be related, this can be used to bound the probability that 
any CDR3 similarity cutoff would erroneously cluster two unrelated sequences into a 
single lineage. The cutoffs for 99% confidence under this framework varied between 
80.6% and 86.1%, quite similar to previously used values based on within-patient 
analysis. Secondly, to mitigate the effects of V- and J-gene mis-assignment and 
sequencing error, all clusters were subsequently sorted into superclusters solely based 
on CDR3 similarity, using the same per-patient cutoffs. Within each supercluster, 
clusters were ranked by read count, then only the top-ranked clusters within each 
supercluster were used for subclass connectivity analysis and lineage analysis through 
phylogenetic trees. This eliminated only ~10% of the total reads in each sample, but also 
eliminated anywhere from one-half to five-sixths of all clusters, significantly 
ameliorating the effects of sequencing error and germline mis-assignment on the 
construction of lineages. 
 Once sequences have been sorted into lineages, the next task is to draw a 
lineage tree using those sequences, which can offer insight into the temporal structure 
and evolution of the antibody response. Many tools from evolutionary biology can be 
adapted for this purpose, including maximum parsimony and maximum likelihood 
algorithms (350). Briefly, a maximum parsimony algorithm considers a set of sequences, 
and arranges them in a tree to minimize the total number of mutations (351), while a 
maximum likelihood method takes different site-specific mutation rates into account 
when drawing the tree, creating the most likely tree based on a calculated prior 
probability distribution (352). Both of these methods have been applied to antibody 
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sequences (116)(284)(353). Work in this field is ongoing, with more research needed to 
validate these methods and compare them against each other in immunological 
sequence datasets (47). 
In order to ensure the robustness of our conclusions, we used both maximum 
parsimony (through ChangeO and PHYLIP’s dnapars program) and maximum likelihood 
(through PASTA) algorithms to analyze anti-Dsg lineages containing both IgG1 and IgG4 
sequences. Both methods generated trees with similar topologies, suggesting our 
conclusions were robust to the phylogenetic method selected. Additionally, ChangeO’s 
particular implementation of maximum parsimony also calculates the sequence of 
inferred ancestors in the tree. This was particularly useful for determining the sequence 
of the most recent common ancestor (MRCA) in each lineage; these could then be 
synthesized (along with several other sequences in each tree) and tested by ELISA in 
order to trace the onset and development of anti-Dsg reactivity. 
 
1.3.5  Conclusion 
It is clear that high-throughput sequencing can offer many insights into the antibody 
repertoire. In particular, the ability to infer lineage relationships within the antibody 
repertoire is intriguing, and is particularly relevant to the task of tracing the lineage of 
anti-Dsg B cells belonging to different antibody subclasses. By sequencing subclass-
specific amplicons and sorting them into cross-subclass lineages, one can map the global 
relationship between IgA1, IgA2, IgG1, and IgG4. Furthermore, by combining this data 
with phage display as a means to isolate Dsg-specific heavy chains, we have the ability 
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to not only determine which sequences within the repertoire are autoreactive, but how 
they arose and how they relate to each other across antibody subclasses. The results of 
this repertoire sequencing study can be found in chapter 3.  
 
1.4  Experimental Approach 
1.4.1  Rationale 
The focus of this thesis is to analyze the role of antibody subclass in the 
pathogenesis of PV. Because previous studies have shown that variable regions alone, 
either in Fab or single-chain variable fragment (scFv) form, are sufficient to cause 
blistering in model systems, there are broadly speaking two ways in which the subclass 
of an anti-Dsg antibody could be relevant to its role in pathogenesis. First, the subclass 
could be directly involved in the binding activity of the antibody, by altering the binding 
properties of the variable region. For example, a given anti-Dsg variable region could 
have different binding affinity when attached to either IgG1 or IgG4, due solely to 
structural differences in the constant region. The influence of the constant region on 
antibody affinity and pathogenicity is the subject of experiments found in chapter 2.  
Alternatively, the subclass of an antibody could simply reflect the developmental 
history of the B cell synthesizing it. In other words, the structure or effector function of 
the heavy chain constant region that determines subclass may itself not be particularly 
important, but mapping the pathway leading autoreactive antibodies to occupy a 
particular antibody subclass may shed light on the processes involved in PV 
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pathogenesis. We can infer these pathways by analyzing clonal overlaps between anti-
Dsg variable regions of different subclasses, tracing the lineages of autoreactive B cells 
as they switch from one subclass to another. In this way, analyzing subclass-specific B 
cell repertoires in PV will shed light on the mechanisms leading to the development of 
anti-Dsg antibodies across subclasses, and elucidate the contribution of class-switching 
to the pathogenesis of PV and antibody-mediated autoimmunity in general. 
Experiments tracing subclass-specific B cell lineages in a panel of PV patients are found 
in chapter 3. 
 
1.4.2  Chapter 2 
Experiments conducted in chapter 2 of this thesis analyze the possibility that 
epitope characteristics and of anti-Dsg antibodies are affected by subclass. While the 
variable region of an antibody is thought to be responsible for most of its binding 
properties, some studies have shown a role for the constant region in modulating 
reactivity (354). The anti-HIV bNAb 2F5 shows increased affinity and the ability to bind a 
new epitope when expressed as IgA2 than as IgG1 (355).  Another group found that the 
catalytic DNA cleavage activity (356) and renal pathogenicity (357)(358) of the murine 
anti-nuclear antibody PL9-11 is influenced by its isotype. These findings raise the 
possibility that anti-Dsg3 IgG1 and IgG4 antibodies are closely related, and that class-
switching from IgG1 to IgG4 is all that’s needed to cause the same variable region to 
become pathogenic.  
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In chapter 2, we clone three anti-Dsg antibody variable regions previously 
isolated from PV patients onto IgG1 and IgG4 backbones. Then, we compare them 
pairwise for epitope preferences, ELISA and IIF titer, blistering ability on skin explants, 
and ability to internalize Dsg on the surface of keratinocytes. By cloning the same 
variable regions onto two different constant regions, we show that an antibody’s 
affinity, pathogenicity, and ability to trigger Dsg internalization of an antibody is not 
significantly modulated by whether it expresses an IgG1 or IgG4 constant region.  
 
1.4.3  Chapter 3 
Experiments conducted in chapter 3 trace anti-Dsg B cells across the IgG1, IgG4, 
IgA1, and IgA2 subclasses in the peripheral B cell repertoire of a panel of four PV 
patients. These experiments are conducted using RNA from peripheral blood 
mononuclear cells (PBMC) isolated from 50 mL of peripheral blood from each patient. 
This quantity of blood represents approximately 1% of the peripheral repertoire (given 
that humans harbor approximately 5L of blood) and 0.02% of the total B cell repertoire 
(given that 2% of the B cell repertoire is in the periphery (46)). The RNA is used to 
generate subclass-specific amplicons using a 3’ primer binding to the hinge of the 
constant region and 5’ primers binding to the beginning of FWR1 on the variable region. 
These amplicons are then used to create sequencing libraries for the Illumina MiSeq 
2x300 bp paired-end sequencing protocol, and to create subclass-specific phage display 
libraries, which are subsequently panned against both Dsg1 and Dsg3 in order to isolate 
Dsg-reactive antibodies from each patient-subclass pair. Anti-Dsg clones isolated by 
43 
 
panning were subject to both ELISA and indirect immunofluorescence to confirm 
binding to desmoglein and recapitulation of the PV cell-surface binding phenotype, 
respectively. 
Antibody phage display is a method of isolating antigen-specific antibodies by 
cloning heavy and light chains into a phagemid vector, which allows the antibody to be 
expressed as either a scFv or Fab on the surface of filamentous bacteriophage. A library 
of phage can then be subject to several rounds of selection and amplification against an 
immobilized antigen, isolating clones reactive to the antigen of interest (359). The 
technique is particularly useful to this study because it has the power to screen up to 
109 different transformants in a single library, giving much higher throughput than single 
B cell cloning or heterohybridoma methods and conferring the power to find and 
characterize both rare and common clones. Phage display has been used to clone 
autoantibodies in acquired thrombotic thrombocytopenia purpura (360), idiopathic 
thrombocytopenia purpura (361), pemphigus foliaceus (362), and systemic lupus 
erythematosus (363)(364).  
Previous phage display experiments in PV, in which all IgG subclasses were 
cloned into single libraries (making IgG1 and IgG4 indistinguishable), have been used to 
show that VH gene usage in anti-Dsg3 antibodies is highly restricted (208,365–367). 
Another set of phage-display derived pathogenic antibodies demonstrated a D/E-X-X-X-
W motif in the heavy chain CDR3, suggesting that shared heavy chain sequence 
characteristics may be used to distinguish and target autoantibodies (209,368). Because 
of this restriction, and because of the fact that heavy chains are more diverse, are more 
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important for antigen binding, and generate traceable lineages, most of our analyses 
focus on heavy chain repertoires in PV. 
However, it is worth noting a key drawback of phage display is the random 
pairing of heavy and light chains in the library, since each is amplified separately from 
total RNA and PCR-overlapped into a single insert. Because of this, information about 
the actual heavy-light pairing is lost during cloning, creating the possibility that either a 
reactive heavy chain does not find a suitable light chain to pair with, or that a non-
reactive heavy chain pairs with a light chain that makes it reactive. There are a few 
reasons to suggest that this is less of a problem than it initially appears. As would be 
suggested from its diversity, the heavy chain CDR3 has been experimentally 
demonstrated to be the main determinant of antibody specificity, with the light chain 
being less important. In one study, surface plasmon resonance assays showed that the 
heavy chain of an anti-thyroglobulin antibody recognizes its epitope in the complete 
absence of a light chain, showing the primacy of heavy chain interactions for binding 
(369). The primacy of the heavy chain was also shown by another group creating phage 
display libraries from a pool of several heavy chains with synthetic CDR3 regions and a 
single invariant light chain, and demonstrating that they harbor clones reactive against 
several haptens and protein antigens (370)(371). Another group showed that transgenic 
mice expressing a single heavy chain V gene, but the full complement of D and J genes, 
developed high-affinity antibodies in response to several different injected antigens, 
despite restricted combinatorial diversity, showing that the combinatorial and junctional 
diversity within the heavy chain CDR3 was sufficient to generate such responses (372). 
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By tracing the B cell repertoire across multiple subclasses, we were able to 
determine that the IgG4 anti-Dsg lineages tended to be solitary, containing only IgG4 
clones. Furthermore, when IgG1 and IgG4 shared a lineage, they often diverged from a 
common ancestor early, rather than showing a direct switch between IgG1 and IgG4. 
This is in contrast to IgA1 and IgA2, which commonly showed IgA1 to IgA2 direct-switch 
relationships. We also found that IgA subclasses tended to switch directly from IgG 
subclasses, rather than the other way around, suggesting that IgA may serve as a 
disease-modifying factor in PV, rather than serving as a source of anti-Dsg IgG clones. 





















Figure 1-1. Diagram of VDJ Recombination at the Human Heavy Chain Locus. A D and J 
segment are randomly selected then joined together by RAG1/2, with nucleotides at the 
junction (in red) added by TdT or removed by exonuclease chewback. A similar process then 
occurs with a randomly selected V and the already-joined DJ segment, creating the final VDJ 










Figure 1-2. Diagram of VJ Recombination at the Human (A) Kappa and (B) Lambda Locus. A V 
and J segment are randomly selected then joined together by RAG1/2, with nucleotides at the 
junction (in red) added by TdT or removed by exonuclease chewback. In the Kappa locus, there’s 
a single constant region exon on the 3’ end of the locus, while in the Lambda locus, there’s a 





Figure 1-3. CDRs and FWRs are Interspersed among the V, D and J Genes of the Variable Heavy 
Chain. In particular, the V gene contributes to both the CDR1 and CDR2, but all three genes 
contribute to the CDR3. Red indicates junctional nucleotides added during VDJ recombination 
















Figure 1-4. Clonality Plot. 2000 sequences obtained by deep sequencing from PV8 were 
randomly selected. After binning sequencing by V, J and CDR3 length, the nearest-neighbor 
hamming distance between CDR3s are measured, in order to separate clonally related 
sequences from unrelated sequences. The red arrow indicates the minimum in the histogram, 
which would be used to set a CDR3 similarity cutoff for clonality. Distance = (Hamming distance, 











Figure 1-5. Diagram of Human IgH Constant Region Locus. Each exon encodes a different heavy 
chain constant region, as indicated. Circles immediately adjacent to each exon represents switch 
regions, which serve as substrates for AID to initiate class switching. Note that class switching 
occurs from left to right, so for example, an IgM to IgG4 switch is possible, but not vice versa, as 
the intervening DNA is excised. Note that as displayed, there is no switch region in front of IgD, 
consistent with its co-expression with IgM. However, a small proportion of B cells do switch to 
expressing solely IgD, made possible due to the presence of a rudimentary switch region 
between IgM and IgD (121,373). 
 
Adapted from: Figure 4a of  
Berkowska MA, Driessen GJA, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et 
al. Human memory B cells originate from three distinct germinal center-dependent and -














Swapping the Constant Region in Pathogenic IgG1 and IgG4 Autoantibodies in Pemphigus 
Vulgaris Does Not Alter Blister-Inducing Ability or Epitope Preference 
 
2.1 Abstract 
Pemphigus vulgaris (PV) is characterized by IgG1 and IgG4 autoantibodies to desmoglein 
3 (Dsg3), causing suprabasal blistering of skin and mucous membranes. Both IgG1 and IgG4 
appear during active disease, whereas IgG1 can be associated with remittent disease; this 
partially reciprocal relationship, and the relative positions of heavy chain constant region loci, 
suggests the possibility that IgG1 clones switch to IgG4 clones over the course of disease. To 
investigate the possible role of the IgG constant region on modulating blister-inducing ability 
and binding properties in anti-Dsg3 autoantibodies, we tested whether three pathogenic PV 
mAbs from three different patients demonstrate differences in antigen affinity, epitope 
specificity, or blister-inducing ability in model systems when expressed as IgG1 or IgG4. F706 
anti-Dsg3 IgG4 and F779 anti-Dsg3 IgG1, previously isolated as heterohybridomas, and Px43, a 
monovalent cross-reactive anti-Dsg3/Dsg1 IgG antibody isolated by phage display, were 
subcloned to obtain paired sets of IgG1 and IgG4 mAbs. Using ELISA and cell surface staining 
assays, F706 and F779 demonstrated similar antigen binding affinities of IgG1 and IgG4. Px43 
showed 3 to 8-fold higher affinity of IgG4 versus IgG1 by ELISA, but identical binding affinities to 
human skin, perhaps due to targeting of a quaternary epitope best displayed in tissues.  All 3 
monoclonal antibody (mAb) pairs targeted the same extracellular cadherin domain on Dsg3, 
caused Dsg3 internalization in primary human keratinocytes, and caused suprabasal blisters in 
human skin at comparable doses. This work suggests that switching the IgG1 and IgG4 




2.2    Introduction 
 Pemphigus vulgaris is a potentially life threatening autoimmune blistering disease 
caused by IgG autoantibodies against Dsg3 +/- Dsg1, desmosomal adhesion proteins of 
keratinocytes (374). In mucosal PV, autoantibodies react against Dsg3, which is the major Dsg 
isoform expressed in basal keratinocytes of the mucosa, leading to suprabasal blistering. In 
mucocutaneous PV, autoantibodies target both Dsg3 and Dsg1, causing suprabasal blisters in 
both mucosa and skin. Antibody cloning studies from PV patients have shown that a single mAb 
can bind Dsg3 only, or both Dsg3 and Dsg1 (375)(208)(376). Epitope mapping studies indicate 
that autoantibodies from pemphigus patients with active disease bind near the N-terminus of 
Dsg3, where residues important for cis- and trans-adhesive interactions reside (225,376).  
 Although monovalent anti-Dsg antibody variable region fragments are sufficient to 
cause skin blisters in the absence of the constant region (377), preferential use of IgG subclasses 
has been identified in pemphigus patients. In active disease, anti-Dsg3 IgG4 autoantibodies are 
predominantly found in PV sera, followed by IgG1, and occasionally IgG2 and IgG3 (243). In 
contrast, patients in remission and sometimes healthy relatives of PV patients can demonstrate 
anti-Dsg3 IgG1 (245,378). These early studies in the field suggested that IgG4 antibodies could 
induce blisters but IgG1 antibodies could not.  Subsequently, heterohybridomas produced from 
PV patients have shown that pathogenic anti-Dsg3 mAb can derive from either the IgG1 or IgG4 
subclass (367,375,376). 
While it is clear that IgG4 is associated with active disease in PV, it is unknown whether 
the same variable region of a pathogenic IgG4 mAb, expressed on an IgG1 constant region, 
directly affects antibody function, through altering antibody affinity, epitope binding 
characteristics, Dsg3 internalization, or blister-inducing ability. In the study presented here, we 
selected three representative pathogenic PV mAbs cloned from 3 different PV patients: F706, an 
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anti-Dsg3 IgG4 isolated by heterohybridoma, F779, an anti-Dsg3 IgG1 isolated by 
heterohybridoma, and Px43, an anti-Dsg3/Dsg1 monovalent IgG antibody of unknown subclass 
isolated by phage display, and generated pairs of recombinant IgG1 and IgG4 antibodies 
expressing identical variable regions. To determine whether the constant region modulates 
affinity, epitope specificity, or pathogenic properties of anti-Dsg variable regions, we compare 
these antibodies pairwise by ELISA titer, IIF titer, pathogenicity in skin explants, and Dsg 
internalization ability. 
 
2.3  Materials and Methods 
2.3.1 Human Anti-Dsg3 mAb Cloning 
The three patients from whom the antibodies were cloned had active, extensive PV 
involving both mucosa and skin. The diagnosis of PV was confirmed by histology and 
immunofluorescence. All patients were untreated at the time of blood draw. F706 IgG4 and 
F779 IgG1 were isolated from two different patients by heterohybridoma as described 
(367,379). Px43 was isolated from a third PV patient by phage display (208). 
 
2.3.2 Recombinant mAb Subcloning, Expression, and Purification 
Primers were designed to amplify the F706 and F779 heavy chain (HC) and light chain 
(LC) variable domains for subcloning into the pHC or pLC vector (380,381). Primers are designed 
to bind to the 5’ UTR (leader) and the 3’ end of the JH-gene, while light chain primers bind to the 
5’ UTR (leader) and the constant region. Primer sequences were as follows (restriction sites 
underlined): 
5’ F706HC NheI: TCTAGCTAGCCGCCACCATGGACTGGACCTGGAGGGTCTT 
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3’ F706HC HindIII: TAGGGCAAGCTTGCTGAGGAGACGGTGACCAGG 
5’ F706LC NheI: TCTAGCTAGCCGCCACCATGAGGCTCCTTGCTCAGCT 
3’ F706LC NotI: TAGGGCGCGGCCGCAGTTCGTTTGATTTCCACCTT 
5’ F779HC NheI: TCTAGCTAGCCGCCACCATGGACTGGACCTGGAGGGTCTT 
3’ F779HC HindIII: TAGGGCAAGCTTGCTGAGGAGACGGTGACCAGG 
5’ F779LC NheI: TCTAGCTAGCCGCCACCATGAGGCTCCTTGCTCAGCT 
3’ F779LC NotI: TAGGGCGCGGCCGCAGTTCGTTTGATCTCCAGCTT 
  
Recombinant DNA plasmids encoding cognate heavy and light chains were co-
transfected into CHO-K1 cell lines using Lipofectamine 2000 (Invitrogen, Grand Island, NY), with 
IgG1 and IgG4 heavy chains cloned into separate lines. Transfectants were cloned by limiting 
dilution in selective media (RPMI containing 10% fetal bovine serum, 10µg/mL puromycin, 
800µg/mL G418) to establish permanent cell lines. The antibody supernatant was collected and 
purified by affinity chromatography on a Sepharose protein G column with acid glycine elution. 
F71 IgG1 mAb (targeting an unknown antigen) and anti-HIV b12 IgG4 mAb were used as isotype 
antibody controls for some in vitro experiments.  
Px43 IgG1 and IgG4 were cloned as previously described (368)(382). Briefly, heavy and 
light chains were individually amplified from Px43 scFv in the pComb3X vector, then cloned into 
the PIGG vector (383). The heavy chain was amplified to introduce a SacI cloning site on the 5’ 
end and an ApaI cloning site on the 3’ end (the endogenous ApaI site in the CH region of IgG). 
After PCR purification using the Qiaquick PCR purification kit (Qiagen, Valencia, CA), digestion 
using SacI and ApaI (New England BioLabs, Ipswitch, MA) and gel purification using the Qiaquick 
gel extraction kit (Qiagen), the heavy chain fragment was subcloned into the SacI-ApaI site on 
the PIGG vector. The light chain was amplified from the same template, using a 5’ primer that 
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abolishes the SacI site and introduces a HindIII site, and a 3’ primer that binds to the 3’ end of 
the J gene. The light chain constant region was amplified from a separate Fab-expressing vector, 
then the light chain variable and constant regions were joined by overlap PCR. The overlap PCR 
reaction was PCR purified, digested with HindIII and XbaI (New England BioLabs), and gel 
purified (Qiagen) before being subcloned into the HindIII-XbaI site of the PIGG vector. A 
complete set of primers is available in (368).  
 Px43 IgG1 and IgG4 were expressed and purified as previously described(368). Briefly, 
endotoxin-free plasmid maxipreps (Qiagen) were transfected into five 10cm culture dishes of 
HEK293T cells at approximately 70% cell density and DMEM plus 10% ultralow IgG fetal bovine 
serum (Gibco/Life Technologies, division of ThermoFisher Scientific, Waltham, MA) using jetPEI 
reagent (Polyplus-Transfection SA, Illkirch, France) according to manufacturers instructions. 
Antibody was harvested on Day 3 and Day 6 from culture supernatant, by centrifuging non-
adherent cells then neutralization of media by 1/100 volume 1M Tris pH 7.5. Antibody was 
purified using Protein A agarose (ThermoFisher Scientific). After 2 hours of rotation at room 
temperature, agarose was transferred to disposable chromatography columns, washed with 20 
column volumes of PBS, eluted with 6 column volumes of 100 mM glycine pH 3, then neutralized 
with 1/10 volume Tris pH 7.5. Concentration was determined by non-reducing SDS-PAGE 
followed by Coomassie Blue staining, using an IgG standard.  
 
2.3.3 Epitope Mapping 
All epitope mapping vectors were generously provided by Masayuki Amagai. For epitope 
mapping, extracellular full length and domain-swapped Dsg1/Dsg3 or Dsg2/Dsg3 molecules 
were produced in the baculovirus-Sf9 system as previously described (226,384). For each 
experiment, culture supernatants containing domain-swapped constructs were incubated with 
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antibody followed by precipitation using protein A or protein G agarose. After boiling in Laemmli 
sample buffer, beads are run on SDS-PAGE gel, then transferred to polyvinylidene difluoride 
(PVDF) membrane. Immunoblotting was conducted using alkaline phosphatase-conjugated goat 
antihuman IgG (Zymed Laborators, San Francisco, CA) for the Dsg1/Dsg3 swapped molecules 
(because their C-terminus consists of the IgG1 constant region) or anti-E HRP (ab19400, Abcam, 
Cambridge, MA) for the Dsg2/Dsg3 swapped molecules (because they express a C-terminal E-
tag) 
 
2.3.4 Antibody ELISA 
Dsg1 or Dsg3 ELISA (MBL International, Woburn, MA or Euroimmun, Luebeck, Germany) 
was used to measure relative binding affinities of IgG subclasses. Serial dilutions of IgG1 and 
IgG4 antibodies were incubated with Dsg1 or Dsg3 coated plates for 1 hour at room 
temperature using kit sample buffer or TBS buffer containing 1mM CaCl2 and 5% dry milk. After 
washing, bound antibody was detected using HRP-conjugated mouse monoclonal anti-human 
IgG F(ab')2 (MBL International, Woburn, MA) or mouse monoclonal anti-human lambda (clone 
JDC-12, Abcam). After 1 hour incubation at room temperature, plates were washed, developed 
with 3,3’,5,5’ tetramethylbenzidine substrate, and optical density determined at 450 or 490 nm 
using an automated plate reader.   
 Relative affinity was determined using regression analysis of double-reciprocal plots of 






2.3.5 Direct and Indirect Immunofluorescence 
Direct immunofluorescence (DIF) was performed on frozen human skin sections after 
mAb injection (see methods subsection on the human skin blistering assay – the same sample 
was split after injection for DIF and H&E). Bound antibody in human skin was detected with 
Alexa Fluor 594 anti-human IgG (Invitrogen, Grand Island, NY) in TBS buffer containing 1mM 
CaCl2 and 1% BSA and visualized using an Olympus BX61 microscope. 
 Indirect immunofluorescence (IIF) was performed by incubating serial dilutions of mAb 
on frozen normal human skin sections (obtained through the Penn Skin Disease Research 
Center) in TBS buffer containing 1mM CaCl2 and 1% BSA. Bound antibody was subsequently 
detected with FITC-conjugated anti-human lambda light chain (clone JDC-12, Abcam) and 
visualized using an Olympus BX61 microscope. The titer is reported as the last dilution at which 
epidermal cell surface staining is clearly positive.  
 
2.3.6 Immunoreactivity Using Live Cell Staining ELISA  
Human oropharynx epithelial tumor cell line, UM-SCC-47 (SCC-47), was obtained from 
Dr. Thomas Carey, University of Michigan. Cell line was grown in 10% FBS-DMEM medium 
containing 10% heat inactivated FBS, 2mM L-glutamine, 0.1 mM sodium pyruvate, 0.1 mM non-
essential amino acids, and 10 µg/ml gentamicin. A live cell based ELISA was employed using SCC-
47 cells seeded in a 96-well flat bottom plate for two days. Serial dilutions of PV IgG1 and IgG4 
mAbs and isotype control antibodies were added to the cells for one hour. After washing, bound 
antibody was detected using biotin-conjugated goat anti-kappa chain antibody (1:5000) 
(Southern Biotech, Birmingham, AL) for one hour. The plate was washed and HRP-conjugated 
streptavidin (1:10,000) (SouthernBiotech) was added and incubated for 45 minutes. After a final 
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wash, o-phenylenediamine (OPD) substrate (Sigma, St. Louis, MO) was added, and the plate was 
incubated for 20 min and read at 490nm. 
 
2.3.7 Human Skin Blistering Assay 
All experiments using primary human skin samples were obtained using procedures 
approved by the Institutional Review Board. Fresh normal human skin specimens (otherwise 
discarded from excisional skin surgery) were obtained from the Penn Skin Disease Research 
Center. Skin was trimmed of fat and cut into 5 mm sections. 25-50 µg of purified isotype mAb, 
with or without 100 ng of Staphylococcus aureus exfoliative toxin A (ETA, Toxin Technology, Inc., 
Sarasota, FL) to inactivate Dsg1, was injected into skin sections, followed by incubation of skin 
pieces on transwell inserts (Corning, Lowell, MA), with defined keratinocyte serum free media 
(Invitrogen, Grand Island, NY) containing 1.2 mM CaCl2 in the outer compartment. Skin was 
harvested at 16-24 hours for direct immunofluorescence (see methods subsection on 
immunofluorescence) by embedding in OCT compound (TissueTek, Sakura, Netherlands) and for 
histology by fixation in 10% phosphate buffered formalin.  
 Primary human epidermal keratinocytes (PHEK) obtained from the Penn Skin Disease 
Research Center were treated with 50 µg/ml anti-Dsg3 mAbs for the indicated amount of time 
during calcium-induced (0.07 mM shift to 1.2 mM calcium) desmosome assembly as described 
(221). At 8 hours, cells were double-labeled with Alexa Fluor 594 anti-human IgG and mouse 
anti-human Dsg3 (5G11) followed by Alexa Fluor 488 anti-mouse IgG, and nuclei were counter-





2.4  Results 
2.4.1  IgG1 and IgG4 Variants of Pathogenic PV mAbs Recognize the Same 
Antigenic Epitopes 
Because the hinge region of IgG1 differs from IgG4, creating differences in the 
orientation of the variable regions (253), Dsg3 affinity, epitope specificity, or blister-inducing 
ability could be affected by the presence of the IgG1 versus IgG4 Fc.  To explore this further, 
IgG1 and IgG4 variants of pathogenic PV mAbs, bearing the identical variable region, were 
generated. 
 To determine whether the IgG1 or IgG4 constant region affects epitope specificity, we 
first tested F706 and F779 IgG1 and IgG4 mAbs against recombinant purified Dsg1 and Dsg3 
antigens. ELISA showed that F706 and F779 IgG1 and IgG4 mAbs specifically bound to Dsg3 but 
not Dsg1 (Figure 2-1A), indicating that the switch of constant region from IgG1 to IgG4 or from 
IgG4 to IgG1 in these pathogenic antibodies did not affect Dsg isoform specificity. To further 
define the epitope specificities, we performed conformational epitope mapping of IgG1 and 
IgG4 mAbs using Dsg3 domain-swapped chimeric molecules. F706 and F779, both IgG1 and IgG4, 
mapped to the first 161 amino acids of Dsg3 (Figure 2-1B).  Similarly, Px43 IgG1 and IgG4 
mapped to the same epitope within the first 101 amino acids of Dsg3. Thus, class-switched IgG1 
and IgG4 variants do not change the variable region epitope specificity. 
 
2.4.2 PV IgG1 versus IgG4 mAbs Demonstrate Similar Antigen Affinities 
To determine whether IgG1 or IgG4 constant regions affect antigen affinity, we 
evaluated IgG1 and IgG4 variants of pathogenic PV mAbs by ELISA and keratinocyte cell surface 
staining.  IgG1 and IgG4 variants of F706 and F779 show a similar level of binding to Dsg3 by 
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ELISA (Figure 2-2A). The apparent affinity of F706 IgG1 and IgG4 mAbs for Dsg3 is 0.10 µM and 
0.067 µM, respectively, and 0.015 µM or 0.021 µM for F779 IgG1 or IgG4, respectively. 
Consistent with these data, binding isotherms of F706 and F779 IgG1 and IgG4 mAbs to Dsg3+ 
human oropharynx keratinocyte tumor cells by immunolabeling are similar (Figure 2-2B). Px43 
IgG1 demonstrates 8-fold and 3-fold lower affinity for Dsg3 and Dsg1 than Px43 IgG4 by ELISA 
(Figure 2-2A); however their human skin IIF titers are identical at 0.5 ng/µL (Figure 2-2C).  
 
2.4.3 PV mAb IgG1 Versus IgG4 Demonstrate Comparable Blister Forming 
Ability in Human Skin Explants 
We next investigated the blister-inducing ability of IgG1 and IgG4 recombinant mAbs, to 
determine whether IgG subclass could play a role in modulating the pathogenic effects of Dsg3-
reactive variable regions. In skin, Dsg1 can provide compensatory adhesion if Dsg3 is inactivated 
(235,385). Consequently, human skin assays to determine blister-inducing ability of anti-Dsg3 
mAbs require inactivation of Dsg1, for example by co-injection of Staphylococcal exfoliative 
toxin A (ETA), which specifically cleaves Dsg1 (386).  We injected 25-50 µg of anti-Dsg3 IgG1 or 
IgG4 mAbs, plus or minus ETA as required, into human skin sections, followed by incubation for 
16-24 hours prior to harvest for immunofluorescence and histology. F706, F779, and Px43 all 
caused suprabasal blisters at comparable doses of IgG1 and IgG4 (Figure 2-3A). A similar extent 
of blistering was observed at both 25 µg and 50 µg doses (Figure 2-3B). Direct 
immunofluorescence of injected skin sections showed comparable binding of PV IgG to the cell 
surface of keratinocytes (Figure 2-3C).   
 Previously, pathogenic but not non-pathogenic human PV mAbs were shown to cause 
Dsg3 internalization in primary human keratinocytes (221). Consistent with these studies, 
primary human keratinocytes treated with F706, F779, or Px43 IgG1 and IgG4 exhibited 
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depletion of cell surface Dsg3 within 4 hours after antibody treatment, concomitant with an 
increase in cytoplasmic vesicular staining of Dsg3 (Figure 2-4). Thus, IgG1 and IgG4 variants of 
F706, F779, and Px43 comparably induce loss of cell surface Dsg3 in primary human epidermal 
keratinocytes and suprabasal blisters in human skin.  
 
2.5 Discussion 
 This study demonstrates that epitope specificity, antigen affinity, and blister-inducing 
ability of PV mAbs are not directly affected by the presence of the IgG1 versus IgG4 constant 
region.  Although our conclusions are limited by the study of only three mAbs, these mAbs were 
cloned from 3 different patients and represent three distinct types of pathogenic PV mAbs that 
have been described in the literature, including anti-Dsg3 IgG1, anti-Dsg3 IgG4, and a cross-
reactive anti-Dsg3/Dsg1 IgG.  
 All PV mAbs tested in this study bind the Dsg3 extracellular cadherin (EC) 1-2 domains 
that are crucial for cis- and trans-adhesive interactions of the Dsgs. This result agrees with a 
previous large scale mapping study of PV sera in which 91% of PV sera mapped to the Dsg3 EC1 
domain (226).  
 Although F706, F779, and Px43 all demonstrated comparable antigen affinity of IgG1 
and IgG4 variants by ELISA and/or IIF staining, Px43 IgG1 and IgG4 were notable for 
demonstrating differing results by ELISA and IIF. Px43 was previously shown to recognize only 
mature conformational Dsg3 (387) and by surface plasmon resonance binds Dsg3 with complex 
kinetics that best fit to a conformational change model (367). It is possible that Px43 binds a 
quaternary epitope in Dsg3 and Dsg1 that is predominant in native human skin but may be 
differentially displayed in ELISA, which may account for the difference in relative affinities 
observed between IgG1 and IgG4 variants. Nevertheless, these results indicate that the binding 
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affinity of Px43 variable regions to Dsg3 in human skin is not significantly altered by the 
presence of the IgG1 versus IgG4 constant region.  
 No change of blister-inducing ability among PV IgG1 and IgG4 mAb variants was 
observed, either in regard to Dsg3 internalization or the ability to cause suprabasal blisters in 
human skin. These data are consistent with the finding that the constant region is not required 
for blister formation in PV (377) or for Dsg3 internalization after monovalent PV mAb binding 
(221).  Our data now further indicate that the IgG1 versus IgG4 constant region does not 
modulate the functional effects of pathogenic PV mAbs in regard to either Dsg3 internalization 
or suprabasal blister induction.  
With no difference in pathogenicity, the question arises as to why IgG4 is preferentially 
associated with active disease. IgG4 is typically observed in conditions of chronic antigen 
stimulation, such as in individuals undergoing allergic desensitization or beekeepers (253). Class 
switch recombination is a complex process regulated by cytokines (388). IL-4 has a central role 
in stimulating antibody class switch (389). CD40 and IL-4 can initiate class switch by inducing 
enzymes and other transcripts required for site-specific DNA recombination. IgG1 is the most 
abundant serum IgG subclass, in part due to its proximal location within the constant region 
locus. Repeated antigenic exposure can encourage subsequent isotype switching. IL-4 and IL-13 
promote isotype switching first to IgG4 and subsequently to IgE (390), whereas IL-10 and IL-21 
potentiate IL-4-induced switching to IgG4 over IgE (391,392). Upregulation of the Th2 cytokines 
IL-4, IL-5, IL-10, and IL-13 has been described in pemphigus patients (393,394). These cytokines 
would promote an IgG4>IgG1 serum antibody profile, coinciding with the spectrum of observed 
autoantibody isotypes in patients with active disease. A deeper understanding of how 
pathogenic variable regions segregate among the IgG subclasses would require isotype-specific 
antibody cloning, as seen in chapter 3. 
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In summary, we have found that subclass-switching between IgG1 and IgG4 constant 
regions has no significant effect on epitope specificity, antigen binding affinity, or blister-
inducing ability in 3 human PV mAbs isolated from 3 different PV patients. Although limited by 
the study of only three antibodies, this study provides the first direct evidence that the 
immunochemical and pathogenic properties of PV pathogenic variable regions are not 
significantly modulated by antibody subclass, supporting the conclusion that the antibody 
variable region is most important for determining pathogenicity in PV. The possible ontogeny of 
the variable region in PV, and specifically the lineage relationships between anti-Dsg variable 
regions in PV, will be further investigated in chapter 3 of this thesis. 
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2.6  Figures and Tables 
 
Figure 2-1.  IgG1 and IgG4 PV mAbs target epitopes within the same Dsg3 extracellular 
domains. (A) F706 and F779 mAbs bind desmoglein 3 (Dsg3) but not Dsg1. Subclass-switched 
anti-human Dsg3 F706 and F779 IgG1 and IgG4 were tested by ELISA for binding to Dsg3 and 
Dsg1. Negative and positive controls were provided by the manufacturer. F71 IgG1 and b12 IgG4 
antibodies served as isotype controls. (B) Deduced epitopes of IgG1 and IgG4 variants of PV 
mAbs show that mAb pairs recognize epitopes within the same Dsg3 extracellular domains. 





Figure 2-2.  Immunoreactivity of anti-Dsg3 PV mAbs by ELISA and IIF. (A) Serial dilutions of 
recombinant human IgG1 (♦) or IgG4 (□) variants of mAbs (F706 against Dsg3 in upper left , 
F779 against Dsg3 in upper right, Px43 against Dsg3 in lower left and Px43 against Dsg1 in lower 
right) were incubated with Dsg3- coated ELISA plates. Bound antibody was detected using HRP 
conjugated mouse anti-human (H+L) Ab. Results are the mean of duplicate wells and are 
representative of 2-3 independent experiments. The relative affinity of each Ab was calculated 
by Lineweaver-Burk plot. (B) IgG1 and IgG4 variants of F706 and F779 mAbs show comparable 
immunoreactivity to the Dsg3+ human oropharynx tumor cell line SCC-47. F71 IgG1 and b12 
IgG4 served as isotype controls. Other negative controls included HRP substrate OPD added 
alone or with secondary reagents only (secondary (2nd) biotinylated anti-human Fc Ab (Biotin 
Ab) or 2nd Ab with HRP-conjugated streptavidin Ab (Bio + SA Abs) in absence of tested PV mAbs.  
OPD: o-phenylenediamine dihydrochloride. (C) Px43 IgG1 and IgG4 demonstrate different 
relative affinities by ELISA but comparable affinity by indirect immunofluorescence (IIF) binding 




Figure 2-3.  IgG1 and IgG4 variants of anti-Dsg3 PV mAbs are pathogenic and cause suprabasal 
blisters in human skin. (A) 25 µg anti-Dsg3 PV IgG1 or IgG4 was injected ex vivo into human skin 
sections and incubated for 18 hours prior to harvest for histologic analysis. IgG1 and IgG4 of 
three anti-Dsg3 PV mAbs, F706, F779 and Px43 induced suprabasal blisters in human skin. 
PBS/ETA served as negative control. Scale bar, 100 microns. (B) The extent of histologic 
blistering caused by IgG1 and IgG4 mAb variants is comparable.  (C) Direct immunofluorescence 
(DIF) staining of human skin with PV isotype mAbs illustrates cell surface binding in skin 






Figure 2-4.  Pathogenic F706 and F779 IgG1 and IgG4 cause loss of cell surface Dsg3. Primary 
human keratinocytes were incubated for 8 hours with 50 µg/mL F706/F779 IgG1 or IgG4. Cells 
were prepared for IF staining using anti-human IgG or anti-Dsg3 (5G11) primary antibodies. Px44 
negative and Px43 positive control antibodies were previously characterized (386). Scale bar, 20 















Lineage Analysis of Immune Repertoires in Pemphigus Vulgaris Reveals 
Distinct Pathways for Development of Autoreactive IgG4 versus IgG1 and 
IgA B Cells  
 
3.1  Abstract 
Analyzing lineage relationships among autoreactive B lymphocytes is key to 
understanding the origins of autoimmunity. In pemphigus vulgaris (PV), characterized by 
blistering of the skin and mucosa, autoreactive anti-desmoglein (Dsg) antibodies 
predominantly belong to the IgG4 antibody subclass, and less prominently IgG1 and IgA. 
This compelled us to investigate whether anti-Dsg IgG4 B cells share lineages with anti-
Dsg clones from the IgG1, IgA1, and IgA2 subclasses, suggestive of either evolution from 
common precursors or direct parent-child relationships. By sequencing B cell repertoires 
from the blood of four PV patients, we were able to sample over 70% of the circulating B 
cell lineages of each of subclass in each patient. We combined this approach with 
subclass-specific antibody phage display to identify and mark Dsg-reactive lineages 
within the larger repertoire. After identifying several Dsg-reactive lineages bridging 
subclasses, we found that the majority of anti-Dsg IgG4 B cells lack identifiable 
circulating relatives in other antibody subclasses. Specifically, direct IgG1-IgG4 switching 
comprises a minority pathway for the development of anti-Dsg IgG4 B cells, even when 
circulating IgG1 and IgG4 B cells appear to share a lineage. Within circulating anti-Dsg B 
cell lineages, parent-child relationships were observed between IgA1 and IgA2, between 
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IgG1 and IgA1, and between IgG4 and IgA2, indicating that IgA B cells in PV often derive 
either directly from or independent of IgG B cells and often switch between IgA1 and 
IgA2 subclasses. These findings suggest that class-switching between IgG and IgA may 
serve as a disease-modifying pathway in PV, and that the reciprocal relationship 
between IgG1 to IgG4 observed in chronic antigen stimulation may be in part due to the 
production of new antigen-specific lineages from non-IgG1 subclasses, rather than 
sequential class-switching of already extant IgG1 clones. 
 
3.2  Introduction 
The staggering sequence diversity of antibody variable regions comes at a price – 
the generation of autoreactive clones alongside those required to protect from 
pathogens (140,395). While the variable region determines antigen reactivity, the 
antibody constant region confers diverse effector functions (e.g. agglutination, 
complement fixation, and activation of different leukocyte populations through Fc 
receptors) that can also contribute to the pathogenesis of autoimmunity by causing end-
organ damage (396,397). During clonal expansion and affinity maturation, B cells can 
change their constant region to one of nine subclasses by recombining the IgH constant 
region locus – a tightly-regulated process known as class switching (388). While most 
current knowledge on human B cell class switch pathways derives from in vitro 
experiments (398,399), the advent of high-throughput sequencing has recently allowed 
the collection of large-scale in vivo data on class-switch relationships in normal and 
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allergic individuals (133)(137). However, very little is known about class switch pathways 
that contribute to human autoimmunity. 
An ideal disease for investigating the potential role of class switch in 
autoimmunity, pemphigus vulgaris (PV) is a potentially fatal condition in which 
autoantibodies against the keratinocyte adhesion protein desmoglein 3 (Dsg3) induces 
mucosal blistering, with subsequent development of antibodies to Dsg1 causing wider 
skin involvement in its mucocutaneous subtype. Similar to other autoimmune diseases 
(242), PV patients with active disease demonstrate predominantly anti-Dsg IgG4 and 
less so anti-Dsg IgG1 (243); PV autoantibodies do not appear to associate with IgG2 and 
IgG3 subclasses (243,246). This anti-Dsg IgG4 predominance is so pronounced that PV 
patients demonstrate enrichment of total serum IgG4 (244). Intriguingly, whereas PV 
patients with active disease demonstrate anti-Dsg3 IgG1 and IgG4, unaffected relatives 
of PV patients (rarely), HLA-matched controls (rarely), and PV patients in remission can 
demonstrate anti-Dsg3 IgG1 (245,378). Th2-type cytokines such as interleukin-4 can 
stimulate B cell class switch to both IgG1 and IgG4 (400), although whether this switch 
occurs independently or sequentially is unknown. Additionally, the majority of PV 
patients demonstrate serum anti-Dsg IgA during active disease (243,258,259). Given 
that disease often begins in the mucosa and mucosal IgA plasmablasts can be self-
reactive or polyreactive even in non-autoimmune subjects (265), IgA B cells could serve 
as an origin for autoreactive IgG4 clones.  
The existence of multiple subclasses of autoantibodies targeting the same 
antigen suggests that class-switching is likely an important mechanism of pathogenesis 
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and diversification of the autoreactive B cell response in PV, and led us to investigate 
the origin of autoreactive B cells, particularly IgG4 B cells. To trace the developmental 
pathway of autoreactive B cells in PV across four key subclasses (IgA1, IgA2, IgG1, and 
IgG4), we paired deep sequencing of subclass-specific B cell repertoires with antibody 
phage display against Dsg to identify antigen-specific heavy chains, allowing us to 
simultaneously identity anti-Dsg clones and . This combined approach allowed us to 
both characterize the global lineage relationships between these four subclasses and to 
define the class-switch pathways that lead to the formation of autoreactive B cells in PV. 
 
3.3 Materials and Methods 
3.3.1 Peripheral Blood Collection and Processing 
Phage display libraries were produced as previously described (401), with minor 
modifications to generate biological replicates and facilitate the production of IgG1, 
IgG4, IgA1, and IgA2 specific amplicons for Next Generation Sequencing (NGS) and 
antibody phage display. In brief, 60 mLs of lithium-heparin anticoagulated peripheral 
blood was collected by venipuncture from four patients (PV8, PV16, PV17, PV18) 
following informed consent using an Institutional Review Board-approved protocol. 
Patient characteristics can be found in Table 3-1. The diagnosis of PV was established by 
typical clinical presentation, histology and immunofluorescence. For PV17 and PV18, 
two separate 30 mL blood samples were collected on the same day and processed 
independently to evaluate reproducibility among biological replicates.  
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Peripheral blood mononuclear cells (PBMCs, ~108 per 60 mL blood) were isolated 
by Ficoll-Paque Plus (GE healthcare) gradient centrifugation according to the 
manufacturer’s recommendations and snap-frozen in methanol prior to storage (-80oC) 
and further processing.  
 
3.3.2 Library Preparation and Sequencing 
Total RNA was isolated from PBMCs after rotor-stator-mediated cell 
disruption/homogenization (Omni international) with the RNeasy Midi Kit (Qiagen) 
according to the manufacturer’s recommendation. The typical yield from 108 PBMCs 
was 60-120ug of total RNA. Oligo-dT primed mRNA was reversely transcribed into cDNA 
in 15ug batches and subsequently destroyed by RNase digest with the Superscript First 
Strand synthesis system for RT-PCR (Thermo Fisher) following the manufacturer’s 
protocol. In order to create NGS and phage display compatible amplicons, cDNA 
(equivalent of 7-8ug total RNA for each subclass) was subjected to 30 cycles of PCR with 
primers targeting the 5’ end of the VH gene and the hinge region of the respective 
isotype subclass (subsequently called 1st round PCR reaction). The 1st round PCR 
reaction was conducted with Platinum Taq high fidelity polymerase (Thermo Fisher) as 
opposed to proof reading enzymes with lower error rate to maximize the yield and 
diversity of the libraries and all subsequent steps. PCR products were identified by gel 
electrophoresis, purified (Wizard SV PCR Clean-Up system, Promega) and reamplified in 
a semi-nested manner with primers for the 5’ end of the VH gene and primers targeting 
the 5’ end of the first constant region (CH1), leaving the first 9 nucleotides of this region 
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unprimed to allow for identification of the original template encoded isotype (i.e. IgA vs. 
IgG; this is subsequently called the 2nd round PCR reaction). The primer position at the 5’ 
end of the CH1 harbors 2 distinct advantages that we reasoned were essential: (1) it 
allows the isotype to be directly confirmed from the template (as opposed to using J 
gene primers), while (2) it maximizes the length of the overlap during assembly of the 
paired end NGS reads, thereby creating higher confidence base calls in a 150 base pair 
window including CDR1, CDR2 and a significant proportion of the CDR3.  
We generated phage display and NGS libraries from the same first round 
amplicon by modifying the flanking regions of the 2nd round PCR primers: In case of 
further processing for antibody phage display, the primers of the 2nd round PCR reaction 
were flanked by sequences encoding the GS-linker (5’ primer; to be overlapped with the 
light chain amplicons for generation of scFvs) and a library-specific signature (3’ primer, 
to exclude phage-mediated contamination during library screening).  
NGS libraries were generated with 2nd round PCR primers that were flanked by a 
transposase sequence (5’ and 3’ primers) and in addition encoded a library-specific 
signature (3’ primer only), thereby implementing a triple protection against falsely 
assigned cross-isotype relationships: the template-encoded isotype-specific start of the 
CH1 region, the library-specific signature, and the amplicon-specific Illumina barcodes. 
In order to minimize sampling error, 2nd round PCRs were performed with 3 and 6 
technical replicates per primer combination for phage display libraries and NGS, 
respectively. Subsequent processing of the amplicons for phage display and NGS is 
described in the following 2 sections. 
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3.3.3 Antibody Phage Display  
To identify Dsg-reactive heavy chain sequences in the deep sequencing data, 
antibody phage display libraries were constructed using the aforementioned isotype-
specific VH amplicons generated during 30 cycles of 2nd round PCRs. For PV17 and PV18, 
1st round PCR products were produced for each biological replicate and subjected to 2nd 
round PCR amplification after equimolar pooling. These VH amplicons were fused by 
overlap extension PCR with VL amplicons to create scFv sequences with the 
configuration VL-GS-linker-VH. The scFvs sequences were flanked by SfiI sites 
(introduced during overlap extension PCR), which allows for directional cloning into 
pComb3X as previously described (208). Electroporation (Micropulser Electroporation 
apparatus, Bio-Rad, 12.5 kVcm-1, exponential decay with time constants between 3.4-
4.0ms) of libraries into XL-1 blue cells (Agilent) achieved a total number of 108-109 
transformants per library. Libraries were generated and screened separately. All 
libraries were panned separately against Dsg3 and Dsg1 at room temperature for three 
to five rounds of panning, with the exception of PV16 IgG4 and PV16 IgG1, which were 
panned against Dsg3 and against Dsg3 and Dsg1 in alternation (in the order 3,1,3,1). Up 
to 200 colonies were analyzed for each patient from all rounds of panning that showed 
binding to Dsg1 or Dsg3 by pooled phage ELISA.   
Unique clones were produced as soluble scFv in E. coli. In brief, 2ul of plasmid 
was added to 5-10 ul of Top10F’ cells, then transformed and plated on LB/ampicillin 
plates according to the manufacturer’s instructions. Single colonies were diluted into 
20mL SB containing 20mM MgCl2 and 0.05 mg/mL carbenicillin, grown overnight at 30C, 
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then diluted 1:100 in 400mL of SB with the same concentration of MgCl2 and 
carbenicillin. Cultures were grown to OD600 of 0.5-1.0, then induced with 1mM IPTG 
and grown at 30C for an additional four hours (which was further optimized for some 
clones to improve production). Cultures were spun down and pellets were re-suspended 
in 30-35 mL of FastBreak lysis reagent (Promega), then processed and subject to cobalt 
affinity chromatography (Talon, Clontech) according to the manufacturer’s instructions. 
Purified scFv concentration was determined by SDS-PAGE followed by Coomassie blue 
staining, using BSA standards for quantitation. 
Cloned scFv were validated using indirect immunofluorescence at 50 mg/mL on 
frozen normal human skin sections (obtained through the Penn Skin Disease Research 
Center) in TBS buffer containing 1mM CaCl2 and 1% BSA. Bound antibody was detected 
with rat anti-HA antibody (3F10, Roche), then by 1:200 Alexa Flour 594 donkey anti-rat 
IgG (Thermo Fischer Scientific). IF was visualized using an Olympus BX61 microscope, 
images acquired using SlideBook 4.2 software (Olympus) and a Hamamatsu Orca ER 
camera. 
Cloned scFv were also tested by ELISA against Dsg3, Dsg1, and an irrelevant 
antigen (either tetanus toxoid or BP180) as a negative control (Euroimmun), performed 
according to manufacturer’s instructions.  
 
3.3.4 Next Generation Sequencing  
Isotype-specific 1st round PCR VH amplicons were amplified with 2nd round PCR 
primers as mentioned above. In order to minimize PCR induced mutations, the NGS 
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libraries were produced with Q5 polymerase (NEB) using a maximum of 3ng per reaction 
and only 12 PCR cycles. After visualization and purification (Wizard SV PCR Clean-Up 
system, Promega), the 2nd round product concentration was quantified (NanoDrop, 
Thermo Fisher) and PCR products were pooled with equal amounts of DNA input 
representing each primer pair. Subsequently, pooled PCR products were subjected to 12 
cycles of PCR amplification to attach the Illumina Nextera barcodes and adapters, 
followed by gel purification (Wizard SV gel purification system, Promega) and additional 
purification with AmPure beads (Beckman Coulter) according to the manufacturer’s 
recommendations. NGS library concentrations were determined (Qubit dsDNA HS, 
Thermo Fisher) and pooled accordingly. The concentration of sequencing-competent 
amplicons was additionally analyzed by qPCR (KAPA Biosystems), and the purity was 
confirmed (Bioanalyzer, Agilent) before subjecting the amplicons to paired end 2x300 
base pair sequencing (Illumna MiSeq). In order to estimate the frequency of artificial 
mutations introduced during library production and sequencing, we generated an 
additional amplicon with comparable length derived from a Sanger sequencing-verified 
plasmid encoding the CD8-CD137 transition of a chimeric antigen receptor (CAR). The 
plasmid was subjected to the same number of PCR cycles and procedures as the 
abovementioned amplicons and added to the library mixture comprising 1% of the total 
amount of DNA (as determined by Qubit). 
Technical replicates were generated by production of 2 NGS libraries from the 
same cDNA with identical primers (except for barcodes and signatures) and sequencing 
those 2 libraries separately. Biological replicates were generated by processing 2 blood 
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samples (so that B cell clones shared between the replicates have to be derived from 
each aliquot and therefore represent physically separate B cells) separately for NGS 
library production.  
 
3.3.5 Raw Data Processing and Lineage Clustering 
Libraries were sequenced as mentioned above using Illumina Miseq 300bp 
paired end sequencing (Institute for Genome Science, University of Maryland; Next-
Generation Sequencing Core, University of Pennsylvania). Forward and reverse reads 
were merged using PEAR (402), and identical reads were merged into non-redundant 
(NR) sequences. All non-redundant sequences with isosignature exactly matching the 
predicted isosignature for a given library were kept, and uploaded to IMGT-Hi-VQUEST 
for VDJ assignment. The IMGT results were filtered to only productive hits.  
Clonality was defined by first binning all sequences from all four patients by V, J 
and CDR3 length, then for each bin calculating the nearest neighbor nucleotide 
hamming distance from a given CDR3 to all CDR3 in the same V-J-length bin belonging to 
another patient. This allowed us to define an upper limit on allowed clonal divergence. A 
per-patient nucleotide hamming distance cutoff was selected such that the resulting 
clusters would have 99% confidence of unrelated sequences being excluded. Sequences 
within each patient-subclass pair were then clustered using a customized perl script and 
a centroid (UPGMC) linkage function implemented in the Algorithm::Cluster module. 
Within each patient-subclass pair, clusters were subsequently superclustered by their 
consensus CDR3 sequence, without regard to VDJ gene assignment, and only the cluster 
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with the largest number of reads (toprank) was considered for large scale subclass 
connectivity analysis. Heavy chains found by phage display were matched back to NGS 
clusters by searching for consensus CDR3 falling within the original clonality CDR3 
nucleotide identity cutoff for each patient.   
 
3.3.6 Estimation of Clonal Richness/Diversity and Total Population Size 
To estimate the total population size and the fraction of the total population that 
was captured by sequencing, all biological and technical replicates for a given subclass-
patient pair were pooled and subject to rarefaction analysis and asymptotic diversity 
estimation using the iNEXT package in R (304) and the online implementation of iNEXT 
(http://chao.shinyapps.io/iNEXTOnline/). Each supercluster was treated as a “species”, 
and abundance-based rarefaction was conducted on the number of reads. Furthermore, 
in order to determine the amount of total diversity in the sample capture, the 
asymptotic Shannon Diversity, Simpson Index, and Species Richness were compared to 
the actual values for those metrics in a given sample. To correct for the artificial inflation 
of low-abundance taxa due to sequencing and amplification error, the number of 






To determine the reproducibility of lineages among technical and biological 






A lineage was considered existing in one replicate if it appears with five reads in that 
replicate, and existing in both replicates if it appears with at least five reads in each 
replicate in question. 
 
3.3.7 Quantitation of Subclass Connectivity 
Average pairing rates between subclasses were computed as the harmonic mean 
of the frequency of shared lineages appearing between the subclasses, in order to 
normalize for differing subclass sizes. For example, if n lineages are shared between 





For comparing pairing rates between the anti-Dsg and global repertoire, the 
calculated pairing rate was bootstrapped down to the size of the anti-Dsg repertoire for 
any given subclass pair. 
 
3.3.8 Lineage Analysis 
Lineages of interest were selected as those phage-display-derived heavy chain 
sequences mapping to top-rank clusters in other subclasses with at least 5 reads, with 
an additional constraint that the top-rank cluster in the “home” subclass of the Dsg-
reactive clone have an identical V-gene (without consideration of the allele). Sequences 
within each lineage of interest were subject to primer trimming and full-length 
clustering at 97% radius using the cluster_otus command in USEARCH (315). Trees were 
drawn after removing all nodes with fewer than 5 reads. For visualization, some trees 
were drawn with all nodes with fewer than 10 reads removed, though this did not affect 
their topology. Parameters were tested on a monoclonal CD137 template subject to the 
same amplification procedure as the libraries (Figure 3-23). In total, 19 trees were 
produced (Table 3-2). Maximum parsimony trees were generated using the Change-O 
package (116), which calls dnapars.exe from PHYLIP (403). Intermediates from 
maximum parsimony trees were synthesized as gblock gene fragments (Integrated DNA 
Technologies) with nucleotide additions allowing either overlap PCR with the 





3.3.9 Epitope Mapping 
Epitope mapping was performed as previously described for patient sera (22) 
and scFv (24), using chimeric Dsg3/2 or Dsg1/2 molecules expressed in either baculoviral 
or HEK293-derived supernatants. Dsg3-reactive clones were tested by 
immunoprecipitation against Dsg3/2 constructs followed by western blotting using an 
anti-E-tag HRP antibody, and Dsg1-reactive clones were tested against Dsg1/2 
constructs in an analogous manner 
 
3.4  Results 
3.4.1 High-Throughput Sequencing of Subclass-Specific B Cell Repertoires 
in PV Indicates a Predominance Of Anti-Dsg IgG4 Lineages, Followed by 
IgA1, IgG1, and IgA2   
A better understanding of the isotype relationships of autoreactive B cells 
requires deep sequencing of B cell repertoires to obtain large-scale B cell lineage 
information, as well as a method for identification of antigen-specific clones. We 
performed high-throughput sequencing of IgG4, IgG1, IgA1, and IgA2 B cell repertoires 
in a panel of four PV patients with active disease (patient characteristics can be found in 
Table 3-1). RNA was isolated from PBMC derived from 50-60 mL of peripheral blood, 
representing approximately 2 x 106 class-switched B cells ([50 mL of blood] x [4 x 105 B 
cells/mL of blood] x [10% B cells are class-switched]), per patient. Sequencing libraries 
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were prepared from an amplicon generated using a 3’ primer specific for the unique 
hinge region of each subclass. Subsequent amplification for library production was 
conducted using a 3’ primer containing a constant-region-specific binding sequence, a 
custom library barcode for every patient-subclass pair, and an Illumina index sequence. 
The constant region sequence and the library barcode were collectively called the 
isosignature (Figure 3-1). Ensuring the index sequence and isosignature were 
concordant allowed high-confidence discrimination between subclasses and stringent 
filtering of potentially mis-assigned sequences that would be falsely interpreted as 
cross-subclass relationships. This amplification scheme allowed us to generate ~225,000 
to ~6 million paired-end raw reads per patient-subclass pair on the Illumina MiSeq 
2x300 bp platform (Table 3-3). Furthermore, each sequencing run was accompanied by 
a monoclonal template subject to the same amplification steps, to give a bound on 
amplification and sequencing-induced error. 
Antibody phage display libraries were prepared from the same hinge-primed 
amplicon and panned against Dsg3 and/or Dsg1 to select subclass-specific Dsg-reactive 
clones. Across 16 libraries representing four patients and four subclasses, each 
representing 100 million to 1 billion total transformants, up to 200 clones were 
characterized for anti-Dsg ELISA reactivity and cell-surface staining by indirect 
immunofluorescence to independently verify the PV phenotype, resulting in 96 total 
unique anti-Dsg B cell clones representing 80 lineages (Table 3-4). Characterized clones 
showed a wide variety of V-gene usage and a lack of stereotyped CDR3 sequences, 
demonstrating a highly polyclonal anti-Dsg response across subclasses. The plurality of 
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unique Dsg-reactive clones belong to the IgG4 subclass (34), followed by 21 IgA1 clones, 
18 IgG1 clones, and 13 IgA2 clones. We found a comparable number of IgA and IgG4 
clones among the four patients (34 of each), suggesting a diversified anti-Dsg response 
in both the IgG and IgA isotypes.  
 
3.4.2 Anti-Dsg Clonal Lineages Bridge Multiple Subclasses 
After sampling anti-Dsg clones from each of the sixteen subclass-patient 
libraries, we first sought to determine the lineage relationships of these Dsg-reactive 
clones across the four sequenced subclasses. To that end, we determined the clonal 
structure of the global antibody repertoire by partitioning sequences into lineages. First, 
across all patients, sequences sharing V, J, and CDR3 length were binned together. Then, 
by comparing the CDR3 sequences from each of the four patients against the other 
three, we derived a per-patient CDR3 nucleotide identity cutoff that gives 99% 
confidence that two clustered sequences do not belong to different lineages (Figure 3-
2). CDR3 nucleotide similarity cutoffs ranged from 80.6% in PV8 to 86.1% in PV18. 
Finally, to mitigate the effects of VJ misassignment and sequencing error creating 
spurious lineages, we further grouped all clusters together that meet the same CDR3 
cutoff, without requiring matching V or J genes; this allowed us to sort clusters by read 
count into ranked lists called superclusters, and to eliminate non-top-ranked clusters 
within a supercluster from consideration during lineage analysis to improve stringency.  
85 
 
We subsequently mapped the phage-display derived heavy chain sequences to 
deep-sequencing derived clonal lineages, finding 80 Dsg-reactive lineages that span 
between one and four subclasses (Figure 3-3a). We further analyzed these 80 Dsg-
reactive lineages in terms of pairwise overlaps between subclasses (Figure 3-3b and 3-
3c), which demonstrated that a majority of IgA1- and IgA2-containing Dsg-reactive 
lineages contain relatives in other subclasses; in particular, the majority of IgA1 have 
relatives in IgA2 and vice versa. By contrast, only a minority of IgG4-containing Dsg-
reactive lineages can be found in other subclasses. It is noteworthy that when IgG4-
containing lineages bridge subclasses, that they show a slight preference for IgG1 (21%) 
over IgA1 (15%) and IgA2 (13%). To determine whether IgG4 is unique among subclasses 
in its lack of relationships, we compared the proportion of single-subclass and multi-
subclass Dsg-reactive lineages between all four subclasses (Figure 3-3d). Only 28% of 
IgG4-containing Dsg-reactive lineages are multi-subclass, which, by Fisher’s exact test, is 
significantly fewer than the other three subclasses combined (P = 6.31 x 10-6).  
 
3.4.3 Large-Scale Clonal Analysis Indicates anti-Dsg IgG4 B cells Show 
Increased Connections to Other Subclasses Relative to IgG4 B cells in the 
Global Repertoire 
We have demonstrated that the anti-Dsg IgG4 repertoire is disconnected from 
other subclasses compared to anti-Dsg lineages in other subclasses, and that the anti-
Dsg IgA repertoire is highly connected. To determine whether this is a unique feature of 
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the anti-Dsg repertoire relative to the global B cell repertoire, we next sought to 
compare the connectivity of the anti-Dsg B cell repertoire to the global repertoire. To 
understand the large-scale structure of the repertoire, we calculated the average pairing 
rate of each subclass pair by taking the harmonic mean of the proportion of overlapping 
lineages between a given subclass pair (see Methods). First, we compared the between-
subclass pairing rate of the Dsg-reactive and global repertoire for all four patients and all 
four subclasses. This demonstrated that the Dsg-reactive repertoire is significantly more 
interconnected than the global one (p < 0.0001, Figure 3-4a). Separating out the Dsg-
reactive repertoire by subclass shows that IgA1 and IgA2 show the highest 
interconnectedness, both in the global and Dsg-reactive repertoires (Figure 3-4b).  
 We next determined the subclass pairings which were enriched in the Dsg-
reactive repertoire in order to determine lineage relationships important in PV. For each 
of the six possible subclass pairs, we normalized the pairing rate of the Dsg-reactive 
repertoire to the global repertoire (Figure 3-4c). To account for the possibility that this 
increase in IgG4 connectivity is simply a positive correlation with lineage size, we 
compared the number of reads mapping to the IgG4 subclass in single-subclass anti-Dsg 
lineages vs multi-subclass anti-Dsg lineages containing IgG4 in each patient. No 
significant difference in IgG4 read number between multi-subclass and single-subclass 
autoreactive lineages was found, indicating that lineage size and/or sampling depth 
appears to have a minimal effect on connectivity (Figure 3-4d). Though it remains 
isolated in an absolute sense, the Dsg-reactive IgG4 repertoire shows an increased 
connectivity to other subclasses compared to anti-Dsg lineages in the global repertoire. 
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3.4.4 Anti-Dsg IgG4 B Cells Predominantly Demonstrate No Subclass 
Connectivity but can Rarely Switch Directly From anti-Dsg IgG1 B Cells 
Our global repertoire data demonstrates that anti-Dsg IgG4 is disconnected from 
the larger anti-Dsg repertoire relative to other subclasses. Of the 39 total IgG4-
containing Dsg-reactive lineages, 28 contained sequences from only IgG4, while 11 
contained sequences from multiple subclasses (Figure 3-3d). To better understand the 
clonal development of the Dsg-reactive IgG4 repertoire on a fine level, we further 
analyzed seven lineages containing both IgG4 and IgG1 by generating maximum 
parsimony phylogenetic trees for each lineage (Figure 3-5, 3-6, 3-7, 3-8). 1/7 of these 
lineages showed evidence of a direct IgG1 to IgG4 switch, with the IgG1 clone differing 
from the IgG4 clone by a single substitution (Figure 3-5a). The remainder do not show 
an identifiable direct switch between IgG1 and IgG4, either due to very early divergence 
from germline and subsequent independent evolution of each subclass (Figure 3-5b, 3-
7), late divergence after some mutation of a precursor (Figure 3-5c), or show co-
evolution and intermingling between IgG1 and IgG4 without evidence of direct class 
switch (Figure 3-5d). 
To understand the onset and development of Dsg reactivity within each lineage, 
we produced several selected sequenced and inferred nodes from seven of the IgG4-
containing multi-subclass lineages and several sequences with a germline-reverted 
heavy chain from lineages containing only IgG4 Dsg3. ELISA indicated that in all except 
one multi-subclass lineages tested, relatives of Dsg-reactive clones in other subclasses 
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showed similar ELISA reactivity (Figure 3-21a); only the PV17.G1.D1.P4.8 lineage (Figure 
3-5d) showed no reactivity in other subclasses. Furthermore, in multi-subclass lineages 
with confirmed reactive sequences across multiple subclasses, 4/6 most recent common 
ancestors (MRCA) and 8/11 germline heavy chain sequences (Figure 3-21b) show strong 
anti-Dsg reactivity mirroring the reactivity of phage-display derived clones and 
sequenced nodes. 
  
3.4.5 Anti-Dsg IgG4 B Cells Evolve Independently of IgA1 but can Directly 
Give Rise to anti-Dsg IgA2 B Cells  
As PV blistering often begins in the mucosa, we next sought to identify potential 
direct-switch relationships between IgA clones and IgG4 that could imply a mucosal 
origin for autoimmune B cells in PV. Anti-Dsg3 IgG4 clones share three lineages with 
IgA2 and two with IgA1. IgA1 and IgG4 show no evidence of direct switching, lying on 
different branches of the two analyzed lineages in which they coexist (Figure 3-5a, 3-5d). 
Two IgG4-IgA2 lineages show a direct switch from IgG4 from IgA2 (Figure 3-8, 3-9), while 
in the other case, the IgA2 switches from IgA1 and the IgG4 switches from IgG1 (Figure 
3-5a). In both of these IgG4-IgA2 direct switches, the IgA2 clone remains anti-Dsg 




3.4.6 Anti-Dsg IgA1 Shows Close Relationships to Both anti-Dsg IgG1 B 
Cells and anti-Dsg IgA2 by Direct Switch  
After studying the relationships between IgG4 and each of the other three 
subclasses, we next sought to apply the same analysis to the lineage relationships 
between IgA1, IgA2, and IgG1. Interestingly, IgG1 and IgA1 show a direct switch in four 
of six analyzed lineages in which they coexist. We also found that in two lineages 
demonstrating an IgG1 to IgA1 switch, there is evidence of a subsequent switch to IgA2 
with a few mutations (Figure 3-9, 3-10), suggesting that IgA1 can act as a hub for clonal 
maturation from IgG1 to IgA2. There are no examples of direct IgG1 to IgA2 switching 
present without IgA1 sharing the IgG1 sequence, implying the necessity of an IgA1 
intermediate in this switch pathway. 
The connection between IgA1 and IgA2 is particularly strong in the autoreactive 
lineages we have studied, mirroring their high pairing rate in the global repertoire. 
There is evidence of direct switch in 10/11 analyzed lineages in which IgA1 and IgA2 co-
exist. In the other case (Figure 3-16), the IgA1 and IgA2 appear on adjacent terminal 
nodes, but show no direct switch. In total, of the 13 multi-subclass lineages containing 
IgA2, 10 show a direct switch from IgA1 (two of which originate from a shared IgG1/IgA1 





3.4.7 Repertoire Sequencing Effectively Captures Each Subclass’ Diversity 
Our study indicates that the majority of anti-Dsg IgG4 B cells in PV do not 
demonstrate lineage relationships to IgG1 or IgA. Our inability to identify IgG1-IgG4 B 
cell lineage relationships or direct class-switches could be due to the fact that such 
relationships simply do not occur, meaning IgG4 B cells are switching directly from 
upstream non-IgG1 subclasses (IgM, IgG2, IgG3). Alternatively, we simply could have 
failed to sample the IgG1 precursor of any given IgG4. Because we are able to identify 
cross-subclass lineage relationships and ongoing class-switching for the majority of anti-
Dsg IgA1 B cell lineages, a population that is likely as diverse in the circulation as IgG1, 
and because we are able to find several instances of ongoing IgG1 to IgA1 class-
switching, we find it unlikely that we lack the power to detect relevant class-switching 
relationships between IgG1 and IgG4 due to undersampling. However, to address the 
issue of potential undersampling of the circulating repertoire, we performed rarefaction 
analysis and asymptotic estimation of sample coverage for each patient-subclass pair 
(Figure 3-22). Asymptotic estimation of species richness (e.g. determining the total 
number of lineages in the population by estimating how many lineages we would find 
had we continued sampling indefinitely) shows that we have captured 71-97% total 
estimated lineages present in each patient. Furthermore, we also determine the 
percentage of total lineage diversity we have sampled using asymptotic estimation of 
the Shannon diversity and Simpson index, which are used in ecology to determine the 
diversity of common and dominant taxa in ecological samples. Looking across each 
patient-subclass pair, we have captured 97-99.98% of the lineage Shannon diversity and 
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99.6-100% of the lineage Simpson diversity, indicating we have sampled most of the 
common and dominant antibody sequences from circulating IgA1, IgA2, IgG1, and IgG4 
B cells in the repertoire. 
To determine the relative contribution of technical and biological factors to 
undersampling, biological replicates were performed for PV17 and PV18 by taking two 
separate 30 mL blood draws, and for PV16, PV17, and PV18, each biological replicate 
(one for PV16, two for PV17 and PV18) was sequenced twice as technical replicates to 
determine the sufficiency of sequencing depth. Each pair of biological or technical 
replicates were compared for overlapping lineages, and population size estimators were 
used to determine what fraction of lineages were being captured (Table 3-5). After 
filtering those lineages containing below five reads, mark-and-recapture analysis using 
the Chapman estimator demonstrates that 96.57-99.97% of the lineages within a 
sample are captured by pooled technical replicates, and over 35.46-81.99% of the 
lineages within the circulation are captured by pooled biological replicates, suggesting 
that most of the undersampling in the experiment is due to biological, rather than 
technical, limits. 
 
3.4.8 Epitope Mapping Shows N-terminal Preference of IgG4 Relative to 
Other Subclasses 
Our data have shown, with high confidence, that the anti-Dsg IgG4 repertoire 
does not share lineage relationships or direct class-switch origins from IgG1 or IgA1. We 
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have also demonstrated that the anti-Dsg IgG1, IgA1, and IgA2 repertoires often share 
lineages separate from anti-Dsg IgG4. To determine whether this division in the 
repertoire could be explained by differing epitope reactivity, we determined the Dsg 
extracellular (EC) domain specificity of Dsg-reactive clones (Table 3-7)(226). Dsg-reactive 
clones sharing a lineage mapped to the same epitope in all cases. The plurality of clones 
within each subclasses demonstrated reactivity against the amino-terminal EC1, and in 
aggregate, at least two Dsg-reactive clones react to each of the five extracellular 
domains. However, there is a statistically significant shift towards EC1 reactivity in the 
IgG4 subclass compared to all other subclasses (p = 0.009 by Fischer’s exact test). This is 
especially pronounced when comparing IgG4 to the IgA subclasses, which show more 
evenly-distributed reactivity to all five extracellular domains. 
 
3.5 Discussion 
 Class-switching is largely directed by the cytokine milieu and T-cell help that a B 
cell encounters during an ongoing immune response, where it serves to modify and 
diversify the effector functions of antibodies. In this study, we have presented evidence 
that despite co-occurring with several other subclasses and responding to the same 
antigen, the IgG4 Dsg-reactive repertoire arises largely independently of the other 
subclasses in a panel of PV patients. By cloning each subclass into a separate phage 
display library, we have the ability to screen for rare autoreactive clones from more 
infrequent B cell subclasses (like IgG4 and IgA2) at unprecedented depth, free of 
competition from clones in more diverse subclasses. Furthermore, our sequencing 
93 
 
method managed to capture a majority of the total lineages in each sample, including in 
particularly diverse subclasses like IgA1 and IgG1, allowing us to obtain a representative 
picture of the class-switch landscape in the circulating B cell repertoire of PV patients. 
Only a minority of detected Dsg-reactive IgG4 lineages also contain IgG1 
sequences, with only a single lineage showing a direct switch between IgG1 and IgG4. 
The existence of a switch pathway from IgG1 to IgG4 in the normal B cell repertoire was 
characterized in a large-scale repertoire study of the human class-switching landscape, 
with direct switches from IgM, IgG2, and IgG3 to IgG4 occurring at similar frequencies 
(137). Due to their relative unimportance in PV, our study did not include IgG2 or IgG3, 
leaving open the possibility of an IgG2 or IgG3 clone – most likely a non-reactive one - 
during a switch to IgG4. Even given that caveat, our data suggest a mostly disjoint 
relationship between the IgG1 and IgG4 anti-Dsg repertoires, in which both evolve 
independently from different precursors and with IgG4 only rarely switching from IgG1. 
Furthermore, only 28% of IgG4 belonged to multi-subclass lineages, and 4/6 lineages 
containing confirmed reactive IgG1 and IgG4 clones showed early divergence between 
the two, suggesting that even when anti-Dsg IgG1 and IgG4 share a lineage, they 
develop largely independently within said lineage.  
Sequences mapped to anti-Dsg IgG4 lineages showed significantly fewer 
connections to other subclasses than IgA1, IgA2, or IgG1, suggesting a pathway in which 
the majority of the Dsg-reactive IgG4 repertoire originates from a non-IgG1 subclass 
(like IgM, IgG2, or IgG3), creating its own self-contained thoroughfare of autoreactivity 
in the overall class-switching landscape. This is further supported by the fact that a 
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majority of anti-Dsg3 IgG4 reverted to either their MRCA (2/3) or germline (8/11) 
sequence remained reactive. A similar finding has recently been published for an 
endemic form of pemphigus foliaceus found in Brazil (fogo selvagem); reversion of 
mutations to germline in two clones found both of them to remain cross-reactive to 
Dsg1 and the sandfly salivary antigen LJM11 (404). We have also previously found some 
anti-Dsg3 IgG using the VH1-46 gene segment retain reactivity at germline (367). Of the 
14 anti-Dsg3 IgG4 clones we have reverted, only one used VH1-46 (though it was 
germline-reactive), demonstrating that the IgM repertoire may demonstrate a wider 
range of Dsg reactivity than previously suggested. Further studies, including repertoire 
cloning of IgM, IgG2, and IgG3, comparing germline-derived sequences from different 
subclasses in the anti-Dsg repertoire in terms of polyreactivity, affinity, and epitope 
preferences, and determining the integrity of central tolerance mechanisms in PV 
patients, will shed more light on the divergent origins of Dsg-reactive IgG1 and IgG4. 
Interestingly, though anti-Dsg IgG4 was the most solitary of all the anti-Dsg 
subclasses, it demonstrated a noticeable increase in connectivity relative to the global 
anti-Dsg repertoire – in fact, this increase in connectivity between subclasses in Dsg-
reactive lineages relative to the global repertoire occurs in all subclasses. Determining 
whether this increase in connectivity occurs in any ongoing antigen-specific immune 
response, or specifically in the context of PV or other autoantibody-mediated disease, 
will require further study. Theoretically, an increase in subclass connectivity in an 
antigen-reactive section of the B cell repertoire could simply reflect increased class-
switching as part of an ongoing immune response. In the specific case of IgG1 and IgG4, 
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however, this connectivity is not the result of direct switching between the two 
subclasses, but due to lineages containing Dsg-reactive IgG1 and IgG4 sharing divergent 
origins from precursors. Conversely, the connectivity in anti-Dsg IgA1-IgA2 shared 
lineages seem to arise mainly from direct switching. This suggests that increased direct 
switching is not the only mechanism increasing subclass connectivity in an ongoing 
immune response. For example, it may be the case that IgM B cells with an intrinsic 
propensity for switching divergently to different subclasses are specifically induced to 
proliferate during PV, or that the cytokine milieu in PV specifically induces some IgM B 
cells to switch to IgG1 and IgG4 independently, thus driving an increase in subclass 
connectivity without an increase in direct-switch relationships. 
The lack of identified precursor-product relationships between IgG1 and IgG4 
may also be explained by the difficulty of capturing the full diversity of the human B cell 
repertoire. Through mark-and-recapture analysis, we have shown that our approach is 
primarily constrained by biological sampling. Although we used over 50 mL of blood 
(approximately 1% of total blood) from each patient to maximize coverage, we are still 
most likely missing rare circulating clones. This is made worse by the fact we may be 
biasing against sequencing memory B cell clones due to the presence of highly 
transcriptionally active plasmablasts “washing out” the mRNA contribution from 
memory cells. Furthermore, there is the possibility of non-circulating related IgG1 B cell 
clones occupying niches inaccessible to our sampling, or that hypothetical precursor 
IgG1 are completely consumed by the switch to IgG4 and have disappeared from the 
circulation by the time of disease onset. These caveats can be partly minimized due to 
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our rarefaction analysis showing that we have effectively captured over 70% of lineages 
in every sample, even in diverse subclasses, and by the fact that that we have found 
robust evidence of direct switching between IgG1-IgA1, IgA1-IgA2, and IgG4-IgA2 as part 
of an ongoing anti-Dsg response, making the absence of IgG1-IgG4 direct sequences 
particularly conspicuous in this context, even given the constraints listed. Nevertheless, 
given these caveats, it is entirely possible that longitudinal subclass-specific repertoire 
studies in PV, or studies of the splenic, mucosal, and/or bone marrow repertoire in PV, 
may reveal new relationships between subclasses that we are unable to detect in 
peripheral blood.  
The class-switch pathways leading to IgG4 are of fundamental interest not only 
in the study of PV, but also the mechanism of several other autoimmune diseases (242) 
and states of chronic antigen stimulation. Beekeepers (248), patients with chronic 
helminth infections (252), and patients undergoing allergen desensitization therapy 
(251) all develop IgG4, which serves as a blocking antibody to dampen the response to 
the given antigen. In particular, novice beekeepers tend to show IgG1 to bee venom 
antigens, while more experienced beekeepers who have been tolerized to bee stings 
over time show IgG4 to the same antigens (256). Similarly, in fogo selvagem, healthy 
people in the endemic focus often display anti-Dsg1 IgG1, whereas patients with active 
disease display anti-Dsg3 IgG4 (405,406). A larger implication of the existence of 
independent IgG1 and IgG4 anti-Dsg repertoires is that the reciprocal relationship 
between IgG1 and IgG4 in some forms of chronic antigen stimulation may be due to 
separate populations of B cells independently switching to IgG1 and IgG4 in response to 
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antigen challenge, rather than direct switch between IgG1 and IgG4. It has been shown 
that in allergen desensitization therapy and in tolerized beekeepers, the blocking IgG4 is 
exclusively secreted by a population of IL-10 secreting regulatory B cells (407). 
Expansions of regulatory B cells can be found in PV and other autoimmune conditions 
(408,409); while we cannot draw conclusions about cell of origin from our experiments, 
these data are which is mildly suggestive of the idea that pathogenic IgG4 in PV – and 
protective IgG4 in other forms of chronic antigen stimulation - may arise from these 
same cells developing independently of IgG1 responses to the same antigen. Single B 
cell cloning experiments in PV patients targeting this population, or similar experiments 
conducted longitudinally over a period of chronic antigen stimulation, will be able to 
shed light on this hypothesis. Determining the developmental pathway of pathogenic or 
protective IgG4 would lead to a better understanding of IgG4-mediated autoimmune 
disease, allergen tolerization, and other IgG4-dependent processes. 
 We have also characterized, for the first time, the lineage relationships of IgA in 
PV. We discovered a highly diverse IgA response to Dsg1 and Dsg3, which in several 
lineages overlaps strongly with the IgG1 repertoire by direct switching from IgG1 to 
IgA1. A high-throughput analysis of class switching recently showed that IgG1-IgA1 
parent-child relationships are the second most common in the class-switching landscape 
(137). Both the direct IgM to IgA1 switch and the sequential IgM to IgG1 to IgA1 have 
previously been shown to be dependent on TGF-beta and CD40 activation in cultured 
human B cells (410). IgA switching can also be triggered in a T-cell independent manner 
on mucosal surfaces by TLR4 engagement and secretion of the cytokines BAFF and APRIL 
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by dendritic cells (264). The role of TGF-beta in PV is not well-characterized; one study 
found its serum levels elevated relative to controls (36), though others found otherwise 
(411,412). Serum BAFF and APRIL also have an unclear role, having been found to be 
elevated in bullous pemphigoid, but not PV (413,414).  
Furthermore, we have characterized antigen-specific switching from IgG4 to IgA2 
for the first time. The functional relevance of this switch pathway is unknown. 78% of all 
IgA2-containing Dsg-reactive lineages were multi-subclass, and all except one of the 12 
well-represented IgA2 multi-subclass lineage characterized shows a direct switch from 
either IgA1 or IgG4, and the other lies close enough to IgA1 terminal nodes within the 
tree to suggest that the an IgA1 to IgA2 switch probably occurred but wasn’t captured 
by sequencing. IgA2 is the predominant IgA subclass in the mucosa (415). The 
production of IgA2 is known to occur in the colonic lamina propria through secretion of 
IL-10 and APRIL secreted from colonic epithelium in response to normal intestinal flora; 
this occurs in both an IgM-to-IgA2 and IgA1-to-IgA2 fashion (91).  
Given our results suggesting that anti-Dsg IgA clones either develop 
independently from, or switch directly from, anti-Dsg IgG clones, and literature showing 
that IgA-inducing cytokines have an unclear role in PV pathogenesis, it may be the case 
that the existence of anti-Dsg IgA1 and IgA2 is simply a post-hoc epiphenomenon of PV, 
catalyzed by the localized effect of IgA class-switch mediators like TGF-beta, LPS, BAFF, 
or APRIL on Dsg-reactive IgM, IgG1, or IgG4. This seems especially likely for IgA2, as it 
lies on the 3’ end of the IgH locus and therefore cannot serve as a class-switch 
intermediate or harbor of pathogenic clones. It may be the case that the clones found in 
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IgG1-IgA1 or IgG4-IgA2 parent-child pairs are cross-reactive to some antigen found in 
the normal flora or present on mucosal surfaces. Somewhat suggestive of this possibility 
is the fact that some anti-Dsg antibodies are cross-reactive to the rotavirus coat protein 
VP6 (401). A circulating anti-Dsg IgG1 or IgG4 may enter a mesenteric lymph node or 
Peyer’s patches in the lamina propria, where it is induced to switch from IgG1 to IgA1 
(and, potentially, subsequently IgA2) or from IgG4 to IgA2 by the presence of said 
antigen and a permissive cytokine milieu. The identity of said antigen(s) is beyond the 
scope of this study, though it could be determined by targeted sequencing of the 
mucosal IgA repertoire in PV and screening of anti-Dsg IgA clones for cross-reactivity 
against a library of mucosal antigens found in normal flora. 
 In conclusion, it appears that in PV, the majority of anti-Dsg IgG4 B cells show no 
evidence of arising from other subclasses, while anti-Dsg IgA1, IgG1, and IgA2 B cells 
show more extensive relationships among each other. These results also imply that 
sequential class switching is not a dominant pathway of IgG4 production in PV, despite 
its temporal relationship with IgG1 in the setting of chronic antigen stimulation. Further 
repertoire analysis and B cell lineage tracing in IgG4-centric conditions, like PV and other 

























































































Figure 3-22. Quantification of Sampling Coverage by Asymptotic Diversity Estimation. 
Coverage is calculated by dividing the given diversity measure against the asymptotic estimation 
of that measure, i.e. the value of that measure had we sampled each patient-subclass pair 
infinitely. In this way, we can determine the percentage of the total of any given diversity 
measure that we have captured. Results indicate that we have captured between 71-97% of the 
species richness, meaning 71-97% of all lineages. The percentage of overall species richness 
captured is lower than the percentage of Shannon or Simpson diversity captured, because 
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CHAPTER 4:  
Discussion and Future Directions 
 
4.1  Summary of Findings 
 We have elucidated the role of autoantibody subclass in pemphigus vulgaris by 
determining the effects of the constant region on variable region affinity, specificity, and 
blistering ability, as well as investigated the relationships between variable regions 
across different subclasses in order to determine the class-switch pathways are most 
relevant to disease.  Our results have substantiated the idea that there are partially 
disjoint sub-populations within the set of anti-Dsg antibodies in PV, partitioned by 
preferred class-switch pathways – namely, a prominent IgA1 to IgA2 switch, a fairly 
common IgG1 to IgA1 switch, and a notable, but not as prominent, IgG4 to IgA2 switch. 
Notably minor was a direct switch connecting IgG1 and IgG4, the two subclasses 
thought to be most important for disease, and the two subclasses that have a reciprocal 
relationship during chronic antigen stimulation (which shifts from IgG1 to IgG4 in some 
cases). Because both IgG1 and IgG4 are present during active disease, and IgG1 
predominates during remission, we had hypothesized that the IgG4 and IgG1 could be 
clonally related – our data instead suggests the idea that most anti-Dsg IgG1 and anti-
Dsg IgG4 lineages do not overlap. This has implications not only on the pathogenesis of 
PV, but on the development of the IgG4 repertoire in general. These results can help 
understand IgG4-mediated autoimmune disease, allergen desensitization, and any other 
process, pathological or protective, resulting in IgG4 production.  
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While previous studies have shown that injection of anti-Dsg3 scFv or Fab was 
sufficient to cause blistering in model systems, there remained the possibility that the 
IgG1 or IgG4 constant region directly modulated the affinity or pathogenicity of an anti-
Dsg antibody. By cloning several anti-Dsg3 variable regions onto both IgG1 and IgG4 
constant regions, we managed to show that the constant region does not modulate the 
blister-inducing ability, Dsg3 internalization ability, or epitope preferences of pathogenic 
anti-Dsg3 antibodies. This suggests that a change in constant region from IgG1 to IgG4 
alone is not sufficient to explain the pathogenic role of IgG4 autoantibodies in PV (see 
chapter 2).  
This result buttressed further investigation of the lineage relationships between 
IgG1 and IgG4 in a panel of four PV patients (chapter 3). Through subclass-specific 
repertoire cloning, we have shown that the IgG4 anti-Dsg repertoire in PV mostly 
develops independently from the IgG1, sharing few lineages and few direct-switch 
relationships. This was an unexpected finding; given the reciprocal relationship between 
IgG1 and IgG4 over the course of disease in PV (IgG1 predominance during remission, 
IgG4 predominance during active disease) and the arrangement of constant region 
exons on the IgH locus, we expected to find that the majority of IgG4 clones switched 
from IgG1 during active disease. We have also characterized the relationship between 
IgA and IgG in PV for the first time, showing that IgA1, IgG1 and IgA2 often share clonal 
lineages with each other, and that IgA subclasses appear to switch from IgG subclasses 
(if they are related by direct switch at all), rather than the reverse. In particular, IgA1 
and IgA2 in pemphigus are highly related, and some IgG1 share lineages with, or even 
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directly class switch to, IgA1. Also notable is the lack of detected lineage relationships 
between IgA1 to IgG4, casting doubt on the idea that the mucosal to mucocutaneous 
disease course in PV is due to cross-reactivity hiding in IgA1. More generally, the fact 
that switching seems to proceed in the IgG to IgA direction suggests that IgA is not 
important for the ontogeny of PV, but may instead be an epiphenomenon or serve a 
disease-modifying function, possibilities we discuss later in this chapter. 
Our results suggest that there exist two major axes of class-switching in PV, 
tracing two different paths through the antibody repertoire. First there is an 
interconnected IgG1-IgA1-IgA2 repertoire reactive to a wide range of epitopes on the 
Dsg molecule, and a solitary IgG4 +/- IgA2 repertoire tightly focused on the N-terminal 
domains of Dsg. The implications of these newly-characterized lineage relationships in 
PV, and in other will be discussed in the next sections. 
 
4.2 Discussion and Future Directions 
4.2.1 The Autoantibody Repertoire in PV is Highly Diverse 
 For the first time, we have categorized subclass-specific repertoires in 
pemphigus vulgaris, managing to isolate an unprecedented 80 lineages worth of 
validated anti-Dsg3 and anti-Dsg1 antibodies. Particularly notable is the fact that the 
response is highly polyclonal, encompassing many different CDR3 sequences and VH 
genes; this stands in contrast with the fact that some antigen-specific sequences appear 
to be highly stereotyped and shared between patients (416). Repertoire studies of 
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dengue fever (275), influenza vaccination (417), and HIV (418) have shown convergent 
CDR sequences, and some autoantibodies show shared VH gene usage across patients 
(419)(420)(421). Previous antibody cloning efforts in PV identified shared usage of the 
VH1-46 gene segment between patients (367), and also found that some pathogenic 
anti-Dsg antibodies share a D/E-X-X-X-W motif (209). In contrast, we only found VH1-46 
antibodies in two of our four patients, only one of which had VH1-46 IgG. Furthermore, 
there were no convergent CDR3 sequences between patients 
Our results suggest that the response to desmoglein has the potential to be 
much more polyclonal than initially anticipated, across all subclasses studied. Despite 
this, the plurality of clones across the panel of patients seem to bind to the EC1 domain 
of Dsg; this EC1 preference is particularly notable in the IgG4 clones. The reasons for this 
are unclear; perhaps particular epitopes within the EC1 domain are more easily 
displayed on dendritic cells or other antigen-presenting cells, or more easily shed into 
the circulation and taken up by antigen-presenting cells after keratinocyte death (thus 
triggering an immune response), or are particularly proficient at triggering an IgG4 class 
switch pathway. More generally, it may still be the case that within each EC domain, 
different subclasses preferentially bind to different amino acid residues. Finer mapping 
using competition ELISA or hydrogen-deuterium exchange (422,423) may reveal that 
IgG4 clones segregate to different epitopes in the EC1 and EC2 domain than N-terminal-
binding IgG1, IgA1, or IgA2 clones, possibly explaining the relationship between IgG4 
and disease activity. It would be particularly interesting, for example, if IgG4 clones 
preferentially bound to residues critical for adhesion, while other subclasses did not. 
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4.2.2 The Potential Role of IgA in PV 
The possibility of cross-reactivity to mucosal antigens in PV has previously been 
investigated by our laboratory in the context of the shared VH gene usage theory. 
Because VH1-46 antibodies with low somatic mutation counts were found in several PV 
patients (367), and the VH1-46 segment is also prominent in the response to rotavirus 
(424), it was postulated that VH1-46 antibodies could be cross-reactive to both Dsg3 and 
rotavirus coat protein; several such antibodies were isolated from a PV patient’s IgM 
repertoire (401). The idea of an IgA origin of disease was also particularly intriguing 
because a substantial portion of the mucosal repertoire has been found to be 
polyreactive, suggesting that the tolerance mechanisms in the mucosal immune system 
are somewhat relaxed to help fend off infection and keep commensal bacteria in check 
(265,425,426). Our experiments have instead suggested that anti-Dsg IgG4 antibodies 
likely do not originate from IgA1. This is not entirely unexpected - the IgA1 to IgG4 
pathway is relatively rare, representing 4% of all direct switches to IgG4 in the class-
switching landscape outlined by the Quake group (137), and had not been characterized 
prior to that study. Furthermore, because IgA2 is distal to IgG4 on the IgH locus, IgA2 
cannot be the origin of anti-Dsg IgG4.  
Collectively, our experiments seem to demonstrate the opposite relationship – 
that of at least some IgA clones switching from IgG clones. There is a demonstrable 
parent-child relationship between some anti-Dsg IgG1 and some IgA1 in autoreactive B 
cell lineages in PV, suggesting that at least part of the anti-Dsg IgA1 repertoire arises 
directly from IgG1 through class switching. In vitro experiments have shown that CD40 
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engagement and TGFbeta can induce an IgM-IgG1-IgA sequential switch (410). In the 
Quake dataset, the IgG1 to IgA1 class-switch pathway is the second most common in the 
overall class-switching landscape, second only to the IgM to IgA1 switch (137). 
Unexpectedly, our results also showed a close relationship between some anti-
Dsg IgG4 and anti-Dsg IgA2 in PV. Such a relationship in the normal antibody repertoire 
was first discovered earlier this year in the Quake dataset; across a panel of 22 patients, 
totaling 120000 unique IgA2 sequences and 16000 unique IgG4 sequences, that study 
found a total of two sequences identical between IgG4 and IgA2, making our finding all 
the more remarkable (137). Because our protocols called for separately amplifying and 
sequencing each subclass using hinge-specific amplicons, our experiment is particularly 
well-powered to find potentially rare class-switch pathways like this one, compared to 
previous studies. Whether this IgG4-IgA2 axis is equally prevalent in normal individuals, 
or specifically upregulated in pathological states like PV or other IgG4-mediated 
conditions, is unknown, and could be the subject of future subclass-specific repertoire 
sequencing experiments.  
It is also notable that the majority of characterized anti-Dsg IgA2-containing 
lineages show direct switching from IgA1, which often occurs via a well-characterized 
extrafollicular T-independent class-switch pathway induced by the secretion of APRIL 
from intestinal epithelial cells, triggered by antigens from mucosal normal flora (91). The 
possibility therefore exists that autoreactive IgA2 arises through both GC and 
extrafollicular responses. However, because we have not tracked the cell of origin 
135 
 
through its development, we cannot determine for sure which pathway gave rise to any 
given anti-Dsg clone. 
Collectively, these experiments suggest that anti-Dsg IgA are not the origin of 
autoreactivity in PV, and that therefore the switch from IgG to IgA could simply be an 
epiphenomenon triggered by the localized effect of IgA class-switch mediators and/or 
cross-reactivity of anti-Dsg IgG clones to some unknown antigens present in the mucosa. 
However, it raises the possibility that an IgG to IgA switch could serve a disease-
modifying function in PV. It would be interesting, for example, to determine by 
immunostaining whether the IgA deposits in the skin of patients with neutrophilic 
infiltrate belong to the IgA1, IgA2, or both subclasses. It would be even more interesting 
to determine whether the IgA-secreting B cells creating those deposits switched from 
IgG by repertoire cloning of IgA+ plasma cells. An IgG1 to IgA or IgG4 to IgA2 class-switch 
would then be shown to be contributing to the painful inflammation experienced by PV 
patients due to neutrophilic infiltrates. 
 
4.2.3 The Relationship Between Antigen-Specific IgG1 and IgG4 in PV 
The inverse relationship between IgG1 and IgG4 in the setting of chronic antigen 
stimulation is well-characterized, but subclass-specific repertoires have not extensively 
been analyzed in this context. The Quake dataset suggests that approximately 25% of all 
class switches leading to IgG4 originate in IgG1, while the plurality (38%) originate in 
IgG2 (137). Our results indicate that rather than a sequential switch, it appears to be the 
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case that anti-Dsg IgG1 and IgG4 exist in independent lineages, with the latter emerging 
during active disease.  
A priori, there exist three possibilities for the relationship between anti-Dsg IgG1 
and IgG4: direct switch from IgG1 to IgG4, independent switch from common 
precursors, or independent evolution. Of 39 anti-Dsg IgG4-containing lineages found by 
our study, 8 of them contain both IgG1 and IgG4 sequences, and only one of them 
displays and IgG1 to IgG4 direct switch. Taken at face value, this seems to suggest that 
the majority (31/39) of anti-Dsg IgG4 arises completely independently of IgG1, a small 
minority arises through direct switch (1/39), while the rest share common precursors 
with IgG1 without displaying a direct switch. In contrast, there exist 30 anti-Dsg IgA2-
containing lineages; 21 of them contain IgA1 reads. Furthermore, of the 11 lineages 
containing IgA1 and IgA2 reads that we subjected to phylogenetic analysis, 10 of them 
showed a direct switch from IgA1 to IgA2.  
Because we robustly detect overlap between two subclasses (IgA1 and IgA2) and 
by contrast, do not detect it in another pair (IgG1 and IgG4), our data suggests we are 
sufficiently powered to detect multi-subclass anti-Dsg lineages in PV. This suggests that 
at the level of our sampling, the IgG1 and IgG4 anti-Dsg clones are disjoint compared to 
IgA1 and IgA2; in particular, we have demonstrated that anti-Dsg IgG4 preferentially 
segregates into single-subclass over than multi-subclass lineages compared to the other 
three subclasses we have analyzed (see Figure 3-3D).  
However, we cannot conclusively conclude that there do not exist IgG1 relatives 
for anti-Dsg IgG4 clones, for two overarching reasons. First, sufficient sampling of the B 
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cell repertoire by sequencing is an issue. While rarefaction analysis indicates that the 
repertoire sequencing has sampled over 70% of the lineages in the peripheral 
repertoire; however, we have only drawn 1% of the total peripheral blood, and only 2% 
of a human’s B cells are circulating at any given time (46); there is always the possibility 
that the IgG1 relatives (either IgG1 precursors of IgG4 or IgG1 shared or of our detected 
anti-Dsg IgG4 clones simply have escaped sequencing, either because they are 
circulating and not captured or because they are residing in a secondary lymphoid organ 
and thus cannot be sampled by a blood draw. A repertoire-cloning experiment that 
sequences several more biological replicates of blood and obtains tissues from other 
organs (spleen, MALT, skin-draining lymph nodes) would improve the chances of 
capturing these putative IgG1 relatives. Related to this is the issue that, because the 
experiments sampled directly from whole PBMC RNA, we are probably over-
representing transcripts from plasmablasts, which dilutes the contribution from 
memory B cells and therefore make them less likely to be captured by our amplification. 
To counteract this issue, future repertoire studies could bulk sort memory and 
plasmablasts separately (or sort single B cells), and prepare sequencing libraries from 
them independently, which would ensure that plasmablast RNA does not swamp out 
the contribution from memory B cells. Second, there is the possibility is that IgG1 
precursors or relatives no longer exist; they may have existed only as transient 
intermediates during an IgM to IgG1 to IgG4 switch. Future experiments could solve this 
issue by longitudinally cloning subclass-specific repertoires during disease onset and 
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remission, though even this may not capture transient IgG1 intermediates if they don’t 
circulate for sufficient duration. 
There are also some drawbacks to the phage display technique worth 
considering as a source of error or undersampling. First is the issue of light chains, which 
presents several caveats. Even though we can screen between 100 million and 1 billion 
transformants per patient-subclass pair, the random pairing of heavy and light chains 
may have failed to pair some reactive heavy chains with compatible light chains. This 
leads to the possibility that there exists some related IgG1-IgG4 pair that wasn’t 
sampled in either the IgG1 or IgG4 libraries, and therefore wasn’t analyzed. This can be 
solved by constructing multiple libraries from a single patient-subclass pair and panning 
them independently, increasing the chances that a given anti-Dsg heavy chain pairs with 
a permissive light chain. Alternatively, a future study could use a technique that 
preserves heavy-light pairing (for example trapping individual cells in emulsified droplets 
(427)), perhaps coupled to a flow-cytometry-based technique for sorting single B cells 
for Dsg-reactivity; this would ensure that every heavy chain is screened while expressed 
alongside its cognate light chain, eliminating the question of whether an in vivo reactive 
heavy chain is missed.  
There is also the possibility that some of our anti-Dsg antibodies primarily gain 
their reactivity from their light chain, rather than their heavy chains. While antibodies 
generally make most of their contacts through heavy chain CDR residues, there are 
examples in the literature where antigen recognition is encoded by the light chain 
(428)(429). In many cases, we found several anti-Dsg reactive heavy chains bound to 
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different light chains, suggesting that the heavy chain remains the most important 
determinant in binding in many cases; however, it may be the case that some of our 
anti-Dsg heavy chains actually have no anti-Dsg activity in vivo and are therefore 
irrelevant to disease, due to all anti-Dsg activity being mediated by the (mispaired) light 
chain. The methods outlined above, which preserve heavy-light pairing, would mitigate 
the possibility of irrelevant heavy chains entering the analysis.  
Another overarching issue is that phage display is designed to find a particular 
type of antibody, rather than sample the full breadth of response to a given antigen. 
Phage display is optimized to find high-affinity clones, and in particular our stringent 
washing procedures may be selecting for high-affinity clones with slow disassociation 
rates. This has a few implications. First, high-affinity clones may be out-competing 
disease-relevant low-affinity clones binding to the same epitope, or simply due to high-
affinity clones dominating growth during phage amplification. There may be entire 
lineages of disease-relevant low-affinity clones missed by our panning for this reason. 
Amplifying and panning the unbound phage from each round, or decreasing washing 
time, may pick up some of these low-affinity binders. Furthermore, it may be the case 
that disease-relevant antibodies derive their high affinity from short association rates, 
rather than long dissociation rates. Antibodies with short association rates could 
theoretically be found by decreasing the initial incubation time of the library, which 
would favor clones that quickly associated with Dsg. 
Another drawback of our pipeline is that is that some positive clones may be 
toxic to phage or bacteria, meaning they fail to amplify during panning or may confer 
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growth disadvantages to the phage and will therefore be out-competed (430). Even 
small differences in growth rate in a library can lead to dropout of positive binders 
(431), suggesting that our screen may be missing several clones. This is further 
exacerbated by the fact that about half of the scFv that we attempted to produce in this 
experiment did not express in sufficient quantities for characterization, possibly due to 
aggregation or toxicity; this may be mitigated by expression and screening in eukaryotic 
systems. Another way to circumvent this issue is by using alternate screening 
technologies, like antigen-specific B cell sorting (432), yeast display (433), ribosome 
display (434), or mammalian cell surface display (435).  
Given these caveats, it may be the case that we are missing certain relevant anti-
Dsg antibodies and relatives in our samples. However, given the fact that our sampling, 
both through phage display and through sequencing, was sufficient to show that direct 
class-switching between anti-Dsg IgG1 and IgG4 in the periphery is not the predominant 
pathway of IgG4 production. The larger implications of this fact will be discussed in the 
next section. 
 
4.2.4 Mechanisms of PV Pathogenesis and Their Larger Implications 
The predominance of antigen-specific IgG4 in PV during active disease mirrors 
several other conditions, including other antibody-mediated autoimmune diseases (242) 
and subjects undergoing continuous antigen challenge, like allergen desensitization 
therapy (255,436), helminth infection (249)(437), and continuous exposure to bee 
venom antigens (248). In particular, an IgG1 to IgG4 shift occurs in beekeepers 
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undergoing repeated challenge by bee venom antigens; tolerant beekeepers produce 
IgG4 against bee venom from IL-10 secreting regulatory B cells, which dampen allergic 
reactions (407). Because IgG4 has no effector function, it is believed to serve as a 
“brake” on the immune response, competing with the binding of antibodies from other 
subclasses (253)(252). Further evidence for this fact includes that the regulatory 
cytokine IL-10 is responsible for biasing class-switch to IgG4 over IgE (438); this further 
suggests that the aforementioned IL-10 secreting B cells will bias other B cells to switch 
to IgG4 in the setting of chronic inflammation. 
Because of the temporal relationships between IgG1 and IgG4 in endemic PF 
triggered by continuous exposure to sandfly antigens (404)(406)(439) and in 
beekeepers, as well as the presence of IgG1, but not IgG4, in some healthy relatives of 
PV patients (246), it is tempting to suggest that PV arises by a similar mechanism of 
chronic antigen stimulation, though rather than some external antigen it could be Dsg 
doing the stimulating. Perhaps, for example, continuous shedding of Dsg3 extracellular 
domain from apoptotic keratinocytes, which is then taken up and presented in skin-
draining lymph nodes by Langerhans cells, cross-reactive B cells, or other antigen-
presenting cells, eventually leads to a germinal center response in genetically 
susceptible individuals. Possibly suggestive of this, studies have found that 
polymorphisms in the pro-apoptotic molecule ST18 are associated with PV in some 
populations, and that ST18 is expressed at higher levels in the skin of PV patients 
compared to controls (440)(441). Also suggestive is the fact that HLA-susceptible 
individuals sometimes have circulating autoreactive T cells; in particular, some HLA-
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susceptible individuals without disease seem to almost exclusively show autoreactive 
Th1 cells, while those with disease show both autoreactive Th1 and Th2 (442); this is 
concordant with the fact that IgG4 class-switch occurs in response to Th2 cytokines like 
IL-4 and IL-13 (443). This low-level stimulation over a lifetime would then trigger the 
switch to IgG4-secreting regulatory B cells, just like in beekeepers and the allergen-
desensitized – however, rather than the IgG4 serving a protective role, it actually is the 
hallmark of active disease, causing blistering and pathogenesis rather than dampening 
the response as it has evolved to do. Repertoire cloning from regulatory B cell subsets 
could determine whether this portion of the mechanism is plausible; if, like in allergen 
desensitization therapy and in beekeepers, the anti-Dsg IgG4 is exclusively secreted by 
regulatory B cells, this would suggest a shared mechanism between these situations. 
While the idea of continuous self-inoculation by Dsg resulting in disease is a 
plausible model, there are other possibilities for the shift to IgG4 that don’t involve a 
direct response to chronic antigen stimulation. For example, a normally protective IgM B 
cell cross-reactive to both Dsg and some pathogen could be induced to switch to IgG4 in 
the presence of a permissive Th2 cytokine milieu, rather than responding to Dsg 
directly; this appears to be the mechanism in endemic PF, in which persistent challenge 
with sandfly antigens leads to IgG4 that is cross-reactive to Dsg1 (404). This possibility is 
particularly raised due to the cross-reactivity of VH1-46 IgM antibodies cloned from PV 
patients to both Dsg3 and the rotavirus protein VP6 (401); however, because we have 
determined that the anti-Dsg response is not VH restricted, such a single inciting event 
of cross-reactivity may not be sufficient to explain all instances of PV. It would be 
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intriguing, however, if cross-reactivity shaped and modified the response in some way. It 
is possible that, for example, IgG1 and IgG4 that arise from common precursors due so 
due to cross-reactivity of their IgM precursors to some pathogen (followed by a Th2 
response that leads the same IgM B cell to switch independently to IgG1 and IgG4). 
Further testing of germline IgG4 and IgG1 precursors for polyreactivity or cross-
reactivity to pathogens is necessary to determine whether this is a feasible outcome.  
If PV, in fact, arises through the same mechanisms as other forms of chronic 
antigen stimulation, the largely disjoint lineage relationship between IgG1 and IgG4 we 
have characterized in PV suggests that chronic antigen stimulation could lead to the 
production of circulating IgG4 plasma cells directly from IgM, IgG2, or IgG3, which like 
IgG1 lie 5’ to the IgG4 constant region on the IgH locus. These results also have 
implications for other IgG4-dominant autoimmune diseases and the IgG4 response to 
chronic antigen stimulation. It would be interesting, for example to longitudinally clone 
IgG1 and IgG4 in beekeepers to determine whether they share a lineage or arise 
independently, which would answer a fundamental question about the immune 
system’s self-limiting response to constant antigen challenge. Determining the cell of 
origin, lineage, and maturation pathways of IgG4 in different types of chronic antigen 
stimulation, for example, could lead to therapeutics that specifically up-regulate (in the 
case where it’s protective, i.e. allergen desensitization therapy) or down-regulate (in the 
case where it’s pathogenic, i.e. PV and other IgG4-mediated autoimmune diseases) the 
IgG4 response in these situations, leading to more targeted therapies against 
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pathogenic IgG4-mediated conditions and superior responses to existing therapies that 
require an IgG4 response.  
Confirming this idea of two separate switch pathways for the majority of IgG4 
and the majority of IgG1 will require subclass-specific repertoire sequencing of IgG2 and 
IgG3 in PV patients; there remains a possibility that affinity maturation and class 
switching from these subclasses is the true origin of anti-Dsg IgG4, though this appears 
unlikely due to the lack of involvement of these subclasses in disease. Ruling those out 
at intermediates would then suggest that IgG4 originate directly from IgM. It would then 
be very interesting if in their germline configuration, anti-Dsg IgG4 clones show altered 
affinity, epitope coverage, and/or polyreactivity relative to anti-Dsg IgG1 germline 
sequences. Our experiments showed significant germline and early reactivity to Dsg in 
IgG4-containing lineages, suggesting that there is broader potential for naïve B cell anti-
Dsg reactivity than previously appreciated, and that IgG4 may arise from such anti-Dsg 
IgM clones.  
 
4.3  Summary 
 This thesis has sought to answer the question of whether autoreactive IgG4 B 
cells arise from other autoreactive subclasses in PV. More broadly, we have asked the 
question: what are the clonal relationships between autoreactive B cells belonging to 
different subclasses in PV? We have provided compelling evidence that autoreactive 
IgG4 clones in PV largely do not share lineages with other subclasses, suggesting that 
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IgG4 in other settings may also arise independently. This has implications on the 
pathogenesis of other IgG4-mediated autoimmune disease and on the mechanism 
behind the response to chronic antigen stimulation in general. Future experiments 
should focus on generalizing this result to include more patients and more subclasses, 
on testing the implications of this result for IgG4 responses in the setting of chronic 
antigen stimulation or autoimmune disease, and on further characterization of germline 
and somatically mutated intermediates in established anti-Dsg lineages to better 
understand the evolution of the autoreactive B cell repertoire in PV and the IgG4 













CHAPTER 5:  
References 
 
1.  Borges JL, Giral A. The Library of Babel. Boston: David R. Godine Publisher; 2000. 
39 p.  
2.  Dennett DC. Darwin’s Dangerous Idea: Evolution and the Meaning of Life. Reprint 
edition. Simon & Schuster; 2014. 594 p.  
3.  Ostermeier M. Beyond cataloging the Library of Babel. Chem Biol. 2007 
Mar;14(3):237–8.  
4.  Arnold FH. “The Library of Maynard-Smith: My Search for Meaning in the protein 
universe”. Adv Protein Chem. 2000;55:ix–xi. 
5.  Autoimmune Statistics [Internet]. AARDA. [cited 2016 Sep 7]. Available from: 
https://www.aarda.org/autoimmune-information/autoimmune-statistics/ 
6.  Hirano M, Das S, Guo P, Cooper MD. The evolution of adaptive immunity in 
vertebrates. Adv Immunol. 2011;109:125–57.  
7.  Matsuda F, Ishii K, Bourvagnet P, Kuma K, Hayashida H, Miyata T, et al. The 
Complete Nucleotide Sequence of the Human Immunoglobulin Heavy Chain 
Variable Region Locus. J Exp Med. 1998 Dec 7;188(11):2151–62.  
8.  McBride OW, Hieter PA, Hollis GF, Swan D, Otey MC, Leder P. Chromosomal 
location of human kappa and lambda immunoglobulin light chain constant region 
genes. J Exp Med. 1982 May 1;155(5):1480–90.  
9.  Krangel MS. The Ties that Bind (the Igh Locus). Trends Genet TIG. 2016 
May;32(5):253–5.  
10.  Tonegawa S. Somatic generation of antibody diversity. Nature. 1983 Apr 
14;302(5909):575–81.  
11.  Hozumi N, Tonegawa S. Evidence for somatic rearrangement of immunoglobulin 
genes coding for variable and constant regions. Proc Natl Acad Sci U S A. 1976 
Oct;73(10):3628–32.  
12.  Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid 
lineage depends on the transcription factor Pax5. Nature. 1999 Dec 16;402:14–20.  
13.  Lee B, Dekker JD, Lee B, Iyer VR, Sleckman BP, Shaffer AL, et al. The BCL11A 
Transcription Factor Directly Activates RAG Gene Expression and V(D)J 
Recombination. Mol Cell Biol. 2013 May 1;33(9):1768–81.  
147 
 
14.  Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent 
genes that synergistically activate V(D)J recombination. Science. 1990 Jun 
22;248(4962):1517–23.  
15.  McBlane JF, van Gent DC, Ramsden DA, Romeo C, Cuomo CA, Gellert M, et al. 
Cleavage at a V(D)J recombination signal requires only RAG1 and RAG2 proteins 
and occurs in two steps. Cell. 1995 Nov 3;83(3):387–95.  
16.  Kim M-S, Lapkouski M, Yang W, Gellert M. Crystal Structure of the V(D)J 
Recombinase RAG1-RAG2. Nature. 2015 Feb 26;518(7540):507–11.  
17.  Ru H, Chambers MG, Fu T-M, Tong AB, Liao M, Wu H. Molecular Mechanism of 
V(D)J Recombination from Synaptic RAG1-RAG2 Complex Structures. Cell. 2015 
Nov 19;163(5):1138–52.  
18.  Lapkouski M, Chuenchor W, Kim M-S, Gellert M, Yang W. Assembly Pathway and 
Characterization of the RAG1/2-DNA Paired and Signal-end Complexes. J Biol 
Chem. 2015 Jun 5;290(23):14618–25.  
19.  Yaoita Y, Matsunami N, Choi CY, Sugiyama H, Kishimoto T, Honjo T. The D-JH 
complex is an intermediate to the complete immunoglobulin heavy-chain V-region 
gene. Nucleic Acids Res. 1983 Nov 11;11(21):7303–16.  
20.  Baltimore D. Is terminal deoxynucleotidyl transferase a somatic mutagen in 
lymphocytes? Nature. 1974 Mar 29;248(447):409–11.  
21.  Desiderio SV, Yancopoulos GD, Paskind M, Thomas E, Boss MA, Landau N, et al. 
Insertion of N regions into heavy-chain genes is correlated with expression of 
terminal deoxytransferase in B cells. Nature. 1984 Oct 25;311(5988):752–5.  
22.  Motea EA, Berdis AJ. Terminal Deoxynucleotidyl Transferase: The Story of a 
Misguided DNA Polymerase. Biochim Biophys Acta. 2010 May;1804(5):1151–66.  
23.  Chang HHY, Lieber MR. Structure-Specific nuclease activities of Artemis and the 
Artemis: DNA-PKcs complex. Nucleic Acids Res. 2016 Jun 20;44(11):4991–7.  
24.  Malu S, De Ioannes P, Kozlov M, Greene M, Francis D, Hanna M, et al. Artemis C-
terminal region facilitates V(D)J recombination through its interactions with DNA 
Ligase IV and DNA-PKcs. J Exp Med. 2012 May 7;209(5):955–63.  
25.  Jackson KJ, Gaeta B, Sewell W, Collins AM. Exonuclease activity and P nucleotide 
addition in the generation of the expressed immunoglobulin repertoire. BMC 
Immunol. 2004;5:19.  
26.  Grawunder U, Zimmer D, Fugmann S, Schwarz K, Lieber MR. DNA Ligase IV Is 
Essential for V(D)J Recombination and DNA Double-Strand Break Repair in Human 
Precursor Lymphocytes. Mol Cell. 1998 Oct;2(4):477–84.  
148 
 
27.  Malu S, Malshetty V, Francis D, Cortes P. Role of non-homologous end joining in 
V(D)J recombination. Immunol Res. 2012 Dec;54(1–3):233–46.  
28.  Alt FW, Yancopoulos GD, Blackwell TK, Wood C, Thomas E, Boss M, et al. 
Ordered rearrangement of immunoglobulin heavy chain variable region segments. 
EMBO J. 1984 Jun;3(6):1209–19.  
29.  Zhang M, Srivastava G, Lu L. The pre-B cell receptor and its function during B cell 
development. Cell Mol Immunol. 2004 Apr;1(2):89–94.  
30.  Mårtensson I-L, Almqvist N, Grimsholm O, Bernardi AI. The pre-B cell receptor 
checkpoint. FEBS Lett. 2010 Jun 18;584(12):2572–9.  
31.  Anbazhagan K, Rabbind Singh A, Isabelle P, Stella I, Céline A-DM, Bissac E, et al. 
Human pre-B cell receptor signal transduction: evidence for distinct roles of 
PI3kinase and MAP-kinase signalling pathways. Immun Inflamm Dis. 2013 
Oct;1(1):26–36.  
32.  Melchers F, ten Boekel E, Seidl T, Kong XC, Yamagami T, Onishi K, et al. 
Repertoire selection by pre-B-cell receptors and B-cell receptors, and genetic control 
of B-cell development from immature to mature B cells. Immunol Rev. 2000 
Jun;175:33–46.  
33.  Bergman Y, Cedar H. A stepwise epigenetic process controls immunoglobulin allelic 
exclusion. Nat Rev Immunol. 2004 Oct;4(10):753–61.  
34.  Mårtensson I-L, Rolink A, Melchers F, Mundt C, Licence S, Shimizu T. The pre-B 
cell receptor and its role in proliferation and Ig heavy chain allelic exclusion. Semin 
Immunol. 2002 Oct;14(5):335–42.  
35.  Vettermann C, Schlissel MS. Allelic exclusion of immunoglobulin genes: models and 
mechanisms. Immunol Rev. 2010 Sep;237(1):22–42.  
36.  Nishimoto N, Kubagawa H, Ohno T, Gartland GL, Stankovic AK, Cooper MD. 
Normal pre-B cells express a receptor complex of mu heavy chains and surrogate 
light-chain proteins. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6284–8.  
37.  Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015 
Jun;125(6):2203–10.  
38.  Boyd SD, Gaëta BA, Jackson KJ, Fire AZ, Marshall EL, Merker JD, et al. Individual 
variation in the germline Ig gene repertoire inferred from variable region gene 
rearrangements. J Immunol Baltim Md 1950. 2010 Jun 15;184(12):6986–92.  
39.  Lefranc MP. Nomenclature of the human immunoglobulin heavy (IGH) genes. Exp 
Clin Immunogenet. 2001;18(2):100–16.  
149 
 
40.  Lefranc MP. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 
2001 Jan 1;29(1):207–9.  
41.  Jr CAJ, Travers P, Walport M, Shlomchik MJ, Jr CAJ, Travers P, et al. 
Immunobiology. 5th ed. Garland Science; 2001.  
42.  Lefranc MP. Nomenclature of the human immunoglobulin lambda (IGL) genes. Exp 
Clin Immunogenet. 2001;18(4):242–54.  
43.  Lefranc MP. Nomenclature of the human immunoglobulin kappa (IGK) genes. Exp 
Clin Immunogenet. 2001;18(3):161–74.  
44.  Williams SC, Frippiat JP, Tomlinson IM, Ignatovich O, Lefranc MP, Winter G. 
Sequence and evolution of the human germline V lambda repertoire. J Mol Biol. 
1996 Nov 29;264(2):220–32.  
45.  Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. mAbs. 
2010;2(3):347–56.  
46.  Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR. The 
promise and challenge of high-throughput sequencing of the antibody repertoire. Nat 
Biotechnol. 2014 Feb;32(2):158–68.  
47.  Yaari G, Kleinstein SH. Practical guidelines for B-cell receptor repertoire sequencing 
analysis. Genome Med [Internet]. 2015 Nov 20 [cited 2016 Sep 8];7. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654805/ 
48.  Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996 Jun 
27;381(6585):751–8.  
49.  Ehlich A, Martin V, Müller W, Rajewsky K. Analysis of the B-cell progenitor 
compartment at the level of single cells. Curr Biol. 1994 Jul;4(7):573–83.  
50.  Prak EL, Weigert M. Light chain replacement: a new model for antibody gene 
rearrangement. J Exp Med. 1995 Aug 1;182(2):541–8.  
51.  Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen 
recognition. B Cell Biol. 2013;4:302.  
52.  Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical 
structures of immunoglobulins. J Mol Biol. 1997 Nov 7;273(4):927–48.  
53.  Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the 
complementarity-determining regions in a human antibody with those from a mouse. 
Nature. 1986 Jun 29;321(6069):522–5.  
54.  MacCallum RM, Martin ACR, Thornton JM. Antibody-antigen Interactions: Contact 
Analysis and Binding Site Topography. J Mol Biol. 1996 Oct 11;262(5):732–45.  
150 
 
55.  Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence 
Jones proteins and myeloma light chains and their implications for antibody 
complementarity. J Exp Med. 1970 Aug 1;132(2):211–50.  
56.  Padlan EA. Anatomy of the antibody molecule. Mol Immunol. 1994 Feb;31(3):169–
217.  
57.  Robin G, Sato Y, Desplancq D, Rochel N, Weiss E, Martineau P. Restricted 
Diversity of Antigen Binding Residues of Antibodies Revealed by Computational 
Alanine Scanning of 227 Antibody–Antigen Complexes. J Mol Biol. 2014 Nov 
11;426(22):3729–43.  
58.  Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic 
mutations of the immunoglobulin framework are generally required for broad and 
potent HIV-1 neutralization. Cell. 2013 Mar 28;153(1):126–38.  
59.  Hershberg U, Luning Prak ET. The analysis of clonal expansions in normal and 
autoimmune B cell repertoires. Philos Trans R Soc B Biol Sci [Internet]. 2015 Sep 5 
[cited 2016 Sep 7];370(1676). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528416/ 
60.  Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards 
immune competence. Trends Immunol. 2003 Jun 1;24(6):342–8.  
61.  Agrawal S, Smith SABC, Tangye SG, Sewell WA. Transitional B cell subsets in 
human bone marrow. Clin Exp Immunol. 2013 Oct;174(1):53–9.  
62.  Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, et al. Novel human 
transitional B cell populations revealed by B cell depletion therapy. J Immunol 
Baltim Md 1950. 2009 May 15;182(10):5982–93.  
63.  De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 
2015 Mar;15(3):137–48.  
64.  Avalos AM, Ploegh HL. Early BCR Events and Antigen Capture, Processing, and 
Loading on MHC Class II on B Cells. Front Immunol [Internet]. 2014 Mar 10 [cited 
2016 Sep 13];5. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948085/ 
65.  Batista FD, Harwood NE. The who, how and where of antigen presentation to B 
cells. Nat Rev Immunol. 2009 Jan;9(1):15–27.  
66.  Laydon DJ, Bangham CRM, Asquith B. Estimating T-cell repertoire diversity: 
limitations of classical estimators and a new approach. Philos Trans R Soc B Biol Sci 




67.  Qi H, Cannons JL, Klauschen F, Schwartzberg PL, Germain RN. SAP-controlled T-B 
cell interactions underlie germinal centre formation. Nature. 2008 Oct 
9;455(7214):764–9.  
68.  Okada T, Miller MJ, Parker I, Krummel MF, Neighbors M, Hartley SB, et al. 
Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile 
conjugates with helper T cells. PLoS Biol. 2005 Jun;3(6):e150.  
69.  Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular 
interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. 
Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-
dependent help. J Immunol Baltim Md 1950. 1992 Dec 15;149(12):3817–26.  
70.  Slavik JM, Hutchcroft JE, Bierer BE. CD28/CTLA-4 and CD80/CD86 families: 
signaling and function. Immunol Res. 1999;19(1):1–24.  
71.  Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively 
recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004 
Sep;21(3):401–13.  
72.  Bromley SK, Iaboni A, Davis SJ, Whitty A, Green JM, Shaw AS, et al. The 
immunological synapse and CD28-CD80 interactions. Nat Immunol. 2001 
Dec;2(12):1159–66.  
73.  Chandra V, Bortnick A, Murre C. AID targeting: old mysteries and new challenges. 
Trends Immunol. 2015 Sep;36(9):527–35.  
74.  Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC. Transcription enhances 
AID-mediated cytidine deamination by exposing single-stranded DNA on the 
nontemplate strand. Nat Immunol. 2003 May;4(5):452–6.  
75.  Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. Transcription-targeted 
DNA deamination by the AID antibody diversification enzyme. Nature. 2003 Apr 
17;422(6933):726–30.  
76.  Dickerson SK, Market E, Besmer E, Papavasiliou FN. AID mediates hypermutation 
by deaminating single stranded DNA. J Exp Med. 2003 May 19;197(10):1291–6.  
77.  Schanz S, Castor D, Fischer F, Jiricny J. Interference of mismatch and base excision 
repair during the processing of adjacent U/G mispairs may play a key role in somatic 
hypermutation. Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5593–8.  
78.  Saribasak H, Gearhart PJ. Does DNA repair occur during somatic hypermutation? 
Semin Immunol. 2012 Aug;24(4):287–92.  
79.  Roa S, Li Z, Peled JU, Zhao C, Edelmann W, Scharff MD. MSH2/MSH6 complex 
promotes error-free repair of AID-induced dU:G mispairs as well as error-prone 
hypermutation of A:T sites. PloS One. 2010;5(6):e11182.  
152 
 
80.  Martin A, Scharff MD. AID and mismatch repair in antibody diversification. Nat Rev 
Immunol. 2002 Aug;2(8):605–14.  
81.  Wilson TM, Vaisman A, Martomo SA, Sullivan P, Lan L, Hanaoka F, et al. MSH2-
MSH6 stimulates DNA polymerase eta, suggesting a role for A:T mutations in 
antibody genes. J Exp Med. 2005 Feb 21;201(4):637–45.  
82.  Zeng X, Winter DB, Kasmer C, Kraemer KH, Lehmann AR, Gearhart PJ. DNA 
polymerase η is an A-T mutator in somatic hypermutation of immunoglobulin 
variable genes. Nat Immunol. 2001 Jun;2(6):537–41.  
83.  Meyer-Hermann ME, Maini PK, Iber D. An analysis of B cell selection mechanisms 
in germinal centers. Math Med Biol J IMA. 2006 Sep;23(3):255–77.  
84.  Zhang Y, Garcia-Ibanez L, Toellner K-M. Regulation of germinal center B-cell 
differentiation. Immunol Rev. 2016 Mar 1;270(1):8–19.  
85.  Tangye SG. Staying alive: regulation of plasma cell survival. Trends Immunol. 2011 
Dec 1;32(12):595–602.  
86.  Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-
secreting plasma cells. Nat Rev Immunol. 2015 Mar;15(3):160–71.  
87.  Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015 
Mar;15(3):149–59.  
88.  Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter H-H, et al. 
Human Immunoglobulin M Memory B Cells Controlling Streptococcus pneumoniae 
Infections Are Generated in the Spleen. J Exp Med. 2003 Apr 7;197(7):939–45.  
89.  Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A. Integration of B cell 
responses through Toll-like receptors and antigen receptors. Nat Rev Immunol. 2012 
Apr;12(4):282–94.  
90.  Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce 
CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat 
Immunol. 2002 Sep;3(9):822–9.  
91.  He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria 
trigger T cell-independent immunoglobulin A(2) class switching by inducing 
epithelial-cell secretion of the cytokine APRIL. Immunity. 2007 Jun;26(6):812–26.  
92.  Paus D, Phan TG, Chan TD, Gardam S, Basten A, Brink R. Antigen recognition 
strength regulates the choice between extrafollicular plasma cell and germinal center 
B cell differentiation. J Exp Med. 2006 Apr 17;203(4):1081–91.  
93.  McHeyzer-Williams MG, McLean MJ, Lalor PA, Nossal GJ. Antigen-driven B cell 
differentiation in vivo. J Exp Med. 1993 Jul 1;178(1):295–307.  
153 
 
94.  Belessi C, Stamatopoulos K, Stavroyianni N, Zoi K, Papadaki T, Kosmas C. Somatic 
hypermutation targeting to intrinsic hotspots of immunoglobulin genes in follicular 
lymphoma and multiple myeloma. Leukemia. 2001 Nov;15(11):1772–8.  
95.  Milstein C, Neuberger MS, Staden R. Both DNA strands of antibody genes are 
hypermutation targets. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8791–4.  
96.  Rogozin IB, Kolchanov NA. Somatic hypermutagenesis in immunoglobulin genes. II. 
Influence of neighbouring base sequences on mutagenesis. Biochim Biophys Acta. 
1992 Nov 15;1171(1):11–8.  
97.  Rogozin IB, Diaz M. Cutting Edge: DGYW/WRCH Is a Better Predictor of 
Mutability at G:C Bases in Ig Hypermutation Than the Widely Accepted 
RGYW/WRCY Motif and Probably Reflects a Two-Step Activation-Induced 
Cytidine Deaminase-Triggered Process. J Immunol. 2004 Mar 15;172(6):3382–4.  
98.  Rogozin IB, Pavlov YI, Bebenek K, Matsuda T, Kunkel TA. Somatic mutation 
hotspots correlate with DNA polymerase η error spectrum. Nat Immunol. 2001 
Jun;2(6):530–6.  
99.  Longo NS, Satorius CL, Plebani A, Durandy A, Lipsky PE. Characterization of 
immunoglobulin gene somatic hypermutation in the absence of activation-induced 
cytidine deaminase. J Immunol Baltim Md 1950. 2008 Jul 15;181(2):1299–306.  
100.  Yavuz S, Yavuz AS, Kraemer KH, Lipsky PE. The role of polymerase eta in 
somatic hypermutation determined by analysis of mutations in a patient with 
xeroderma pigmentosum variant. J Immunol Baltim Md 1950. 2002 Oct 
1;169(7):3825–30.  
101.  Yaari G, Vander Heiden JA, Uduman M, Gadala-Maria D, Gupta N, Stern JNH, 
et al. Models of Somatic Hypermutation Targeting and Substitution Based on 
Synonymous Mutations from High-Throughput Immunoglobulin Sequencing Data. 
Front Immunol [Internet]. 2013 Nov 15 [cited 2016 Sep 7];4. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828525/ 
102.  Jolly CJ, Wagner SD, Rada C, Klix N, Milstein C, Neuberger MS. The targeting 
of somatic hypermutation. Semin Immunol. 1996 Jun 1;8(3):159–68.  
103.  Wei L, Chahwan R, Wang S, Wang X, Pham PT, Goodman MF, et al. 
Overlapping hotspots in CDRs are critical sites for V region diversification. Proc Natl 
Acad Sci. 2015 Feb 17;112(7):E728–37.  
104.  Wagner SD, Milstein C, Neuberger MS. Codon bias targets mutation. Nature. 
1995 Aug 31;376(6543):732.  
105.  Saini J, Hershberg U. B cell variable genes have evolved their codon usage to 
focus the targeted patterns of somatic mutation on the complementarity determining 
regions. Mol Immunol. 2015 May;65(1):157–67.  
154 
 
106.  Wilson PC, Bouteiller O de, Liu Y-J, Potter K, Banchereau J, Capra JD, et al. 
Somatic Hypermutation Introduces Insertions and Deletions into Immunoglobulin V 
Genes. J Exp Med. 1998 Jan 5;187(1):59–70.  
107.  Bowers PM, Verdino P, Wang Z, da Silva Correia J, Chhoa M, Macondray G, et 
al. Nucleotide Insertions and Deletions Complement Point Mutations to Massively 
Expand the Diversity Created by Somatic Hypermutation of Antibodies. J Biol 
Chem. 2014 Nov 28;289(48):33557–67.  
108.  Reason DC, Zhou J. Codon insertion and deletion functions as a somatic 
diversification mechanism in human antibody repertoires. Biol Direct. 2006;1:24.  
109.  Briney BS, Willis JR, Crowe JE. Location and length distribution of somatic 
hypermutation-associated DNA insertions and deletions reveals regions of antibody 
structural plasticity. Genes Immun. 2012 Oct;13(7):523–9.  
110.  de Wildt RMT, van Venrooij WJ, Winter G, Hoet RMA, Tomlinson IM. Somatic 
insertions and deletions shape the human antibody repertoire1. J Mol Biol. 1999 Dec 
3;294(3):701–10.  
111.  Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, et al. 
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 
pandemic influenza A (H1N1) viruses. J Virol. 2010 Mar;84(6):3127–30.  
112.  Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, et al. 
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic 
survivors. Nature. 2008 Sep 25;455(7212):532–6.  
113.  Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. Structural basis of 
preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010 Apr 
16;328(5976):357–60.  
114.  Kepler TB, Liao H-X, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, et al. 
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 
broadly reactive neutralizing antibodies. Cell Host Microbe. 2014 Sep 10;16(3):304–
13.  
115.  Tan J, Pieper K, Piccoli L, Abdi A, Foglierini M, Geiger R, et al. A LAIR1 
insertion generates broadly reactive antibodies against malaria variant antigens. 
Nature. 2016 Jan 7;529(7584):105–9.  
116.  Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein 
SH. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire 
sequencing data. Bioinforma Oxf Engl. 2015 Oct 15;31(20):3356–8.  
117.  Chaudhuri J, Basu U, Zarrin A, Yan C, Franco S, Perlot T, et al. Evolution of the 




118.  Flanagan JG, Rabbitts TH. Arrangement of human immunoglobulin heavy chain 
constant region genes implies evolutionary duplication of a segment containing 
gamma, epsilon and alpha genes. Nature. 1982 Dec 23;300(5894):709–13.  
119.  Stavnezer J, Schrader CE. IgH chain class switch recombination: mechanism and 
regulation. J Immunol Baltim Md 1950. 2014 Dec 1;193(11):5370–8.  
120.  Kinoshita K, Harigai M, Fagarasan S, Muramatsu M, Honjo T. A hallmark of 
active class switch recombination: Transcripts directed by I promoters on looped-out 
circular DNAs. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12620–3.  
121.  Geisberger R, Lamers M, Achatz G. The riddle of the dual expression of IgM and 
IgD. Immunology. 2006 Aug;118(4):429–37.  
122.  Pioli PD, Debnath I, Weis JJ, Weis JH. Zfp318 regulates IgD expression by 
abrogating transcription termination within the Ighm/Ighd locus. J Immunol Baltim 
Md 1950. 2014 Sep 1;193(5):2546–53.  
123.  Enders A, Short A, Miosge LA, Bergmann H, Sontani Y, Bertram EM, et al. 
Zinc-finger protein ZFP318 is essential for expression of IgD, the alternatively 
spliced Igh product made by mature B lymphocytes. Proc Natl Acad Sci U S A. 2014 
Mar 25;111(12):4513–8.  
124.  Otero DC, Rickert RC. CD19 Function in Early and Late B Cell Development. II. 
CD19 Facilitates the Pro-B/Pre-B Transition. J Immunol. 2003 Dec 1;171(11):5921–
30.  
125.  Cariappa A, Chase C, Liu H, Russell P, Pillai S. Naive recirculating B cells 
mature simultaneously in the spleen and bone marrow. Blood. 2007 Mar 
15;109(6):2339–45.  
126.  Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-
Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive 
Form of the Hyper-IgM Syndrome (HIGM2). Cell. 2000 Sep 1;102(5):565–75.  
127.  Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class 
Switch Recombination and Hypermutation Require Activation-Induced Cytidine 
Deaminase (AID), a Potential RNA Editing Enzyme. Cell. 2000 Sep 1;102(5):553–
63.  
128.  Longacre A, Storb U. A Novel Cytidine Deaminase Affects Antibody Diversity. 
Cell. 2000 Sep 1;102(5):541–4.  
129.  Shimizu A, Honjo T. Immunoglobulin class switching. Cell. 1984 Apr 
1;36(4):801–3.  
130.  Cameron L, Gounni AS, Frenkiel S, Lavigne F, Vercelli D, Hamid Q. SεSμ and 
SεSγ Switch Circles in Human Nasal Mucosa Following Ex Vivo Allergen 
156 
 
Challenge: Evidence for Direct as Well as Sequential Class Switch Recombination. J 
Immunol. 2003 Oct 1;171(7):3816–22.  
131.  Xiong H, Dolpady J, Wabl M, Curotto de Lafaille MA, Lafaille JJ. Sequential 
class switching is required for the generation of high affinity IgE antibodies. J Exp 
Med. 2012 Feb 13;209(2):353–64.  
132.  Mandler R, Finkelman FD, Levine AD, Snapper CM. IL-4 induction of IgE class 
switching by lipopolysaccharide-activated murine B cells occurs predominantly 
through sequential switching. J Immunol Baltim Md 1950. 1993 Jan 15;150(2):407–
18.  
133.  Looney TJ, Lee J-Y, Roskin KM, Hoh RA, King J, Glanville J, et al. Human B-
cell isotype switching origins of IgE. J Allergy Clin Immunol. 2016 Feb;137(2):579–
586.e7.  
134.  van Zelm MC. B cells take their time: sequential IgG class switching over the 
course of an immune response? Immunol Cell Biol. 2014 Sep;92(8):645–6.  
135.  Jackson KJL, Wang Y, Collins AM. Human immunoglobulin classes and 
subclasses show variability in VDJ gene mutation levels. Immunol Cell Biol. 2014 
Sep;92(8):729–33.  
136.  Berkowska MA, Driessen GJA, Bikos V, Grosserichter-Wagener C, 
Stamatopoulos K, Cerutti A, et al. Human memory B cells originate from three 
distinct germinal center-dependent and -independent maturation pathways. Blood. 
2011 Aug 25;118(8):2150–8.  
137.  Horns F, Vollmers C, Croote D, Mackey SF, Swan GE, Dekker CL, et al. Lineage 
tracing of human B cells reveals the in vivo landscape of human antibody class 
switching. eLife. 2016 Aug 2;5:e16578.  
138.  Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol. 
2007;95:83–110.  
139.  Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. 
Immunity. 2008 Jan;28(1):18–28.  
140.  Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. 
Predominant Autoantibody Production by Early Human B Cell Precursors. Science. 
2003 Sep 5;301(5638):1374–7.  
141.  Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt 
P, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. 
J Clin Invest. 2013 Jun;123(6):2737–41.  
157 
 
142.  Samuels J, Ng Y-S, Coupillaud C, Paget D, Meffre E. Impaired early B cell 
tolerance in patients with rheumatoid arthritis. J Exp Med. 2005 May 
16;201(10):1659–67.  
143.  Lee J, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E, et al. 
Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK 
myasthenia gravis. Ann Clin Transl Neurol. 2016 Apr 27;3(6):443–54.  
144.  Corsiero E, Sutcliffe N, Pitzalis C, Bombardieri M. Accumulation of Self-
Reactive Naïve and Memory B Cell Reveals Sequential Defects in B Cell Tolerance 
Checkpoints in Sjögren’s Syndrome. PLoS ONE [Internet]. 2014 Dec 23 [cited 2016 
Sep 8];9(12). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275206/ 
145.  Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. 
Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 
2005 Mar 7;201(5):703–11.  
146.  Keenan RA, Riva AD, Corleis B, Hepburn L, Licence S, Winkler TH, et al. 
Censoring of Autoreactive B Cell Development by the Pre-B Cell Receptor. Science. 
2008 Aug 1;321(5889):696–9.  
147.  Pewzner-Jung Y, Friedmann D, Sonoda E, Jung S, Rajewsky K, Eilat D. B cell 
deletion, anergy, and receptor editing in “knock in” mice targeted with a germline-
encoded or somatically mutated anti-DNA heavy chain. J Immunol Baltim Md 1950. 
1998 Nov 1;161(9):4634–45.  
148.  Hippen KL, Schram BR, Tze LE, Pape KA, Jenkins MK, Behrens TW. In vivo 
assessment of the relative contributions of deletion, anergy, and editing to B cell self-
tolerance. J Immunol Baltim Md 1950. 2005 Jul 15;175(2):909–16.  
149.  Pelanda R, Torres RM. Central B-Cell Tolerance: Where Selection Begins. Cold 
Spring Harb Perspect Biol. 2012 Apr 1;4(4):a007146.  
150.  Luning Prak ET, Monestier M, Eisenberg RA. B cell receptor editing in tolerance 
and autoimmunity. Ann N Y Acad Sci. 2011 Jan;1217:96–121.  
151.  Hieter PA, Korsmeyer SJ, Waldmann TA, Leder P. Human immunoglobulin 
kappa light-chain genes are deleted or rearranged in lambda-producing B cells. 
Nature. 1981 Apr 2;290(5805):368–72.  
152.  Korsmeyer SJ, Hieter PA, Sharrow SO, Goldman CK, Leder P, Waldmann TA. 
Normal human B cells display ordered light chain gene rearrangements and deletions. 
J Exp Med. 1982 Oct 1;156(4):975–85.  
153.  Langerak AW, Nadel B, De Torbal A, Wolvers-Tettero ILM, van Gastel-Mol EJ, 
Verhaaf B, et al. Unraveling the consecutive recombination events in the human IGK 
locus. J Immunol Baltim Md 1950. 2004 Sep 15;173(6):3878–88.  
158 
 
154.  Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone 
marrow B cells. J Exp Med. 1993 Apr 1;177(4):1009–20.  
155.  Darlow JM, Stott DI. VH replacement in rearranged immunoglobulin genes. 
Immunology. 2005 Feb;114(2):155–65.  
156.  Lang J, Ota T, Kelly M, Strauch P, Freed BM, Torres RM, et al. Receptor editing 
and genetic variability in human autoreactive B cells. J Exp Med. 2016 Jan 
11;213(1):93–108.  
157.  Zhang Z, Wang Y-H, Zemlin M, Findley HW, Bridges SL, Burrows PD, et al. 
Molecular mechanism of serial VH gene replacement. Ann N Y Acad Sci. 2003 
Apr;987:270–3.  
158.  Sun A, Novobrantseva TI, Coffre M, Hewitt SL, Jensen K, Skok JA, et al. VH 
replacement in primary immunoglobulin repertoire diversification. Proc Natl Acad 
Sci. 2015 Feb 3;112(5):E458–66.  
159.  Lange MD, Huang L, Yu Y, Li S, Liao H, Zemlin M, et al. Accumulation of VH 
Replacement Products in IgH Genes Derived from Autoimmune Diseases and Anti-
Viral Responses in Human. Front Immunol [Internet]. 2014 Jul 22 [cited 2016 Sep 
8];5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105631/ 
160.  Huang L, Lange MD, Zhang Z. VH Replacement Footprint Analyzer-I, a Java-
Based Computer Program for Analyses of Immunoglobulin Heavy Chain Genes and 
Potential VH Replacement Products in Human and Mouse. Front Immunol [Internet]. 
2014 Feb 10 [cited 2016 Sep 8];5. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918983/ 
161.  Meng W, Jayaraman S, Zhang B, Schwartz GW, Daber RD, Hershberg U, et al. 
Trials and Tribulations with VH Replacement. Front Immunol [Internet]. 2014 Jan 30 
[cited 2016 Sep 8];5. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906580/ 
162.  Nemazee DA, Bürki K. Clonal deletion of B lymphocytes in a transgenic mouse 
bearing anti-MHC class I antibody genes. Nature. 1989 Feb 9;337(6207):562–6.  
163.  Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, et al. 
Elimination of self-reactive B lymphocytes proceeds in two stages: arrested 
development and cell death. Cell. 1993 Feb 12;72(3):325–35.  
164.  Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination 
from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing 
membrane-bound antigens. Nature. 1991 Oct 24;353(6346):765–9.  
165.  Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic 




166.  Borrero M, Clarke SH. Low-affinity anti-Smith antigen B cells are regulated by 
anergy as opposed to developmental arrest or differentiation to B-1. J Immunol 
Baltim Md 1950. 2002 Jan 1;168(1):13–21.  
167.  Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, et al. 
Altered immunoglobulin expression and functional silencing of self-reactive B 
lymphocytes in transgenic mice. Nature. 1988 Aug 25;334(6184):676–82.  
168.  Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy 
requires constant antigen receptor occupancy and signaling. Nat Immunol. 2005 
Nov;6(11):1160–7.  
169.  Quách TD, Manjarrez-Orduño N, Adlowitz DG, Silver L, Yang H, Wei C, et al. 
Anergic Responses Characterize a Large Fraction of Human Autoreactive Naive B 
Cells Expressing Low Levels of Surface IgM. J Immunol. 2011 Apr 15;186(8):4640–
8.  
170.  Cyster JG, Goodnow CC. Antigen-induced exclusion from follicles and anergy 
are separate and complementary processes that influence peripheral B cell fate. 
Immunity. 1995 Dec;3(6):691–701.  
171.  Ekland EH, Forster R, Lipp M, Cyster JG. Requirements for follicular exclusion 
and competitive elimination of autoantigen-binding B cells. J Immunol Baltim Md 
1950. 2004 Apr 15;172(8):4700–8.  
172.  Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes 
self-reactive cells from the recirculating B-cell repertoire. Nature. 1994 Sep 
29;371(6496):389–95.  
173.  Getahun A, Beavers NA, Larson SR, Shlomchik MJ, Cambier JC. Continuous 
inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain 
unresponsiveness of anergic B cells. J Exp Med. 2016 May 2;213(5):751–69.  
174.  Pao LI, Lam K-P, Henderson JM, Kutok JL, Alimzhanov M, Nitschke L, et al. B 
Cell-Specific Deletion of Protein-Tyrosine Phosphatase Shp1 Promotes B-1a Cell 
Development and Causes Systemic Autoimmunity. Immunity. 2007 Jul 27;27(1):35–
48.  
175.  Maxwell MJ, Duan M, Armes JE, Anderson GP, Tarlinton DM, Hibbs ML. 
Genetic Segregation of Inflammatory Lung Disease and Autoimmune Disease 
Severity in SHIP-1−/− Mice. J Immunol. 2011 Jun 15;186(12):7164–75.  
176.  Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in 
antibody responses and autoimmunity. Nat Rev Immunol. 2005 Nov;5(11):853–65.  
177.  Maclennan I. Germinal-Centers. Annu Rev Immunol. 1994;12:117–39.  
160 
 
178.  Koopman G, Keehnen RM, Lindhout E, Zhou DF, de Groot C, Pals ST. Germinal 
center B cells rescued from apoptosis by CD40 ligation or attachment to follicular 
dendritic cells, but not by engagement of surface immunoglobulin or adhesion 
receptors, become resistant to CD95-induced apoptosis. Eur J Immunol. 1997 
Jan;27(1):1–7.  
179.  Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol 
Rev. 2011 May 1;241(1):133–44.  
180.  Xing Y, Hogquist KA. T-Cell Tolerance: Central and Peripheral. Cold Spring 
Harb Perspect Biol. 2012 Jun 1;4(6):a006957.  
181.  Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. 
Autoreactivity in human IgG+ memory B cells. Immunity. 2007 Feb;26(2):205–13.  
182.  Schroeder K, Herrmann M, Winkler TH. The role of somatic hypermutation in the 
generation of pathogenic antibodies in SLE. Autoimmunity. 2013 Mar;46(2):121–7.  
183.  Zhang J, Jacobi AM, Wang T, Diamond B. Pathogenic autoantibodies in systemic 
lupus erythematosus are derived from both self-reactive and non-self-reactive B cells. 
Mol Med Camb Mass. 2008 Dec;14(11–12):675–81.  
184.  Guo W, Smith D, Aviszus K, Detanico T, Heiser RA, Wysocki LJ. Somatic 
hypermutation as a generator of antinuclear antibodies in a murine model of systemic 
autoimmunity. J Exp Med. 2010 Sep 27;207(10):2225–37.  
185.  Li Y, Takahashi Y, Fujii S, Zhou Y, Hong R, Suzuki A, et al. EAF2 mediates 
germinal centre B-cell apoptosis to suppress excessive immune responses and prevent 
autoimmunity. Nat Commun. 2016;7:10836.  
186.  Russell DM, Dembić Z, Morahan G, Miller JF a. P, BÜrki K, Nemazee D. 
Peripheral deletion of self-reactive B cells. Nature. 1991 Nov 28;354(6351):308–11.  
187.  Ota T, Ota M, Duong BH, Gavin AL, Nemazee D. Liver-expressed Igκ 
superantigen induces tolerance of polyclonal B cells by clonal deletion not κ to λ 
receptor editing. J Exp Med. 2011 Mar 14;208(3):617–29.  
188.  Li Y, Ma L, Shen J, Chong AS. Peripheral deletion of mature alloreactive B cells 
induced by costimulation blockade. Proc Natl Acad Sci. 2007 Jul 17;104(29):12093–
8.  
189.  Rice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in 
peripheral B cell tolerance. Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1608–13.  
190.  Han S, Zheng B, Schatz DG, Spanopoulou E, Kelsoe G. Neoteny in 
Lymphocytes: Rag1 and Rag2 Expression in Germinal Center B Cells. Science. 1996 
Dec 20;274(5295):2094–7.  
161 
 
191.  Brard F, Shannon M, Prak EL, Litwin S, Weigert M. Somatic Mutation and Light 
Chain Rearrangement Generate Autoimmunity in Anti–Single-Stranded DNA 
Transgenic Mrl/lpr Mice. J Exp Med. 1999 Sep 6;190(5):691–704.  
192.  Reed JH, Jackson J, Christ D, Goodnow CC. Clonal redemption of autoantibodies 
by somatic hypermutation away from self-reactivity during human immunization. J 
Exp Med. 2016 Jun 27;213(7):1255–65.  
193.  Sabouri Z, Schofield P, Horikawa K, Spierings E, Kipling D, Randall KL, et al. 
Redemption of autoantibodies on anergic B cells by variable-region glycosylation 
and mutation away from self-reactivity. Proc Natl Acad Sci. 2014 Jun 
24;111(25):E2567–75.  
194.  Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, 
herpetiformis, brasiliensis). Clin Dermatol. 2011 Jul;29(4):432–6.  
195.  Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune 
bullous diseases. J Cell Mol Med. 2007 Jun;11(3):462–81.  
196.  Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical 
manifestations. JDDG J Dtsch Dermatol Ges. 2011 Oct 1;9(10):844–57.  
197.  Asilian A, Yoosefi A, Faghini G. Pemphigus vulgaris in Iran: epidemiology and 
clinical profile. Skinmed. 2006 Apr;5(2):69–71.  
198.  Salmanpour R, Shahkar H, Namazi MR, Rahman-Shenas MR. Epidemiology of 
pemphigus in south-western Iran: a 10-year retrospective study (1991-2000). Int J 
Dermatol. 2006 Feb;45(2):103–5.  
199.  Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous 
pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population 
based cohort study. BMJ. 2008 Jul 9;337:a180.  
200.  Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. 
Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective 
study. Br J Dermatol. 2009 Oct;161(4):861–8.  
201.  Bastuji-Garin S, Souissi R, Blum L, Turki H, Nouira R, Jomaa B, et al. 
Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of 
pemphigus foliaceus in young Tunisian women. J Invest Dermatol. 1995 
Feb;104(2):302–5.  
202.  Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in 
Finnish hospitals between 1969 and 1978. Acta Derm Venereol. 1982;62(6):491–6.  
203.  Hahn-Ristic K, Rzany B, Amagai M, Bröcker E-B, Zillikens D. Increased 
incidence of pemphigus vulgaris in southern Europeans living in Germany compared 
with native Germans. J Eur Acad Dermatol Venereol. 2002 Jan 1;16(1):68–71.  
162 
 
204.  Ding X, Aoki V, Mascaro JM, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal 
and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody 
profiles. J Invest Dermatol. 1997 Oct;109(4):592–6.  
205.  Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical 
phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J 
Am Acad Dermatol. 1999 Feb;40(2 Pt 1):167–70.  
206.  Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of Pemphigus in 
Neonatal Mice by Passive Transfer of IgG from Patients with the Disease. N Engl J 
Med. 1982 May 20;306(20):1189–96.  
207.  Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic 
autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) 
produced by baculovirus. J Clin Invest. 1994 Jul;94(1):59–67.  
208.  Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, et al. Genetic and 
functional characterization of human pemphigus vulgaris monoclonal autoantibodies 
isolated by phage display. J Clin Invest. 2005 Apr;115(4):888–99.  
209.  Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR. Homologous 
regions of autoantibody heavy chain complementarity-determining region 3 (H-
CDR3) in patients with pemphigus cause pathogenicity. J Clin Invest. 2010 
Nov;120(11):4111–7.  
210.  Beutner EH, Jordon RE. DEMONSTRATION OF SKIN ANTIBODIES IN 
SERA OF PEMPHIGUS VULGARIS PATIENTS BY INDIRECT 
IMMUNOFLUORESCENT STAINING. Proc Soc Exp Biol Med Soc Exp Biol Med 
N Y N. 1964 Nov;117:505–10.  
211.  Beutner EH, Jordon RE, Chorzelski TP. The Immunopathology of Pemphigus and 
Bullous Pemphigoid**From the Department of Microbiology, SUNY at Buffalo 
School of Medicine, Buffalo, New York, Mayo Graduate School of Medicine, 
Rochester, Minn., and the Department of Dermatology, Warsaw Medical School, 
Warsaw, Poland. J Invest Dermatol. 1968 Aug 1;51(2):63–80.  
212.  Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel 
epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991 Nov 
29;67(5):869–77.  
213.  Rs B, Ai M. Structure and interactions of desmosomal and other cadherins. Semin 
Cell Biol. 1992 1992;3(3):157–67.  
214.  Nie Z, Merritt A, Rouhi-Parkouhi M, Tabernero L, Garrod D. Membrane-
impermeable cross-linking provides evidence for homophilic, isoform-specific 




215.  Spindler V, Rötzer V, Dehner C, Kempf B, Gliem M, Radeva M, et al. Peptide-
mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-
induced skin blistering. J Clin Invest. 2013 Feb 1;123(2):800–11.  
216.  Kitajima Y. New insights into desmosome regulation and pemphigus blistering as 
a desmosome-remodeling disease. Kaohsiung J Med Sci. 2013 Jan;29(1):1–13.  
217.  Kowalczyk AP, Green KJ. Structure, Function and Regulation of Desmosomes. 
Prog Mol Biol Transl Sci. 2013;116:95–118.  
218.  Hameed A, Khan AA. Microscopic Nikolsky’s sign. Clin Exp Dermatol. 1999 
Jul;24(4):312–4.  
219.  Al-Amoudi A, Díez DC, Betts MJ, Frangakis AS. The molecular architecture of 
cadherins in native epidermal desmosomes. Nature. 2007 Dec 6;450(7171):832–7.  
220.  Harrison OJ, Brasch J, Lasso G, Katsamba PS, Ahlsen G, Honig B, et al. 
Structural basis of adhesive binding by desmocollins and desmogleins. Proc Natl 
Acad Sci. 2016 Jun 28;113(26):7160–5.  
221.  Mao X, Choi EJ, Payne AS. Disruption of Desmosome Assembly by Monovalent 
Human Pemphigus Vulgaris Monoclonal Antibodies. J Invest Dermatol. 2009 
Apr;129(4):908–18.  
222.  Sato M, Aoyama Y, Kitajima Y. Assembly pathway of desmoglein 3 to 
desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured 
keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy. Lab 
Investig J Tech Methods Pathol. 2000 Oct;80(10):1583–92.  
223.  Jolly PS, Berkowitz P, Bektas M, Lee H-E, Chua M, Diaz LA, et al. p38MAPK 
signaling and desmoglein-3 internalization are linked events in pemphigus 
acantholysis. J Biol Chem. 2010 Mar 19;285(12):8936–41.  
224.  Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies 
against the amino-terminal cadherin-like binding domain of pemphigus vulgaris 
antigen are pathogenic. J Clin Invest. 1992 Sep;90(3):919–26.  
225.  Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M. Dominant 
autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal 
adhesive region of desmogleins. J Immunol Baltim Md 1950. 2001 Nov 
1;167(9):5439–48.  
226.  Ohyama B, Nishifuji K, Chan PT, Kawaguchi A, Yamashita T, Ishii N, et al. 
Epitope Spreading Is Rarely Found in Pemphigus Vulgaris by Large-Scale 
Longitudinal Study Using Desmoglein 2–Based Swapped Molecules. J Invest 
Dermatol. 2012 Apr;132(4):1158–68.  
164 
 
227.  Kawasaki H, Tsunoda K, Hata T, Ishii K, Yamada T, Amagai M. Synergistic 
pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies 
on pemphigus vulgaris blister formation. J Invest Dermatol. 2006 Dec;126(12):2621–
30.  
228.  Kumar B, Arora S, Kumaran MS, Jain R, Dogra S. Study of desmoglein 1 and 3 
antibody levels in relation to disease severity in Indian patients with pemphigus. 
Indian J Dermatol Venereol Leprol. 2006 Jun;72(3):203–6.  
229.  Abasq C, Mouquet H, Gilbert D, et al. ELisa testing of anti–desmoglein 1 and 3 
antibodies in the management of pemphigus. Arch Dermatol. 2009 May 
1;145(5):529–35.  
230.  Shimizu H, Masunaga T, Ishiko A, Kikuchi A, Hashimoto T, Nishikawa T. 
Pemphigus Vulgaris and Pemphigus Foliaceus Sera Show an Inversely Graded 
Binding Pattern to Extracellular Regions of Desmosomes in Different Layers of 
Human Epidermis. J Invest Dermatol. 1995 Aug 1;105(2):153–9.  
231.  Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J 
Invest Dermatol. 2012 Mar;132(3 0 2):776–84.  
232.  Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen 
(desmoglein 3) is localized in the lower epidermis, the site of blister formation in 
patients. J Invest Dermatol. 1996 Feb;106(2):351–5.  
233.  Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K. Lack of 
mucosal involvement in pemphigus foliaceus may be due to low expression of 
desmoglein 1. J Invest Dermatol. 1998 Jan;110(1):76–8.  
234.  Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J 
Dermatol Sci. 1999 Jun;20(2):92–102.  
235.  Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. 
Explanations for the clinical and microscopic localization of lesions in pemphigus 
foliaceus and vulgaris. J Clin Invest. 1999 Feb;103(4):461–8.  
236.  Wu H, Wang ZH, Yan A, Lyle S, Fakharzadeh S, Wahl JK, et al. Protection 
against Pemphigus Foliaceus by Desmoglein 3 in Neonates. N Engl J Med. 2000 Jul 
6;343(1):31–5.  
237.  Hata T, Nishifuji K, Shimoda K, Sasaki T, Yamada T, Nishikawa T, et al. 
Transgenic rescue of desmoglein 3 null mice with desmoglein 1 to develop a 
syngeneic mouse model for pemphigus vulgaris. J Dermatol Sci. 2011 Jul;63(1):33–
9.  
238.  Hashimoto T, Amagai M, Garrod DR, Nishikawa T. Immunofluorescence and 
immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus 
sera with desmoglein 3 and desmoglein 1. Epithelial Cell Biol. 1995;4(2):63–9.  
165 
 
239.  Plomp JJ, Huijbers MG, van der Maarel SM, Verschuuren JJ. Pathogenic IgG4 
subclass autoantibodies in MuSK myasthenia gravis. Ann N Y Acad Sci. 2012 
Dec;1275:114–22.  
240.  Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, et al. 
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between 
MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20783–8.  
241.  Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger 
F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired 
thrombotic thrombocytopenic purpura. J Thromb Haemost JTH. 2009 
Oct;7(10):1703–10.  
242.  Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, et al. 
The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J 
Neurol. 2015 Aug 1;22(8):1151–61.  
243.  Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. 
Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J 
Dermatol Sci. 2001 May;26(1):55–61.  
244.  Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O’Leary CE, Payne AS. 
Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol. 2012 
Dec;167(6):1245–53.  
245.  Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease 
activity in pemphigus vulgaris. Dermatol Basel Switz. 1994;189 Suppl 1:85–9.  
246.  Torzecka JD, Woźniak K, Kowalewski C, Waszczykowska E, Sysa-Jedrzejowska 
A, Pas HH, et al. Circulating pemphigus autoantibodies in healthy relatives of 
pemphigus patients: coincidental phenomenon with a risk of disease development? 
Arch Dermatol Res. 2007 Aug;299(5–6):239–43.  
247.  Green MG, Bystryn J-C. Effect of intravenous immunoglobulin therapy on serum 
levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in 
pemphigus vulgaris. Arch Dermatol. 2008 Dec;144(12):1621–4.  
248.  Varga E-M, Kausar F, Aberer W, Zach M, Eber E, Durham SR, et al. Tolerant 
beekeepers display venom-specific functional IgG4 antibodies in the absence of 
specific IgE. J Allergy Clin Immunol. 2013 May;131(5):1419–21.  
249.  Adjobimey T, Hoerauf A. Induction of immunoglobulin G4 in human filariasis: 
an indicator of immunoregulation. Ann Trop Med Parasitol. 2010 Sep;104(6):455–
64.  
250.  Ljungström I, Hammarström L, Kociecka W, Smith CI. The sequential 
appearance of IgG subclasses and IgE during the course of Trichinella spiralis 
infection. Clin Exp Immunol. 1988 Nov;74(2):230–5.  
166 
 
251.  Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific 
immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 
2005 Sep;116(3):608–13.  
252.  Hussain R, Poindexter RW, Ottesen EA. Control of allergic reactivity in human 
filariasis. Predominant localization of blocking antibody to the IgG4 subclass. J 
Immunol Baltim Md 1950. 1992 May 1;148(9):2731–7.  
253.  Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002 
Jan;105(1):9–19.  
254.  van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation 
by IgG4 antibodies. Clin Exp Immunol. 1986 May;64(2):415–22.  
255.  James LK, Till SJ. Potential Mechanisms for IgG4 Inhibition of Immediate 
Hypersensitivity Reactions. Curr Allergy Asthma Rep [Internet]. 2016 [cited 2016 
Sep 19];16. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759210/ 
256.  Aalberse RC, Gaag R van der, Leeuwen J van. Serologic aspects of IgG4 
antibodies. I. Prolonged immunization results in an IgG4-restricted response. J 
Immunol. 1983 Feb 1;130(2):722–6.  
257.  Zenzo GD, Zambruno G, Borradori L. Endemic Pemphigus Foliaceus: Towards 
Understanding Autoimmune Mechanisms of Disease Development. J Invest 
Dermatol. 2012 Nov;132(11):2499–502.  
258.  Mentink LF, de Jong MCJM, Kloosterhuis GJ, Zuiderveen J, Jonkman MF, Pas 
HH. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, 
pemphigus foliaceus and paraneoplastic pemphigus. Br J Dermatol. 2007 
Apr;156(4):635–41.  
259.  Spaeth S, Riechers R, Borradori L, Zillikens D, Büdinger L, Hertl M. IgG, IgA 
and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus 
vulgaris. Br J Dermatol. 2001 Jun;144(6):1183–8.  
260.  Mantis NJ, Rol N, Corthésy B. Secretory IgA’s complex roles in immunity and 
mucosal homeostasis in the gut. Mucosal Immunol. 2011 Nov;4(6):603–11.  
261.  Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells 
carrying commensal bacteria. Science. 2004 Mar 12;303(5664):1662–5.  
262.  Cerutti A, Rescigno M. The Biology of Intestinal Immunoglobulin A Responses. 
Immunity. 2008 Jun;28(6):740–50.  
263.  Berth M, Delanghe J, Langlois M, Buyzere MD. Reference Values of Serum IgA 




264.  Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2008 
Jun;8(6):421–34.  
265.  Benckert J, Schmolka N, Kreschel C, Zoller MJ, Sturm A, Wiedenmann B, et al. 
The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-
specific. J Clin Invest. 2011 May 2;121(5):1946–55.  
266.  Mercer TR, Clark MB, Crawford J, Brunck ME, Gerhardt DJ, Taft RJ, et al. 
Targeted sequencing for gene discovery and quantification using RNA CaptureSeq. 
Nat Protoc. 2014 May;9(5):989–1009.  
267.  Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Kosakovsky Pond 
SL, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. 
Nature. 2016 Feb 4;530(7588):51–6.  
268.  Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic 
architecture and evolution of clear cell renal cell carcinomas defined by multiregion 
sequencing. Nat Genet. 2014 Mar;46(3):225–33.  
269.  Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. 
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc 
Natl Acad Sci. 2008 Sep 2;105(35):13081–6.  
270.  Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddeloh JA, et al. 
Targeted RNA sequencing reveals the deep complexity of the human transcriptome. 
Nat Biotechnol. 2011 Nov 13;30(1):99–104.  
271.  Arnaout R, Lee W, Cahill P, Honan T, Sparrow T, Weiand M, et al. High-
Resolution Description of Antibody Heavy-Chain Repertoires in Humans. PLoS 
ONE [Internet]. 2011 Aug 4 [cited 2016 Sep 16];6(8). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150326/ 
272.  Wu Y-C, Kipling D, Leong HS, Martin V, Ademokun AA, Dunn-Walters DK. 
High-throughput immunoglobulin repertoire analysis distinguishes between human 
IgM memory and switched memory B-cell populations. Blood. 2010 Aug 
19;116(7):1070–8.  
273.  DeWitt WS, Lindau P, Snyder TM, Sherwood AM, Vignali M, Carlson CS, et al. 
A Public Database of Memory and Naive B-Cell Receptor Sequences. PLoS ONE 
[Internet]. 2016 Aug 11 [cited 2016 Sep 18];11(8). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981401/ 
274.  Martin V, Wu Y-C (Bryan), Kipling D, Dunn-Walters D. Ageing of the B-cell 
repertoire. Phil Trans R Soc B. 2015 Sep 5;370(1676):20140237.  
275.  Parameswaran P, Liu Y, Roskin KM, Jackson KK, Dixit VP, Lee J-Y, et al. 




276.  Zhu J, Wu X, Zhang B, McKee K, O’Dell S, Soto C, et al. De novo identification 
of VRC01 class HIV-1–neutralizing antibodies by next-generation sequencing of B-
cell transcripts. Proc Natl Acad Sci. 2013 Oct 22;110(43):E4088–97.  
277.  Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused evolution of 
HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 
2011 Sep 16;333(6049):1593–602.  
278.  Galson JD, Trück J, Clutterbuck EA, Fowler A, Cerundolo V, Pollard AJ, et al. B-
cell repertoire dynamics after sequential hepatitis B vaccination and evidence for 
cross-reactive B-cell activation. Genome Med. 2016;8(1):68.  
279.  Jackson KJL, Liu Y, Roskin KM, Glanville J, Hoh RA, Seo K, et al. Human 
responses to influenza vaccination show seroconversion signatures and convergent 
antibody rearrangements. Cell Host Microbe. 2014 Jul 9;16(1):105–14.  
280.  Jiang N, He J, Weinstein JA, Penland L, Sasaki S, He X-S, et al. Lineage 
Structure of the Human Antibody Repertoire in Response to Influenza Vaccination. 
Sci Transl Med. 2013 Feb 6;5(171):171ra19.  
281.  Laserson U, Vigneault F, Gadala-Maria D, Yaari G, Uduman M, Vander Heiden 
JA, et al. High-resolution antibody dynamics of vaccine-induced immune responses. 
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4928–33.  
282.  Wang C, Liu Y, Cavanagh MM, Le Saux S, Qi Q, Roskin KM, et al. B-cell 
repertoire responses to varicella-zoster vaccination in human identical twins. Proc 
Natl Acad Sci U S A. 2015 Jan 13;112(2):500–5.  
283.  Palanichamy A, Apeltsin L, Kuo TC, Sirota M, Wang S, Pitts SJ, et al. 
Immunoglobulin class-switched B cells form an active immune axis between CNS 
and periphery in multiple sclerosis. Sci Transl Med. 2014 Aug 6;6(248):248ra106.  
284.  Stern JNH, Yaari G, Heiden JAV, Church G, Donahue WF, Hintzen RQ, et al. B 
cells populating the multiple sclerosis brain mature in the draining cervical lymph 
nodes. Sci Transl Med. 2014 Aug 6;6(248):248ra107-248ra107.  
285.  Lu DR, Robinson WH. Street-experienced peripheral B cells traffic to the brain. 
Sci Transl Med. 2014 Aug 6;6(248):248fs31.  
286.  Hershberg U, Meng W, Zhang B, Haff N, St Clair EW, Cohen PL, et al. 
Persistence and selection of an expanded B-cell clone in the setting of rituximab 
therapy for Sjögren’s syndrome. Arthritis Res Ther. 2014;16(1):R51.  
287.  Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et al. 
Diversity, cellular origin and autoreactivity of antibody-secreting cell expansions in 
acute Systemic Lupus Erythematosus. Nat Immunol. 2015 Jul;16(7):755–65.  
169 
 
288.  Sequencing Systems | Sequencer Comparison Table [Internet]. [cited 2016 Sep 
16]. Available from: http://www.illumina.com/systems/sequencing.html 
289.  Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human 
germline IgH repertoires revealed by deep sequencing. J Immunol Baltim Md 1950. 
2012 Sep 15;189(6):3221–30.  
290.  Products - GS FLX+ System : 454 Life Sciences, a Roche Company [Internet]. 
[cited 2016 Sep 16]. Available from: http://454.com/products/gs-flx-system/ 
291.  Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise 
determination of the diversity of a combinatorial antibody library gives insight into 
the human immunoglobulin repertoire. Proc Natl Acad Sci. 2009 Dec 
1;106(48):20216–21.  
292.  Liao H-X, Chen X, Munshaw S, Zhang R, Marshall DJ, Vandergrift N, et al. 
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive 
and highly mutated. J Exp Med. 2011 Oct 24;208(11):2237–49.  
293.  Weinstein JA, Jiang N, White RA, Fisher DS, Quake SR. High-Throughput 
Sequencing of the Zebrafish Antibody Repertoire. Science. 2009 May 
8;324(5928):807–10.  
294.  Jiang N, Weinstein JA, Penland L, White RA, Fisher DS, Quake SR. Determinism 
and stochasticity during maturation of the zebrafish antibody repertoire. Proc Natl 
Acad Sci. 2011 Mar 29;108(13):5348–53.  
295.  Kaplinsky J, Li A, Sun A, Coffre M, Koralov SB, Arnaout R. Antibody repertoire 
deep sequencing reveals antigen-independent selection in maturing B cells. Proc Natl 
Acad Sci U S A. 2014 Jun 24;111(25):E2622–9.  
296.  Greiff V, Miho E, Menzel U, Reddy ST. Bioinformatic and Statistical Analysis of 
Adaptive Immune Repertoires. Trends Immunol. 2015 Nov 1;36(11):738–49.  
297.  Vollmers C, Sit RV, Weinstein JA, Dekker CL, Quake SR. Genetic measurement 
of memory B-cell recall using antibody repertoire sequencing. Proc Natl Acad Sci U 
S A. 2013 Aug 13;110(33):13463–8.  
298.  Chapman DG. The Estimation of Biological Populations. Ann Math Stat. 1954 
Mar;25(1):1–15.  
299.  Abadi F, Botha A, Altwegg R. Revisiting the Effect of Capture Heterogeneity on 
Survival Estimates in Capture-Mark-Recapture Studies: Does It Matter? PLOS ONE. 
2013 Apr 30;8(4):e62636.  
300.  Chao A, Pan H-Y, Chiang S-C. The Petersen-Lincoln estimator and its extension 
to estimate the size of a shared population. Biom J Biom Z. 2008 Dec;50(6):957–70.  
170 
 
301.  Mao CX, Huang R, Zhang S. Petersen estimator, Chapman adjustment, list 
effects, and heterogeneity. Biometrics. 2016 Jun 20;  
302.  Gotelli NJ, Colwell RK. Quantifying biodiversity: procedures and pitfalls in the 
measurement and comparison of species richness. Ecol Lett. 2001 Jul 22;4(4):379–
91.  
303.  Chao A, Gotelli NJ, Hsieh TC, Sander EL, Ma KH, Colwell RK, et al. 
Rarefaction and extrapolation with Hill numbers: a framework for sampling and 
estimation in species diversity studies. Ecol Monogr. 2014 Feb 1;84(1):45–67.  
304.  Hsieh TC, Ma KH, Chao A. iNEXT: an R package for rarefaction and 
extrapolation of species diversity (Hill numbers). Methods Ecol Evol. 2016 Aug 
1;n/a-n/a.  
305.  Bunge J, Böhning D, Allen H, Foster JA. Estimating population diversity with 
unreliable low frequency counts. Pac Symp Biocomput Pac Symp Biocomput. 
2012;203–12.  
306.  Dickie IA. Insidious effects of sequencing errors on perceived diversity in 
molecular surveys. New Phytol. 2010;188(4):916–8.  
307.  Good IJ. The Population Frequencies of Species and the Estimation of Population 
Parameters. Biometrika. 1953 Dec 1;40(3–4):237–64.  
308.  Gale WA, Sampson G. Good‐turing frequency estimation without tears. J Quant 
Linguist. 1995 Jan 1;2(3):217–37.  
309.  Chiu C-H, Chao A. Estimating and comparing microbial diversity in the presence 
of sequencing errors. PeerJ [Internet]. 2016 Feb 1 [cited 2016 Oct 9];4. Available 
from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741086/ 
310.  Briney BS, Willis JR, Finn JA, McKinney BA, Jr JEC. Tissue-Specific Expressed 
Antibody Variable Gene Repertoires. PLOS ONE. 2014 Jun 23;9(6):e100839.  
311.  von Büdingen H-C, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, et 
al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 
2012 Dec 3;122(12):4533–43.  
312.  Mysara M, Leys N, Raes J, Monsieurs P. IPED: a highly efficient denoising tool 
for Illumina MiSeq Paired-end 16S rRNA gene amplicon sequencing data. BMC 
Bioinformatics. 2016;17:192.  
313.  Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, et al. 
Performance comparison of benchtop high-throughput sequencing platforms. Nat 
Biotechnol. 2012 May;30(5):434–9.  
171 
 
314.  Lee DF, Lu J, Chang S, Loparo JJ, Xie XS. Mapping DNA polymerase errors by 
single-molecule sequencing. Nucleic Acids Res. 2016 May 16;gkw436.  
315.  Edgar RC. Search and clustering orders of magnitude faster than BLAST. 
Bioinformatics. 2010 Oct 1;26(19):2460–1.  
316.  Schramm CA, Sheng Z, Zhang Z, Mascola JR, Kwong PD, Shapiro L. SONAR: 
A high-throughput pipeline for inferring antibody ontogenies from longitudinal 
sequencing of B cell transcripts. B Cell Biol. 2016;7:372.  
317.  briney/abtools [Internet]. GitHub. [cited 2016 Sep 17]. Available from: 
https://github.com/briney/abtools 
318.  Kuchenbecker L, Nienen M, Hecht J, Neumann AU, Babel N, Reinert K, et al. 
IMSEQ—a fast and error aware approach to immunogenetic sequence analysis. 
Bioinformatics. 2015 Sep 15;31(18):2963–71.  
319.  Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva 
EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat 
Methods. 2015 May;12(5):380–1.  
320.  Safonova Y, Bonissone S, Kurpilyansky E, Starostina E, Lapidus A, Stinson J, et 
al. IgRepertoireConstructor: a novel algorithm for antibody repertoire construction 
and immunoproteogenomics analysis. Bioinformatics. 2015 Jun 15;31(12):i53–61.  
321.  Ben-Dor A, Shamir R, Yakhini Z. Clustering gene expression patterns. J Comput 
Biol J Comput Mol Cell Biol. 1999 Fall-Winter;6(3–4):281–97.  
322.  Shlemov A, Bankevich S, Bzikadze A, Safonova Y. New algorithmic challenges 
of adaptive immune repertoire construction. ResearchGate [Internet]. 2016 Apr 7 
[cited 2016 Sep 17]; Available from: 
https://www.researchgate.net/publication/301875978_New_algorithmic_challenges_
of_adaptive_immune_repertoire_construction 
323.  Islam S, Zeisel A, Joost S, La Manno G, Zajac P, Kasper M, et al. Quantitative 
single-cell RNA-seq with unique molecular identifiers. Nat Methods. 2014 
Feb;11(2):163–6.  
324.  Kivioja T, Vähärautio A, Karlsson K, Bonke M, Enge M, Linnarsson S, et al. 
Counting absolute numbers of molecules using unique molecular identifiers. Nat 
Methods. 2012 Jan;9(1):72–4.  
325.  Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and 
quantification of rare mutations with massively parallel sequencing. Proc Natl Acad 
Sci U S A. 2011 Jun 7;108(23):9530–5.  
172 
 
326.  Khan TA, Friedensohn S, Vries ARG de, Straszewski J, Ruscheweyh H-J, Reddy 
ST. Accurate and predictive antibody repertoire profiling by molecular amplification 
fingerprinting. Sci Adv. 2016 Mar 1;2(3):e1501371.  
327.  Shugay M, Britanova OV, Merzlyak EM, Turchaninova MA, Mamedov IZ, 
Tuganbaev TR, et al. Towards error-free profiling of immune repertoires. Nat 
Methods. 2014 Jun;11(6):653–5.  
328.  Turchaninova MA, Davydov A, Britanova OV, Shugay M, Bikos V, Egorov ES, 
et al. High-quality full-length immunoglobulin profiling with unique molecular 
barcoding. Nat Protoc. 2016 Sep;11(9):1599–616.  
329.  Casbon JA, Osborne RJ, Brenner S, Lichtenstein CP. A method for counting PCR 
template molecules with application to next-generation sequencing. Nucleic Acids 
Res. 2011 Apr 13;gkr217.  
330.  Sheward DJ, Murrell B, Williamson C. Degenerate Primer IDs and the Birthday 
Problem. Proc Natl Acad Sci. 2012 May 22;109(21):E1330–E1330.  
331.  Jabara CB, Swanstrom R. Reply to Sheward et al.: Two sampling issues in using 
Primer IDs. Proc Natl Acad Sci. 2012 May 22;109(21):E1331–E1331.  
332.  Brodin J, Hedskog C, Heddini A, Benard E, Neher RA, Mild M, et al. Challenges 
with Using Primer IDs to Improve Accuracy of Next Generation Sequencing. PLoS 
ONE [Internet]. 2015 Mar 5 [cited 2016 Sep 17];10(3). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351057/ 
333.  Kou R, Lam H, Duan H, Ye L, Jongkam N, Chen W, et al. Benefits and 
Challenges with Applying Unique Molecular Identifiers in Next Generation 
Sequencing to Detect Low Frequency Mutations. PLOS ONE. 2016 Jan 
11;11(1):e0146638.  
334.  Benichou J, Ben-Hamo R, Louzoun Y, Efroni S. Rep-Seq: uncovering the 
immunological repertoire through next-generation sequencing. Immunology. 2012 
Mar;135(3):183–91.  
335.  Smith TS, Heger A, Sudbery I. UMI-tools: Modelling sequencing errors in 
Unique Molecular Identifiers to improve quantification accuracy. bioRxiv. 2016 May 
9;51755.  
336.  Lan F, Haliburton JR, Yuan A, Abate AR. Droplet barcoding for massively 
parallel single-molecule deep sequencing. Nat Commun. 2016 Jun 29;7:11784.  
337.  Gadala-Maria D, Yaari G, Uduman M, Kleinstein SH. Automated analysis of 
high-throughput B-cell sequencing data reveals a high frequency of novel 




338.  Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable 
domain sequence analysis tool. Nucleic Acids Res. 2013 Jul;41(Web Server 
issue):W34-40.  
339.  Alamyar E, Duroux P, Lefranc M-P, Giudicelli V. IMGT® Tools for the 
Nucleotide Analysis of Immunoglobulin (IG) and T Cell Receptor (TR) V-(D)-J 
Repertoires, Polymorphisms, and IG Mutations: IMGT/V-QUEST and 
IMGT/HighV-QUEST for NGS. In: Christiansen FT, Tait BD, editors. 
Immunogenetics [Internet]. Humana Press; 2012 [cited 2016 Sep 17]. p. 569–604. 
(Methods in Molecular Biology). Available from: http://dx.doi.org/10.1007/978-1-
61779-842-9_32 
340.  Wang X, Wu D, Zheng S, Sun J, Tao L, Li Y, et al. Ab-origin: an enhanced tool 
to identify the sourcing gene segments in germline for rearranged antibodies. BMC 
Bioinformatics. 2008;9(12):1–9.  
341.  Souto-Carneiro MM, Longo NS, Russ DE, Sun H, Lipsky PE. Characterization of 
the human Ig heavy chain antigen binding complementarity determining region 3 
using a newly developed software algorithm, JOINSOLVER. J Immunol Baltim Md 
1950. 2004 Jun 1;172(11):6790–802.  
342.  Russ DE, Ho K-Y, Longo NS. HTJoinSolver: Human immunoglobulin VDJ 
partitioning using approximate dynamic programming constrained by conserved 
motifs. BMC Bioinformatics. 2015;16:170.  
343.  Munshaw S, Kepler TB. SoDA2: a Hidden Markov Model approach for 
identification of immunoglobulin rearrangements. Bioinforma Oxf Engl. 2010 Apr 
1;26(7):867–72.  
344.  Gaëta BA, Malming HR, Jackson KJL, Bain ME, Wilson P, Collins AM. 
iHMMune-align: hidden Markov model-based alignment and identification of 
germline genes in rearranged immunoglobulin gene sequences. Bioinforma Oxf Engl. 
2007 Jul 1;23(13):1580–7.  
345.  Ralph DK, Iv FAM. Consistency of VDJ Rearrangement and Substitution 
Parameters Enables Accurate B Cell Receptor Sequence Annotation. PLOS Comput 
Biol. 2016 Jan 11;12(1):e1004409.  
346.  Chen Z, Collins AM, Wang Y, Gaëta BA. Clustering-based identification of 
clonally-related immunoglobulin gene sequence sets. Immunome Res. 2010 Sep 
27;6(Suppl 1):S4.  
347.  Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien J-P, et al. The Effects 
of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of 
Broadly Neutralizing HIV Antibodies. PLOS Pathog. 2013 Nov 21;9(11):e1003754.  
348.  Frost SDW, Murrell B, Hossain ASMM, Silverman GJ, Pond SLK. Assigning and 
visualizing germline genes in antibody repertoires. Philos Trans R Soc B Biol Sci 
174 
 
[Internet]. 2015 Sep 5 [cited 2016 Sep 18];370(1676). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528417/ 
349.  Briney B, Le K, Zhu J, Burton DR. Clonify: unseeded antibody lineage 
assignment from next-generation sequencing data. Sci Rep. 2016 Apr 22;6:23901.  
350.  Felsenstein J. [24] Inferring phylogenies from protein sequences by parsimony, 
distance, and likelihood methods. In: Enzymology B-M in, editor. Academic Press; 
1996 [cited 2016 Sep 18]. p. 418–27. (Computer Methods for Macromolecular 
Sequence Analysis; vol. 266). Available from: 
http://www.sciencedirect.com/science/article/pii/S0076687996660261 
351.  Day WHE, Johnson DS, Sankoff D. The computational complexity of inferring 
rooted phylogenies by parsimony. Math Biosci. 1986 Sep 1;81(1):33–42.  
352.  Kolaczkowski B, Thornton JW. Performance of maximum parsimony and 
likelihood phylogenetics when evolution is heterogeneous. Nature. 2004 Oct 
21;431(7011):980–4.  
353.  Wu X, Zhang Z, Schramm CA, Joyce MG, Do Kwon Y, Zhou T, et al. Maturation 
and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 
infection. Cell. 2015 Apr 23;161(3):470–85.  
354.  Casadevall A, Janda A. Immunoglobulin isotype influences affinity and 
specificity. Proc Natl Acad Sci. 2012 Jul 31;109(31):12272–3.  
355.  Tudor D, Yu H, Maupetit J, Drillet A-S, Bouceba T, Schwartz-Cornil I, et al. 
Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 
human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A. 2012 Jul 
31;109(31):12680–5.  
356.  Xia Y, Eryilmaz E, Zhang Q, Cowburn D, Putterman C. Anti-DNA antibody 
mediated catalysis is isotype dependent. Mol Immunol. 2016 Jan;69:33–43.  
357.  Xia Y, Pawar RD, Nakouzi AS, Herlitz L, Broder A, Liu K, et al. The constant 
region contributes to the antigenic specificity and renal pathogenicity of murine anti-
DNA antibodies. J Autoimmun. 2012 Dec;39(4):398–411.  
358.  Xia Y, Janda A, Eryilmaz E, Casadevall A, Putterman C. The constant region 
affects antigen binding of antibodies to DNA by altering secondary structure. Mol 
Immunol. 2013 Nov;56(1–2):28–37.  
359.  Hammers CM, Stanley JR. Antibody phage display: technique and applications. J 
Invest Dermatol. 2014 Feb;134(2):e17.  
360.  Ostertag EM, Kacir S, Thiboutot M, Gulendran G, Zheng XL, Cines DB, et al. 
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic 
175 
 
thrombocytopenic purpura: 1. Structural and functional characterization in vitro. 
Transfusion (Paris). 2016 Jul;56(7):1763–74.  
361.  Roark JH, Bussel JB, Cines DB, Siegel DL. Genetic analysis of autoantibodies in 
idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and 
somatic mutation. Blood. 2002 Aug 15;100(4):1388–98.  
362.  Ishii K, Lin C, Siegel DL, Stanley JR. Isolation of pathogenic monoclonal anti-
desmoglein 1 human antibodies by phage display of pemphigus foliaceus 
autoantibodies. J Invest Dermatol. 2008 Apr;128(4):939–48.  
363.  Roben P, Barbas SM, Sandoval L, Lecerf JM, Stollar BD, Solomon A, et al. 
Repertoire cloning of lupus anti-DNA autoantibodies. J Clin Invest. 1996 Dec 
15;98(12):2827–37.  
364.  del Rincon I, Zeidel M, Rey E, Harley JB, James JA, Fischbach M, et al. 
Delineation of the human systemic lupus erythematosus anti-Smith antibody response 
using phage-display combinatorial libraries. J Immunol Baltim Md 1950. 2000 Dec 
15;165(12):7011–6.  
365.  Stanley JR, Ishii K, Siegel DL, Payne AS. Update on the cloning of monoclonal 
anti-desmoglein antibodies from human pemphigus patients: implications for targeted 
therapy. Vet Dermatol. 2009 Oct;20(5–6):327–30.  
366.  Payne AS. Cloning and genetic characterization of human pemphigus 
autoantibodies. J Am Acad Dermatol. 2006 Aug;55(2):e2.  
367.  Cho MJ, Lo ASY, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, et al. 
Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common 
humoral immune responses among patients. Nat Commun. 2014 Jun 19;5:4167.  
368.  Payne AS, Siegel DL, Stanley JR. Targeting pemphigus autoantibodies through 
their heavy-chain variable region genes. J Invest Dermatol. 2007 Jul;127(7):1681–91.  
369.  Noel D, Bernardi T, Navarro-Teulon I, Marin M, Martinetto J-P, Ducancel F, et 
al. Analysis of the individual contributions of immunoglobulin heavy and light chains 
to the binding of antigen using cell transfection and plasmon resonance analysis. J 
Immunol Methods. 1996 Jun 21;193(2):177–87.  
370.  Hoogenboom HR, Winter G. By-passing immunisation. J Mol Biol. 1992 Sep 
20;227(2):381–8.  
371.  Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, et al. 
Antibody fragments from a “single pot” phage display library as immunochemical 
reagents. EMBO J. 1994 Feb 1;13(3):692–8.  
372.  Xu JL, Davis MM. Diversity in the CDR3 Region of VH Is Sufficient for Most 
Antibody Specificities. Immunity. 2000 Jul 1;13(1):37–45.  
176 
 
373.  Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, et al. Immunoglobulin 
D enhances immune surveillance by activating antimicrobial, proinflammatory and B 
cell-stimulating programs in basophils. Nat Immunol. 2009 Aug;10(8):889–98.  
383. Payne AS, Stanley JR. Pemphigus. In: Goldsmith L, Katz S, Gilchrest B, Paller A, 
Leffell D, Wolff K. Fitzpatrick’s Dermatology in General Medicine, Eighth Edition, 
2 Volume set. 8 edition. New York: McGraw-Hill Education / Medical; 2012. 2 p. 
375.  Bhol KC, Ahmed AR. Production of non-pathogenic human monoclonal 
antibodies to desmoglein 3 from pemphigus vulgaris patient. Autoimmunity. 2002 
Mar;35(2):87–91.  
376.  Di Zenzo G, Di Lullo G, Corti D, Calabresi V, Sinistro A, Vanzetta F, et al. 
Pemphigus autoantibodies generated through somatic mutations target the 
desmoglein-3 cis-interface. J Clin Invest. 2012 Oct;122(10):3781–90.  
377.  Mascaró JM, España A, Liu Z, Ding X, Swartz SJ, Fairley JA, et al. Mechanisms 
of acantholysis in pemphigus vulgaris: role of IgG valence. Clin Immunol 
Immunopathol. 1997 Oct;85(1):90–6.  
378.  Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, Rabinov M, Sulkes J, et al. 
The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with 
desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J 
Dermatol. 2000 Aug;143(2):337–42.  
379.  Yeh S-W, Cavacini LA, Bhol KC, Lin M-S, Kumar M, Duval M, et al. 
Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol 
Orlando Fla. 2006 Jul;120(1):68–75.  
380.  Liu F, Bergami PL, Duval M, Kuhrt D, Posner M, Cavacini L. Expression and 
functional activity of isotype and subclass switched human monoclonal antibody 
reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res Hum Retroviruses. 
2003 Jul;19(7):597–607.  
381.  Miranda LR, Duval M, Doherty H, Seaman MS, Posner MR, Cavacini LA. The 
neutralization properties of a HIV-specific antibody are markedly altered by 
glycosylation events outside the antigen-binding domain. J Immunol Baltim Md 
1950. 2007 Jun 1;178(11):7132–8.  
382.  Mao X, Li H, Sano Y, Gaestel M, Mo Park J, Payne AS. MAPKAP kinase 2 
(MK2)-dependent and -independent models of blister formation in pemphigus 
vulgaris. J Invest Dermatol. 2014 Jan;134(1):68–76.  
383.  Rader C, Popkov M, Neves JA, Barbas CF. Integrin alpha(v)beta3 targeted 
therapy for Kaposi’s sarcoma with an in vitro evolved antibody. FASEB J Off Publ 
Fed Am Soc Exp Biol. 2002 Dec;16(14):2000–2.  
177 
 
384.  Futei Y, Amagai M, Sekiguchi M, Nishifuji K, Fujii Y, Nishikawa T. Use of 
domain-swapped molecules for conformational epitope mapping of desmoglein 3 in 
pemphigus vulgaris. J Invest Dermatol. 2000 Nov;115(5):829–34.  
385.  Hanakawa Y, Matsuyoshi N, Stanley JR. Expression of desmoglein 1 
compensates for genetic loss of desmoglein 3 in keratinocyte adhesion. J Invest 
Dermatol. 2002 Jul;119(1):27–31.  
386.  Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous 
impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med. 
2000 Nov;6(11):1275–7.  
387.  Sharma PM, Choi EJ, Kuroda K, Hachiya T, Ishii K, Payne AS. Pathogenic anti-
desmoglein monoclonal antibodies demonstrate variable ELISA activity due to 
preferential binding of mature versus proprotein isoforms of desmoglein 3. J Invest 
Dermatol. 2009 Sep;129(9):2309–12.  
388.  Stavnezer J, Guikema JEJ, Schrader CE. Mechanism and Regulation of Class 
Switch Recombination. Annu Rev Immunol. 2008;26:261–92.  
389.  Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic 
in pemphigus. Cytokine. 2016 Jan;77:189–95.  
390.  Zhang K, Mills FC, Saxon A. Switch circles from IL-4-directed epsilon class 
switching from human B lymphocytes. Evidence for direct, sequential, and multiple 
step sequential switch from mu to epsilon Ig heavy chain gene. J Immunol Baltim Md 
1950. 1994 Apr 1;152(7):3427–35.  
391.  Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 
production can be differentially regulated by IL-10. J Immunol Baltim Md 1950. 
1998 Apr 1;160(7):3555–61.  
392.  Tavakolpour S. Interleukin 21 as a new possible player in pemphigus: Is it a 
suitable target? Int Immunopharmacol. 2016 May;34:139–45.  
393.  Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin 
disorders. J Clin Invest. 2006 May;116(5):1159–66.  
394.  Takahashi H, Amagai M, Tanikawa A, Suzuki S, Ikeda Y, Nishikawa T, et al. T 
Helper Type 2-Biased Natural Killer Cell Phenotype in Patients with Pemphigus 
Vulgaris. J Invest Dermatol. 2007 Feb;127(2):324–30.  
395.  Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic 
mechanisms of self tolerance and autoimmunity. Nature. 2005 Jun 2;435(7042):590–
7.  
396.  Schroeder Jr. HW, Cavacini L. Structure and function of immunoglobulins. J 
Allergy Clin Immunol. 2010 Feb;125(2, Supplement 2):S41–52.  
178 
 
397.  Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. Nat Rev 
Neurosci. 2016 Feb;17(2):103–17.  
398.  Fujieda S, Zhang K, Saxon A. IL-4 plus CD40 monoclonal antibody induces 
human B cells gamma subclass-specific isotype switch: switching to gamma 1, 
gamma 3, and gamma 4, but not gamma 2. J Immunol Baltim Md 1950. 1995 Sep 
1;155(5):2318–28.  
399.  Kracker S, Radbruch A. Immunoglobulin class switching: in vitro induction and 
analysis. Methods Mol Biol Clifton NJ. 2004;271:149–59.  
400.  McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B 
cell development. Annu Rev Immunol. 2005;23:487–513.  
401.  Cho MJ, Ellebrecht CT, Hammers CM, Mukherjee EM, Sapparapu G, Boudreaux 
CE, et al. Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris 
Autoantigen Desmoglein 3 and Rotavirus Antigen VP6. J Immunol. 2016 Jul 
11;1600567.  
402.  Zhang J, Kobert K, Flouri T, Stamatakis A. PEAR: a fast and accurate Illumina 
Paired-End reAd mergeR. Bioinformatics. 2014 Mar 1;30(5):614–20.  
403.  Felsenstein J. PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics. 
1989;5:164–6.  
404.  Qian Y, Jeong JS, Ye J, Dang B, Abdeladhim M, Aoki V, et al. Overlapping IgG4 
Responses to Self- and Environmental Antigens in Endemic Pemphigus Foliaceus. J 
Immunol Baltim Md 1950. 2016 Mar 1;196(5):2041–50.  
405.  Aoki V, Rivitti EA, Diaz LA, the Cooperative Group on Fogo Selvagem 
Research. Update on fogo selvagem, an endemic form of pemphigus foliaceus. J 
Dermatol. 2015 Jan 1;42(1):18–26.  
406.  Warren SJP, Arteaga LA, Rivitti EA, Aoki V, Hans-Filho G, Qaqish BF, et al. 
The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J 
Invest Dermatol. 2003 Jan;120(1):104–8.  
407.  van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, et al. 
IgG4 production is confined to human IL-10-producing regulatory B cells that 
suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013 
Apr;131(4):1204–12.  
408.  Zhu H-Q, Xu R-C, Chen Y-Y, Yuan H-J, Cao H, Zhao X-Q, et al. Impaired 
function of CD19(+) CD24(hi) CD38(hi) regulatory B cells in patients with 
pemphigus. Br J Dermatol. 2015 Jan;172(1):101–10.  
179 
 
409.  Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, et al. 
Characterization of a rare IL-10-competent B-cell subset in humans that parallels 
mouse regulatory B10 cells. Blood. 2011 Jan 13;117(2):530–41.  
410.  Zan H, Cerutti A, Dramitinos P, Schaffer A, Casali P. CD40 Engagement 
Triggers Switching to IgA1 and IgA2 in Human B Cells Through Induction of 
Endogenous TGF-β: Evidence for TGF-β But Not IL-10-Dependent Direct Sμ→Sα 
and Sequential Sμ→Sγ, Sγ→Sα DNA Recombination. J Immunol Baltim Md 1950. 
1998 Nov 15;161(10):5217–25.  
411.  Giordano CN, Sinha AA. Cytokine networks in Pemphigus vulgaris: An 
integrated viewpoint. Autoimmunity. 2012 Sep;45(6):427–39.  
412.  D’Auria L, Bonifati C, Mussi A, D’Agosto G, De Simone C, Giacalone B, et al. 
Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour 
necrosis factor-alpha levels are significantly increased as compared to healthy 
subjects and correlate with disease activity. Eur Cytokine Netw. 1997 Dec;8(4):383–
7.  
413.  Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, et 
al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus 
vulgaris. Br J Dermatol. 2006 Aug;155(2):330–6.  
414.  Watanabe R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Kuwano Y, et 
al. Increased serum levels of a proliferation-inducing ligand in patients with bullous 
pemphigoid. J Dermatol Sci. 2007 Apr;46(1):53–60.  
415.  Corthésy B. Multi-Faceted Functions of Secretory IgA at Mucosal Surfaces. Front 
Immunol [Internet]. 2013 Jul 12 [cited 2016 Sep 16];4. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709412/ 
416.  Henry Dunand CJ, Wilson PC. Restricted, canonical, stereotyped and convergent 
immunoglobulin responses. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 
5;370(1676).  
417.  Strauli NB, Hernandez RD. Statistical inference of a convergent antibody 
repertoire response to influenza vaccine. Genome Med. 2016;8(1):60.  
418.  Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK, et al. 
Sequence and structural convergence of broad and potent HIV antibodies that mimic 
CD4 binding. Science. 2011 Sep 16;333(6049):1633–7.  
419.  Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, 
et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of 
human B cell tolerance. J Clin Invest. 2001 Oct 1;108(7):1061–70.  
420.  Thompson KM, Sutherland J, Barden G, Melamed MD, Randen I, Natvig JB, et 
al. Human Monoclonal Antibodies against Blood Group Antigens Preferentially 
180 
 
Express a VH4-21 Variable Region Gene-Associated Epitope. Scand J Immunol. 
1991 Oct 1;34(4):509–18.  
421.  Steinsbø Ø, Dunand CJH, Huang M, Mesin L, Salgado-Ferrer M, Lundin KEA, et 
al. Restricted VH/VL usage and limited mutations in gluten-specific IgA of coeliac 
disease lesion plasma cells. Nat Commun [Internet]. 2014 Jun 9 [cited 2016 Oct 
15];5. Available from: http://www.nature.com/doifinder/10.1038/ncomms5041 
422.  Coales SJ, Tuske SJ, Tomasso JC, Hamuro Y. Epitope mapping by amide 
hydrogen/deuterium exchange coupled with immobilization of antibody, on-line 
proteolysis, liquid chromatography and mass spectrometry. Rapid Commun Mass 
Spectrom RCM. 2009 Mar;23(5):639–47.  
423.  Pandit D, Tuske SJ, Coales SJ, E SY, Liu A, Lee JE, et al. Mapping of 
discontinuous conformational epitopes by amide hydrogen/deuterium exchange mass 
spectrometry and computational docking. J Mol Recognit JMR. 2012 Mar;25(3):114–
24.  
424.  Weitkamp J-H, Kallewaard N, Kusuhara K, Bures E, Williams JV, LaFleur B, et 
al. Infant and adult human B cell responses to rotavirus share common 
immunodominant variable gene repertoires. J Immunol Baltim Md 1950. 2003 Nov 
1;171(9):4680–8.  
425.  Berkowska MA, Schickel J-N, Grosserichter-Wagener C, Ridder D de, Ng YS, 
Dongen JJM van, et al. Circulating Human CD27−IgA+ Memory B Cells Recognize 
Bacteria with Polyreactive Igs. J Immunol. 2015 Jul 6;1402708.  
426.  Quan CP, Berneman A, Pires R, Avrameas S, Bouvet JP. Natural polyreactive 
secretory immunoglobulin A autoantibodies as a possible barrier to infection in 
humans. Infect Immun. 1997 Oct 1;65(10):3997–4004.  
427.  McDaniel JR, DeKosky BJ, Tanno H, Ellington AD, Georgiou G. Ultra-high-
throughput sequencing of the immune receptor repertoire from millions of 
lymphocytes. Nat Protoc. 2016 Mar;11(3):429–42.  
428.  Sun M, Li L, Gao QS, Paul S. Antigen recognition by an antibody light chain. J 
Biol Chem. 1994 Jan 7;269(1):734–8.  
429.  Song MK, Oh MS, Lee JH, Lee JN, Chung JH, Park SG, et al. Light chain of 
natural antibody plays a dominant role in protein antigen binding. Biochem Biophys 
Res Commun. 2000 Feb 16;268(2):390–4.  
430.  Bruin R de, Spelt K, Mol J, Koes R, Quattrocchio F. Selection of high-affinity 




431.  Derda R, Tang SKY, Li SC, Ng S, Matochko W, Jafari MR. Diversity of Phage-
Displayed Libraries of Peptides during Panning and Amplification. Molecules. 2011 
Feb 21;16(2):1776–803.  
432.  Kodituwakku AP, Jessup C, Zola H, Roberton DM. Isolation of antigen-specific 
B cells. Immunol Cell Biol. 2003 Jun;81(3):163–70.  
433.  Rhiel L, Krah S, Günther R, Becker S, Kolmar H, Hock B. REAL-Select: Full-
Length Antibody Display and Library Screening by Surface Capture on Yeast Cells. 
PLOS ONE. 2014 Dec 12;9(12):e114887.  
434.  Kanamori T, Fujino Y, Ueda T. PURE ribosome display and its application in 
antibody technology. Biochim Biophys Acta BBA - Proteins Proteomics. 2014 
Nov;1844(11):1925–32.  
435.  Zhou C, Shen WD. Mammalian cell surface display of full length IgG. Methods 
Mol Biol Clifton NJ. 2012;907:293–302.  
436.  Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and 
immune tolerance to allergens. World Allergy Organ J [Internet]. 2015 May 14 [cited 
2016 Oct 16];8(1). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430874/ 
437.  Figueiredo JP, Oliveira RR, Cardoso LS, Barnes KC, Grant AV, Carvalho EM, et 
al. Adult worm-specific IgE/IgG4 balance is associated with low infection levels of 
Schistosoma mansoni in an endemic area. Parasite Immunol. 2012 Dec;34(12):604–
10.  
438.  Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of interleukin 10 in 
specific immunotherapy. J Clin Invest. 1998 Jul 1;102(1):98–106.  
439.  Qian Y, Jeong JS, Maldonado M, Valenzuela JG, Gomes R, Evangelista F, et al. 
Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand 
fly salivary LJM11 antigen. J Immunol Baltim Md 1950. 2012 Aug 15;189(4):1535–
9.  
440.  Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, et al. 
Population-specific association between a polymorphic variant in ST18, encoding a 
pro-apoptotic molecule, and pemphigus vulgaris. J Invest Dermatol. 2012 
Jul;132(7):1798–805.  
441.  Vodo D, Sarig O, Geller S, Ben-Asher E, Olender T, Bochner R, et al. 
Identification of a Functional Risk Variant for Pemphigus Vulgaris in the ST18 Gene. 
PLoS Genet [Internet]. 2016 May 5 [cited 2016 Oct 16];12(5). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858139/ 
442.  Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of 
autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus 
182 
 
vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol 
Baltim Md 1950. 2003 Jan 1;170(1):635–42.  
443.  Lundgren M, Persson U, Larsson P, Magnusson C, Smith CI, Hammarström L, et 
al. Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. Eur J Immunol. 
1989 Jul;19(7):1311–5.  
 
 
